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ABSTRACT OF THE DISSERTATION 
Identification of modulators of deoxyribonucleotide pools and replication stress in cancer 
By 
Soumya Poddar 
Doctor of Philosophy in Molecular and Medical Pharmacology 
University of California, Los Angeles, 2018 
Professor Caius G. Radu, Chair 
 Regulation of intracellular deoxyribonucleotide triphosphate (dNTP) pools are critical for 
DNA replication and repair. DNA replication is a highly demanding process, which requires 
precise timing and supply of adequate unmodified dNTPs. Imbalanced dNTP pools can lead to 
genomic instability and result in cancer development. Several studies have reported cancer 
cells are more susceptible than normal cells to perturbations in the quantity, quality and balance 
of dNTP pools. Therefore, therapeutic agents targeting dNTP synthesis have been used for 
treatment of several types of cancer. Despite these studies, the molecular mechanisms that 
regulate quantity and quality of dNTP pools are not completely understood. Studying the 
crosstalk between metabolic and signaling mechanisms for regulation of dNTP pools are 
required to develop better pharmacological interventions against cancer.  
Dysregulation of dNTP pools can occur in different ways -  
 Modulators of dNTP pools’ quantity: Similar to other major branches of cellular 
metabolism, nucleotide biosynthesis consists of redundant and convergent biosynthetic 
pathways. dNTPs required for DNA replication and repair can be produced by the de novo 
pathway (DNP) or by the nucleoside salvage pathway (NSP). Therefore, both pathways are 
required to be targeted simultaneously to achieve therapeutic efficacy.  
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 Modulators of dNTP pools’ quality: Reactive oxygen species (ROS), generated by both 
endogenous and exogenous routes can pose a significant threat to cellular integrity by inducing 
oxidative damage. This results in DNA base modifications, formation of apurinic/apyrimidinic 
lesions, which can be mutagenic and lead to DNA damage. Hence, pharmacological 
intervention by redox modulators is being investigated as promising anti-cancer therapy.  
 Regulation of dNTP pools by signaling pathways: Dysregulation of quantity or quality of 
dNTP pools lead to transient disruption of replication fork progression, termed as replication 
stress (RS), defined by accumulation of unprotected single-stranded DNA (ssDNA) at stalled 
replication forks. In order to protect genomic integrity, cells activate the replication stress 
response (RSR) pathway to limit the amount of ssDNA and subsequent DNA damage. However, 
the metabolic consequences of RSR on nucleotide metabolism are poorly understood.  
This thesis focuses on development of pharmacological modulators to regulate dNTP pools. 
Further it explores the interconnections between these dNTP pool modulators and replication 
stress to establish combination therapies against cancer.  
 In Chapter 1, we identified metabolic alterations in response to ATR inhibition in acute 
lymphoblastic leukemia, and developed a combination therapy targeting the metabolic 
vulnerabilities. 
 In Chapter 2, we developed a novel dCK (the rate-limiting enzyme of NSP) inhibitor, with 
improved metabolic stability and bioavailability. We studied preclinical pharmacokinetics and 
dose-response relationships of dCK inhibitor for translation to first in-human clinical trials.  
 In Chapter 3, we evaluated a series of novel isoquinoline based thiosemicarbazone 
compounds to discover a highly potent copper ionophore which induces oxidative stress and 
DNA damage against aggressive solid tumor models.  
 In Chapter 4, we designed and applied a metabolic modifier screen which identified 
multiple protein kinase inhibitors as having non-canonical targets within pyrimidine metabolism. 
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CHAPTER 1 
Targetable dependence on convergent nucleotide 
biosynthetic pathways in leukemia is facilitated by ATR 
inhibition 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ABSTRACT 
Leukemia cells rely on two nucleotide biosynthetic pathways, de novo and salvage, to produce 
dNTPs for DNA replication. Using metabolomic, proteomic, and phosphoproteomic approaches, 
we show that inhibition of the replication stress sensing kinase ataxia telangiectasia and Rad3-
related protein (ATR) reduced the output of both de novo and salvage pathways by regulating 
the activity of their respective rate-limiting enzymes, ribonucleotide reductase (RNR) and 
deoxycytidine kinase (dCK), via distinct molecular mechanisms. Quantification of nucleotide 
biosynthesis in ATR-inhibited acute lymphoblastic leukemia (ALL) cells revealed substantial 
remaining de novo and salvage activities, and could not eliminate the disease in vivo. However, 
targeting these remaining activities with RNR and dCK inhibitors triggered lethal replication 
stress in vitro and long-term disease-free survival in mice with B-ALL, without detectable toxicity. 
The functional interplay between alternative nucleotide biosynthetic routes and ATR provides 
new therapeutic opportunities in leukemia and potentially other cancers. 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INTRODUCTION 
Unabated proliferation is a hallmark of cancer which requires new DNA synthesis from 
deoxyribonucleotide triphosphates (dNTPs). However, cellular dNTP levels only suffice to 
sustain a few minutes of DNA replication indicating that dNTP pools are produced “on demand” 
via tightly regulated biosynthetic pathways1. These deoxynucleotide biosynthetic pathways, 
termed de novo and salvage, rely on distinct carbon and nitrogen sources2. De novo pathways 
use glucose and amino acids to produce ribonucleotide diphosphates (rNDPs) which are 
converted into deoxyribonucleotide diphosphates (dNDPs) by ribonucleotide reductase (RNR), a 
two-subunit enzyme complex3 upregulated in most cancers4. Salvage pathways convert 
preformed ribonucleosides, deoxyribonucleosides, and nucleobases into nucleotides through 
the actions of metabolic kinases and phosphoribosyltransferases2. Amongst nucleoside salvage 
kinases, deoxycytidine kinase (dCK) has the broadest substrate specificity, encompassing both 
purine and pyrimidine nucleosides5. While tumors are thought to predominantly rely on de novo 
pathways to produce nucleotides6, scavenging of preformed nucleosides via dCK and other 
salvage kinases may also play important roles in the economy of nucleotide metabolism in 
cancer cells. Many of the cell lines included in the Cancer Cell Line Encyclopedia (CCLE)7,8 
express dCK at higher levels than the corresponding normal tissues (Supplementary Fig. 1a 
and 1b). Increased tumor dCK expression relative to matched normal tissues also occurs in 
patient samples, as evidenced by RNASeq data from The Cancer Genome Atlas (TCGA, http://
cancergenome.nih.gov; Supplementary Fig. 1c)9,10. Moreover, in vivo, cancer cells often 
encounter limited supplies of essential de novo pathway substrates, e.g. glucose, glutamine and 
aspartate, because of their avid consumption of these nutrients and inadequate 
vascularization11. An insufficient de novo biosynthetic capacity, coupled with an increased 
demand for dNTPs due to unabated proliferation driven by oncogenic signaling, might increase 
the dependency of certain tumors on salvage pathways for nucleotide production. Consistent 
with this hypothesis, we previously showed that acute lymphoblastic leukemia (ALL) cells 
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display nucleotide biosynthetic plasticity12, defined as the ability to compensate for the inhibition 
of either de novo or salvage pathways by upregulating the alternate pathway. These metabolic 
transitions occurred both in vitro and in vivo; moreover partial inhibition of both de novo and 
salvage biosynthetic routes was required for therapeutic activity in animal models of T and B-
ALL12. 
Collectively, these results described above suggest that, in acute leukemia, and potentially in 
other cancers, nucleoside salvage biosynthetic pathways may be metabolic non-oncogene 
addictions13 targetable by specific inhibitors. However, since both de novo and salvage 
biosynthetic pathways also operate in normal cells14,15, a better understanding of the signaling 
mechanisms that regulate their activity in cancer cells may lead to the development of more 
effective targeted therapies. In this context, the mTOR16–18, Myc19,20 and Ras21 pathways have 
been shown to regulate nucleotide biosynthesis. The replication stress response pathway, 
constitutively upregulated in many tumors, also plays important roles in regulating nucleotide 
metabolism, given its unique ability to ‘sense’ dNTP insufficiency22. The most proximal enzyme 
in the cellular response to replication stress is ataxia telangiectasia and Rad3-related protein 
(ATR), a serine threonine kinase activated at stalled replication forks23 in response to nucleotide 
insufficiency and other replication defects. In addition to its well-established role in regulating 
origin firing and promoting fork stability24, ATR has been recently linked to nucleotide 
metabolism. Inhibition of ATR, or of its downstream effector kinases CHEK1 and WEE1, reduces 
dNTP levels in multiple cancer cell lines25. This effect of ATR inhibition was proposed to involve 
the downregulation of the small RNR subunit RRM2, particularly at the G1/S transition26, when 
cells are most susceptible to nucleotide insufficiency27. Intriguingly, ATR also regulates dCK 
activity in several solid tumor and myeloid leukemia cells by phosphorylation at serine 7428. This 
post-translational modification (PTM) modulates dCK’s catalytic properties and substrate 
specificity29,30. While collectively these findings support a connection between ATR signaling 
and dNTP production, the metabolic consequences of ATR inhibition in malignancies with 
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nucleotide biosynthetic plasticity are yet to be defined. Here, we examined ATR modulation of 
dNTP synthesis and utilization for DNA synthesis, and the consequences for tumor cell viability 
in culture and in vivo in ALL models, using quantitative approaches. A targeted multiplexed mass 
spectrometric (MS) assay was developed to measure the differential contributions of the de 
novo and salvage pathways both to nucleotide pools and newly replicated DNA. This assay was 
used in conjunction with proteomic and phosphoproteomic MS approaches to investigate the 
mechanisms responsible for alterations in nucleotide biosynthesis induced by ATR inhibition. In 
addition, we compared direct targeting of de novo and salvage rate-limiting enzymes, using 
specific inhibitors versus indirect inhibition of these enzymes via interference with ATR signaling. 
These studies identified a synthetically lethal interaction between inhibition of convergent 
nucleotide biosynthetic routes and ATR in ALL. This combination is therapeutically exploitable in 
vivo, resulting in long-term, disease-free survival in a systemic p185BCR-ABLArf–/– pre-B-ALL 
mouse model representative of the human disease31–33. Overall, our findings suggest that 
nucleotide biosynthetic plasticity in lymphoblastic leukemia cells, and potentially in other 
malignancies, is mediated by both ATR signaling and nucleotide metabolic adaptive 
mechanisms which may be targetable without overt toxicity to normal tissues, using existing 
small molecule inhibitors. 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METHODS AND MATERIALS 
Cell culture and culture conditions. Leukemia cell lines: CCRF-CEM, EL4, Jurkat, Molt-4, 
CEM-R, THP-1, HL-60, TF-1, MV-4-11, HH, HuT 78, K-562; ovarian cancer cell lines: Hey-T30, 
PA-1, Caov-3, OVCAR-5, IGROV-1, A2780; hepatocellular carcinoma (HCC) cell lines: 
SNU-475, PRC/PRF/5, SNU-449, Hep 3B, Hep G2, SK-HEP-1; and pancreatic adenocarcinoma 
(PDAC) cell lines: L3.BP1, KPC, BxPC-3, MIA PaCa-2, Hs 766T, AsPC-1, PANC-1 were 
obtained from American Type Culture Collection (ATCC). Nalm-6 and p185BCR-ABLArf–/– pre-B 
cells were gifts from M. Teitell (UCLA) and N. Boulos (CERN Foundation), respectively. Patient-
derived primary cells of leukemia COG332 was gift from Yong-Mi Kim (USC). Patient-derived 
primary cells of glioblastoma (HK-374) and melanoma (M299 and M417) were derived in the 
labs of Drs. Kornblum (UCLA) and Ribas, respectively. With a few exceptions, cell lines were 
cultured in RPMI-1640 (Corning) containing 10% fetal bovine serum (FBS, Omega Scientific) 
and were grown at 37 ºC, 20% O2 and 5% CO2. p185BCR-ABLArf–/– pre-B cells were cultured in 
RPMI-1640 containing 10% FBS and 0.1% β-mercaptoethanol. HK374 was cultured in DMEM-
F12 (Invitrogen) containing B27 supplement (Life Technologies), 20 ng/mL basic fibroblast 
growth factor (bFGF; Peprotech), 50 ng/mL epidermal growth factor (EGF; Life Technologies), 
penicillin/streptomycin (Invitrogen), Glutamax (Invitrogen), and 5 µg/mL heparin (Sigma-Aldrich). 
All cultured cells, except HK374, were incubated in antibiotic free media and were regularly 
tested for mycoplasma contamination using MycoAlert kit (Lonza) following the manufacturer’s 
instructions, except that the reagents were diluted 1:4 from their recommended amount. 
Cell cycle synchronization. Cells were treated with a CDK4/6 inhibitor, Pablociclib or 
PD-0332991 (Selleckchem, S1116) for 18 h to synchronize them in the G1 phase. 
Subsequently, cells were washed twice with PBS containing 2% FBS (Omega Scientific) and 
released into fresh media.  
Proliferation assays. Cells were plated in 384-well plates (1,000 cells/well for suspension cell 
lines and 500 cells/well for adherent cell lines in 30 µL volume). For suspension cells, the plates 
were incubated at 37 ºC for 1 h to allow settling. For adherent cell lines, the plates were 
incubated at 37 ºC overnight to allow the cells to seed. Drugs were serially diluted to the desired 
concentration and an equivalent amount of DMSO was used in vehicle control. After pre-
incubation, 10 µL of the diluted drugs were added to each well. Following a 72 h incubation, 
CellTiter-Glo reagent was added to each well according to manufacturer’s instructions 
(Promega, CellTiter-Glo® Luminescent Cell Viability Assay). The plates were shaken for 2 min, 
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incubated in the dark for 8 min, and then analyzed by SpectraMax luminometer (Molecular 
Devices). 
Isotopic labeling in cell culture. Cells were transferred into RPMI-1640 without glucose and 
supplemented with 10% dialyzed FBS (Gibco) containing the following labeled substrates: 
precursors for de novo [U-13C6]glucose (Sigma-Aldrich, 389374) at 11 mM; precursors for purine 
salvage [U-13C10,15N5]dA (Cambridge Isotopes, CIL 3896), [15N5]dA (Cambridge Isotopes, 
NLM-3895), and [15N5]dG (Cambridge Isotopes, NLM-3899) at 5 µM or as indicated; and 
precursors for pyrimidine salvage: [U-13C9,15N3]dC (Silantes, 124603602) and [U-13C10,15N2]dT 
(Cambridge Isotopes, CNLM-3902) at 5 µM and [15N2]orotate (Cambridge Isotopes, NLM-1048) 
at indicated concentrations. The cells were incubated for 12 h or as indicated before sample 
collection and processing.  
Western blot. Cells were lysed using RIPA buffer supplemented with protease (ThermoFisher, 
78430) and phosphatase (ThermoFisher, 78420) inhibitors, scraped, sonicated, and centrifuged 
(20,000 x g at 4 ºC). Protein concentrations in the supernatant were determined using the Micro 
BCA Protein Assay kit (Thermo), and equal amounts of protein were resolved on pre-made Bis-
Tris polyacrylamide gels (Life Technologies). Primary antibodies: pS345 CHEK1 (Cell signaling, 
#2341), pT68 CHEK2 (Cell signaling, #2197), pS139 H2A.X (Millipore, 05-636), clvd. Casp8 
(Cell signaling, #8592), clvd. Casp9 (Cell signaling, #9502), clvd. Casp3 (Cell signaling, #9662), 
clvd. PARP (Cell signaling, #5625), and anti-actin (Cell Signaling Technology, 9470, 1:10,000). 
Primary antibodies were stored in 5% BSA (Sigma-Aldrich) and 0.1% NaN3 in TBST solution. 
Anti-rabbit IgG HRP-linked (Cell Signaling Technology, 7074) and anti-mouse IgG HRP-linked 
(Cell Signaling Technology, 7076) were used as secondary antibodies. Chemiluminescent 
substrates (ThermoFisher Scientific, 34077 and 34095) and autoradiography film (Denville) 
were used for detection. 
Drugs. The following drugs were used: Pablociclib (Selleckchem, S1116, 1 µM), VE-822 
(ApeXBio, B1381, 1 µM or as indicated), DI-82 (dCKi2, 1 µM), thymidine (Sigma-Aldrich, T1895, 
as indicated), hydroxyurea (Sigma-Aldrich, H8627, as indicated), gallium maltolate (Nanoman 
Industries, CN-GAM-02-1G00-A00, as indicated), 3-AP (ApeXBio, custom, 500 nM or as 
indicated), Pentostatin (Santa Cruz Biotechnology, sc-204177, 10 µM), forodesine or BCX-1777 
(Chemscene, CS-3781, 100 nM), and dasatinib (LC Laboratories, D-3307, 1 nM). 
Sequencing of dasatinib-resistant clones. Bone marrow cells were harvested from dasatinib 
treated mice with disease relapse during sacrifice and cultured in standard culture conditions. 
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Genomic DNA was collected from resistant cell populations and a 2-step nested PCR strategy 
was utilized to amplify the human ABL kinase domain. PCR products were sequenced and 
assessed for the presence of T315I mutation. 
Melanoma mutation assessment. Exome sequencing for M417 and M299 was performed at 
the UCLA Clinical Microarray Core on an Illumina HiSeq3000 using the SeqCap EZ Exome 
Enrichment Kit v3.0 (Roche). Reads were mapped to UCSC hg19 (bwa-mem), deduplicaed 
(PicardTools), and subjected to base quality score recalibration and realignment around known 
indels according to the Broad Institute Genome Analysis Toolkit (GATK) Best Practices v3.0. 
Variants in genes associated with nucleotide biosynthesis were identified using the GATK 
HaplotypeCaller, and annotated with Oncotator (http://portals.broadinstitute.org/oncotator/). 
Mass spectrometry analyses 
dNTP sample processing. 0.5 – 1 x 106 cells were collected into 1.5 mL microcentrifuge tubes 
and centrifuged (450 x g, 4 min, 4 ºC). The supernatant was carefully aspirated and the cells 
were washed twice with 1 mL of cold PBS, followed each time by centrifugation (450 x g, 4 min 
4 ºC). The PBS were aspirated. Thereafter, the pellets were treated with 10 µL of 10% 
trifluoroacetic acid with internal standards (1 µM [15N3]dCMP and [15N3]dCTP, Silantes # 
122303802 and # 120303802, respectively) vigorously vortexed for 30 s, and incubated on ice 
for 10 min. 40 µL of 500 mM ammonium acetate, pH = 9.3, with the same internal standard (1 
µM [15N3]dCMP and [15N3]dCTP) was then added and the samples were vigorously vortexed 
again for 30 s. The samples were centrifuged (14,000 x g, 10 min, 4 ºC) to remove cell debris. 
The supernatants (~ 40 µL) were transferred into HPLC injector vials. Stock solutions (10 mM) of 
rCTP, rCDP, dCMP, dCDP, and dCTP (Sigma Aldrich) were prepared individually in water, and stored at 
–20 ºC before use to generate calibration standards. Calibration standards were prepared and mixed 
together in water with internal standards (1 µM [15N3]dCMP and [15N3]dCTP) to make working stock 
concentrations in 100 nM – 100 µM range. Calibration standards were diluted 10-fold into the same 
nucleotide extraction solution of 10% TFA/500 mM ammonium acetate (1:4, v/v) with internal standards 
(1 µM [15N3]dCMP and [15N3]dCTP) to give a final concentration in 10 nM – 10 µM. Nucleotide and 
calibration samples were processed together to minimize variation. 
DNA sample processing. Genomic DNA from 0.5 – 1 x 104 cells was extracted using the 
Quick-gDNA MiniPrep kit (Zymo Research, D3021) and hydrolyzed to nucleosides using the 
DNA Degradase Plus kit (Zymo Research, E2021), following manufacturer-supplied instructions. 
In the final step of DNA extraction, 50 µL of water was used to elute the DNA into 1.5 mL 
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microcentrifuge tubes. A nuclease solution (5 µL; 10X buffer/DNA Degradase Plus™/water, 
2.5/1/1.5, v/v/v) was added to 20 µL of the eluted genomic DNA in an HPLC injector vial. The 
samples were incubated overnight at 37 ºC. 
Media samples processing. Culture media (20 µL) was collected at the indicated time points. 
Stock solutions (10 mM) of [U-13C10,15N5]dA, and [15N3]dC (Cambridge Isotope Laboratories) 
were prepared individually in dimethyl sulfoxide (DMSO), and stored at – 20 ºC before use as 
internal standards. The solutions were diluted to 20 nM in methanol to generate working 
solutions. Calibration standards were prepared by spiking working stock solutions of 
[U-13C10,15N5]dA and [U-13C9,15N3]dC with blank media to give concentrations in the 10 nM - 10 
µM range. Each 20 µL calibration standard sample was mixed with 60 µL of internal standard 
solution, mixed for 30 s and centrifuged (15,000 x g, 10 min, 4ºC). After centrifugation, 60 µL of 
the supernatant was transferred into an HPLC injector vial for LC-MS/MS-MRM analysis. Media 
samples were processed similarly and in parallel to the calibration standard samples to 
minimize the experimental variability. 
Targeted LC-MS/MS-MRM assays. For genomic DNA and media analysis, an aliquot of the 
hydrolyzed DNA or media samples (20 µL) were injected onto a porous graphitic carbon column 
(Thermo Fisher Scientific Hypercarb, 100 x 2.1 mm, 5 µm particle size) equilibrated in solvent A 
(water 0.1% formic acid, v/v ) and eluted (200 µL/min) with an increasing concentration of 
solvent B (acetonitrile 0.1% formic acid, v/v) using min/%B/flow rates (µL/min) as follows: 
0/0/200, 5/0/200, 10/15/200, 20/15/200, 21/40/200, 25/50/200, 26/100/700, 30/100/700, 
31/0/700, 34/0/700, 35/0/200. For free nucleotide analysis, a modified version of the same 
previously reported method1 was used in which each dNTP lysate sample (20 µL) was injected 
directly onto the Hypercarb column equilibrated in solvent C (5 mM hexylamine and 0.5% 
diethylamine, v/v, pH 10.0) and eluted (200 µL/min) with an increasing concentration of solvent 
D (acetonitrile/water, 50/50, v/v) at the following min/%D/flow rates (µL/min): 0/0/200, 5/0/200, 
10/15/200, 20/15/200, 21/40/200, 25/50/200, 26/100/700, 30/100/700, 31/0/700, 34/0/700, 
35/0/200. The effluent from the column was directed to the Agilent Jet Stream ion source 
connected to the triple quadrupole mass spectrometer (Agilent 6460) operating in the multiple 
reaction monitoring (MRM) mode using previously optimized settings. The peak areas for each 
nucleosides and nucleotides (precursor→fragment ion transitions) at predetermined retention 
times were recorded using the software supplied by the instrument manufacturer (Agilent 
MassHunter). 
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Quantification. The area for nucleotides measurements were obtained from extracted ion 
chromatograms of MRM ion transitions. These measurements were normalized from the spiked 
internal standards ([15N3]dCMP and [15N3]dCTP). A calibration curve was prepared to convert 
the normalized areas of nucleotides to absolute quantitation, pmol/106 cells. For DNA, the area 
for the hydrolyzed labeled nucleosides were obtained from extracted ion chromatograms of 
MRM ion transitions. These measurements were normalized to the total ion current at that 
retention time. To calculate the DNA labeled pmol/106 cells, the peak area ratio for a given 
biosynthetic pathway was multiplied by 1089.3, the dCTP pmol amount needed to replicate the 
entire genomic DNA from 106 cells (assuming the size of the genomic DNA per cell to be 3.2 
billion base pair with 41% GC content). 
Non-targeted LC-MS metabolic assays. 1 x 106 cells were washed with ice-cold 150 mM 
ammonium acetate twice before adding 1 mL of ice-cold 80% methanol with 10 nM norvaline as 
an internal standard. After vigorous vortexing, samples were centrifuged at maximum speed, the 
aqueous layer was transferred to a glass vial and the metabolites were dried under vacuum. 
Metabolites were resuspended in 50 μL 70% acetonitrile (ACN) and 5 μL of this solution used for 
the mass spectrometer-based analysis. The analysis was performed on a Q Exactive (Thermo 
Scientific) in polarity-switching mode with positive voltage 4.0 kV and negative voltage 4.0 kV. 
The mass spectrometer was coupled to an UltiMate 3000RSLC (Thermo Scientific) UHPLC 
system. Mobile phase A was 5 mM ammonium acetate (NH4AcO), pH 9.9, B was acetonitrile 
and the separation achieved on a Luna 3 mm NH2 100 A column (150 × 2.0 mm, Phenomenex). 
The flow was 200 μL/min, and the gradient ran from 15% A to 95% A in 18 min, followed by an 
isocratic step for 9 min and re-equilibration for 7 min. Metabolites were detected and quantified 
as area under the curve based on retention time and accurate mass (≤ 3 p.p.m.) using the 
TraceFinder 3.1 (Thermo Scientific). Relative amounts of metabolites between various 
conditions, as well as percentage of [13C6]glucose labelling, were calculated and corrected for 
naturally occurring 13C abundance. 
Proteomic analyzes. CCRF-CEM cells were treated ± with a CDK4/6 inhibitor, PD-0332991 
(Selleckchem) for 18 h to arrest at G1 phase. Cells were then washed twice with PBS and 
released in fresh media with treatment at a density of 1 x 106 cells/mL. Cells were collected at 
12 h, washed twice with ice-cold PBS, and lysed by trituration using 1 mL per 5 x 107 cells of 
0.5% sodium deoxycholate, 12 mM sodium lauryl sarcosine, and 50 mM triethylammonium 
bicarbonate, pH 8.0. Lysates were heated at 95 ºC for 5 min and water bath sonicated at room 
temperature (RT) for 5 min. Bicinchoninic acid protein assay (Pierce) was performed to 
determine protein concentration. Disulfide bridges were reduced with 5 mM tris(2-
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carboxyethyl)phosphine (final concentration) at RT for 30 min with subsequent treatment with 10 
mM iodoacetamide (final concentration) at RT in the dark for 30 min. Solutions were diluted 1:5 
(v:v) with 50 mM triethylammonium bicarbonate. Proteins were cleaved with sequencing grade 
trypsin (Promega) at 1:100 (enzyme:protein) for 4 h at 37 ºC followed by a second aliquot of 
trypsin 1:100 (enzyme:protein) overnight at 37 ºC. Samples were acidified with 0.5% 
trifluoroacetic acid (final concentration), vortexed rapidly for 5 min, and centrifuged (16,000 x g 
for 5 min, RT) to pellet sodium deoxycholate. Supernatants were transferred to new 
microcentrifuge tubes and 20 µg of total peptide were desalted using C18 StageTips as 
previously described3. On-column dimethyl labeling using C18 StageTips was performed as 
previously described4. Briefly, StageTips were equilibrated with 20 μL of 250 mM 2-(N-
morpholino)ethanesulfonic acid (MES) pH 5.5. Tryptic peptides were dimethyl labeled using 60 
mM sodium cyanoborohydride, 0.4% formaldehyde, and 250 mM MES pH 5.5 for 10 min. 
Dimethyl labeled peptides were eluted from StageTips using 20 μL of 80% acetonitrile with 0.1% 
trifluoroacetic acid and lyophilized to dryness. Labeled peptides were reconstituted with 2% 
acetonitrile and 0.1% formic acid (loading buffer). The light, medium, and heavy labeled 
peptides were mixed 1:1:1 (light:medium:heavy), diluted with loading buffer to a final peptide 
concentration of 0.2 µg/µL and 1 µg total peptide was analyzed using 180 min data-dependent 
nLC-MS/MS on Thermo Orbitrap XL as later discussed. Light, medium, and heavy labeled 
samples were mixed using the protein median ratios as normalization from the “trial” analysis. 
48 µg of mixed light, medium, and heavy labeled peptides were sub-fractionated using strong 
cation exchange (SCX) StageTips as previously described3. Briefly, 8 fractions were made using 
25, 35, 50, 70, 90, 150, 350, and 750 mM ammonium acetate in 30% acetonitrile and 0.5% 
acetic acid. Each SCX fraction was desalted using C18 StageTips, vacuum concentrated to 1 
µL, and resuspended with 10 µL of loading buffer. 5 µL of each fraction was analyzed using 180 
min data-dependent reverse-phase nLC-MS/MS on Thermo Orbitrap XL and Thermo QExactive 
Plus for synchronous and asynchronous cells, respectively, equipped with Eksigent Spark 
autosampler, Eksigent 2D nanoLC, and Phoenix ST Nimbus dual column source. Briefly, 
samples were loaded onto laser-pulled reverse-phase nanocapillary (150 µm I.D., 360 µm O.D. 
x 25 cm length) with C18 (300 Å, 3 µm particle size) (AcuTech Scientific) for 30 min with mobile 
phase A (2% acetonitrile and 0.1% formic acid) at 500 nL/min. Peptides were analyzed over 180 
min linear gradient of 0-40% mobile phase B (98% acetonitrile and 0.1% formic acid) at 300 nL/
min. Electrospray ionization and source parameters for Orbitrap XL were as follows: spray 
voltage of 2.2 kV, capillary temperature of 200oC, capillary voltage at 35 V, and tube lens at 90 
V. Data-dependent MS/MS for Orbitrap XL was operated using the following parameters: full MS 
from 400-1700 m/z with 60,000 resolution at 400 m/z and target ion count of 3 x 105 or fill time 
of 700 ms, and twelve MS/MS with charge-state screening excluding +1 and unassigned charge 
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states, isolation width of 2.0 m/z, target ion count of 5,000 or fill time of 50 ms, CID collision 
energy of 35, and dynamic exclusion of 30 sec. For QExactive Plus, the electrospray ionization 
and source parameters were as follows: spray voltage of 1.6 kV, capillary temperature of 200oC, 
and S-lens RF level of 50. Data-dependent MS/MS for QExactive Plus was operated using the 
following parameters: full MS from 400-1700 m/z with 70,000 resolution at 400 m/z and target 
ion count of 3 x 106 or fill time of 100 ms, and twenty MS/MS with charge-state screening 
excluding +1 and unassigned charge states, 17,500 resolution at 400 m/z, isolation width of 2.0 
m/z, target ion count of 50,000 or fill time of 50 ms, HCD collision energy of 27, and dynamic 
exclusion of 30 sec. Raw data was searched against Uniprot human database using MaxQuant 
1.5.3.30 with standard preset search parameters. Briefly, the search parameters were as 
follows: 3-plex dimethyl labeling to lysine and peptide N-terminus, trypsin cleavage allowing up 
to 2 missed cleavages, fixed modification of carbamidomethyl to cysteines, variable 
modifications of acetylation to protein N-terminus and methionine oxidation, 10 ppm mass error 
for full MS, 0.5 Da and 20 mmu mass errors for MS/MS for Orbitrap XL and QExactive Plus, 
respectively, score of 40 or greater for modified peptides, 1% false-discovery rate on peptide 
and protein identifications, and peptide match between run feature with 1.5 min time window. 
Phosphoproteomic analyses. CCRF-CEM cells were prepared same as the asynchronous 
CEM cells total protein digests above, except that a total of 7.5 mg total protein from 1 x 108 
cells was collected per treatment condition for phosphoproteomic analysis. tC18 Sep-Pak 
cartridges (Waters) were used for peptide desalting and Pierce Quantitative Colorimetric 
Peptide Assay was performed prior to phosphopeptide enrichment. Hydrophilic interaction 
chromatography (HILIC) and immobilized metal affinity chromatography (IMAC) were performed 
same as previously described5. Data dependent nLC-MS/MS was performed on Thermo 
QExactive Plus same as above. Raw data was searched against Uniprot human database using 
MaxQuant 1.5.3.30 with the following search parameters: trypsin cleavage allowing up to 2 
missed cleavages, fixed modification of carbamidomethyl to cysteines, variable modifications of 
acetylation to protein N-terminus, methionine oxidation, and phosphorylation to serine, 
threonine, and tyrosine, 10 ppm and 20 mmu mass errors for full MS and MS/MS, respectively, 
score of 40 or greater for modified peptides, and 1% false-discovery rate on peptide and protein 
identifications. Identified phosphopeptides were manually quantified by area-based extracted 
ion chromatograms of the monoisotopic peak. 
Plasma collection and pharmacokinetic assays. Blood was collected in heparin-EDTA tubes 
by retro-orbital technique at time points 0.25, 1, 6, and 24 h time points from the first set of mice 
and 0.5, 4, and 12 h from the second set of mice. Blood samples were spun at 2000 x g for 15 
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min and the plasma supernatants were collected. All plasma samples were frozen down at –20 
ºC before sample processing. The stock solutions of 3-AP, VE-822, DI-82, 3-AP analog (NSC 
266749), VE-821 (Selleckchem), DI-39 were prepared individually by dissolving the appropriate 
amount of each drug in a known volume of dimethyl sulfoxide (DMSO) to a 10 mM 
concentration and were stored at –20ºC before use. The 3-AP analog, VE-821 and DI-39 
(internal standards) were diluted to 200 nM in methanol to make the internal solution. The 
calibration standards were prepared by spiking working stock solutions of 3-AP, VE-822 and 
DI-82 in plasma from untreated mice to give 0.01-10 pmol/µL range. Each 20 µL calibration 
standard sample was mixed with 60 µL of internal solution (methanol with 200 nM internal 
standards) and vortexed for 30 s. Following centrifugation at 15,000 x g for 10 min, 
approximately 60 µL of sample was carefully transferred into HPLC injector vials for LC-MS/MS-
MRM analysis. Plasma samples were processed the same way as the calibration standard 
samples. 20 μL samples were injected onto a reverse phase column, (Thermo Scientific 
Hypersil GOLD column 3.0 µm; 2.1 x 100 mm) equilibrated in water/formic acid, 100/0.1, and 
eluted (200 μL/min) with an increasing concentration of solvent B (acetonitrile/formic acid, 
100/0.1, v/v: min/% acetonitrile; 0/0, 5/0, 15/60, 16/100, 19/100, 20/0, and 25/0). The effluent 
from the column was directed to the Agilent Jet Stream ion source connected to the triple 
quadrupole mass spectrometer (Agilent 6460) operating in the multiple reaction monitoring 
(MRM) mode using previously optimized settings. The following drug precursor→fragment ion 
transitions were used: 3-AP (196→179), DI-82 (511→369), VE-822 (464→533), VE-821 
(369→276), 3AP-analog (199→182), DI-39 (525→383). The peak areas for each drug 
(precursor→fragment ion transitions) at predetermined retention times were recorded using the 
software supplied by the instrument manufacturer (Agilent MassHunter). 
FACS and flow cytometry analyses 
Cell cycle histograms (measurements of DNA content). Cells were plated at a density of 0.5 
x 106 cells/mL in respective media or drug treated media. Following 24 h incubation, cells were 
harvested and washed twice with PBS twice before staining with 0.5 ml of propidium iodide 
(Calbiochem, #P3566, 1 µg/mL) solution containing Ribonuclease A and 0.3% Triton-X 100. The 
samples were protected from light before acquisition by flow cytometry.  
Cell cycle kinetics (pulse chase analysis) and cell cycle progression (synchronous chase 
pulse analysis) by intracellular detection of DNA-incorporated 5-ethynyl-2-deoxyuridine 
(EdU). CEM T-ALL cells were plated at a density of 0.5 x 106 cells/mL. Cells were pulsed with 
10 µM EdU (Invitrogen) for 1 h, washed twice with PBS, and released in fresh media containing 
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5 µM deoxyribonucleosides, with and without drugs. Cells were collected at different time points 
following release in fresh media, and then fixed with 4% paraformaldehyde and permeabilized 
using saponin perm/wash reagent (Invitrogen). Cells were then stained with azide-Alexa Fluor 
647 by Click reaction according to manufacturer’s protocol (Invitrogen; Click-iT EdU Flow 
cytometry kit, #C10634). The total DNA content was assessed by staining the samples with 
FxCycle-Violet (Invitrogen, #F10347) at 1 µg/mL final concentration in PBS containing 2% FBS. 
To measure the cell cycle progression of a synchronous population of cells, cells were first 
arrested in the G1 phase following treatment with 1 µM Palbociclib for 18 h, then washed and 
released in fresh media supplemented with drugs. Before collecting and fixing the cells at 
different time points, the cells were pulse-labeled with 10 µM EdU for 1 h, and then labeled with 
azide-Alexa Fluor 647 (Invitrogen; Click-iT EdU Flow cytometry kit). Total DNA content was 
assessed by staining with FxCycle-Violet (Invitrogen) at 1 µg/mL final concentration in PBS 
containing 2% FBS. 
pH2A.X staining. Cells were harvested, fixed and permeabilized with cytofix/cytoperm (BD 
biosciences, #554722) for 15 min on ice protected from light. Cells were washed, then 
resuspended in 100 µL 1X Perm/wash buffer (BD Sciences) and incubated for 15 min on ice. 
The cells were washed, then resuspended in 50 µL with phospho-Histone H2A.X (Ser139) 
antibody conjugated to fluorochrome FITC (EMD Millipore, #05-636, 1:800 dilutions in perm/
wash) for 20 min in the dark at RT. Subsequently, cells were washed and stained with 0.5 mL of 
DAPI (Invitrogen, #D1306) for DNA content (1 µg/mL in 2% FBS in PBS) before data 
acquisition.  
Measurement of single stranded DNA (ssDNA) levels using the F7-26 monoclonal 
antibody. Cells were harvested and fixed with ice-cold methanol:PBS (6:1 v/v) for 24h. Staining 
with F7-26 monoclonal mouse antibody was performed according to manufacturer’s instructions 
(EMD Millipore, #MAB3299). Fixed cells were resuspended in 250 µL of formamide and heated 
in a water bath at 75 ºC for 10 min. Cells were then allowed to equilibrate to room temperature 
and then washed with 2 mL of 1% non-fat dry milk in PBS for 15 min. Subsequently, cells were 
resuspended in 100 µL of anti-ssDNA Mab F7-26 (EMD Millipore, 1:10 in 5% FBS in PBS) and 
incubated for 45 min at room temperature. Cells were washed with PBS and stained with 100 µL 
of fluorescence-conjugated goat anti-mouse IgM antibody (Santa Cruz Biotechnology, #sc-3768, 
1:50) for 45 min at room temperature. Cells were then washed with PBS, stained with 0.5 mL of 
DAPI for DNA content (1 µg/mL in 2% FBS in PBS) before data acquisition.  
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Phospho-histone 3 staining. Cells were treated with drug combinations of three drugs. 24 h 
following treatment, cells were fixed and permeabilized with 1% PFA and 1X Perm/wash 
solution respectively.  Following fixation and permeabilization, cells were stained intracellularly 
with pH3 Ser10 antibody conjugated to AF647 (Cell signaling, #12230). Cells were then washed 
with PBS, stained with 0.5 mL of DAPI for DNA content (1 µg/mL in 2% FBS in PBS) before data 
acquisition.  
Annexin V staining. Cells were treated with the indicated treatments for 24 or 72 h, then 
collected and washed twice with 1 mL of FACS buffer (2% FBS in PBS). Induction of apoptosis 
and cell death were assayed by staining the cells with Annexin V-FITC and PI according to 
manufacturer’s instructions (FITC Annexin V Apoptosis Detection Kit, BD Sciences, #556570). 
FACS analysis. All flow cytometry data were acquired on five-laser LSRII cytometers (BD) for 
analysis, and analyzed using FlowJo software (Tree Star). The cell cycle durations were 
calculated using equations for multiple time-point measurements according to previously 
published methods (Terry and White, 2006). 
Animal studies. Mice were housed under specific pathogen-free conditions and were treated in 
accordance with UCLA Animal Research protocol guidelines. All C57BL/6 female mice were 
purchased from the UCLA Radiation Oncology breeding colony. VE-822 (ApeXBio, 40 mg/kg), 
3-AP (ApeXBio, dosage as indicated) and DI-82 (dCKi, Sundia Pharmaceuticals, 50 mg/kg) 
were administered by intraperitoneal (i.p.) injections or oral gavage to recipient animals. For oral 
administration, single agent or combination of drugs were solubilized in a formulation consisting 
of the following: PEG-200: Transcutol: Labrasol: Tween-80 mixed in 5:3:1:1 ratio. For i.p. 
administration, the drugs were solubilized in PEG-400 and 1 mM Tris-HCl in a 1:1 (v:v) ratio. 
Dasatinib (LC Laboratories) was solubilized in 80 mM citric acid (pH 3.1) and was administered 
at a dose of 10 mg/kg by oral gavage. 2 x 105 luciferase expressing p185BCR-ABLArf–/– pre-B-ALL 
cells were injected intravenously into C57BL/6 female mice for leukemia induction. The 
treatment was started 6 or 7 days after the intravenous inoculation of leukemia initiating cells, 
when animals had developed a significant leukemic burden as monitored by bioluminescence 
imaging (IVIS Bioluminescence Imaging scanner). The dosing schedules are indicated in the 
text and figure legends. The mice were observed daily and those that became moribund during 
the trials, (paralysis of hind limbs, significant body weight loss) were sacrificed immediately. 
Kaplan-Meier curves and bioluminescence quantifications were generated using Prism 6.0h 
(Graphpad Software).  
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Bioluminescence imaging (BLI). Mice were anesthetized with 2% isoflurane followed by 
intraperitoneal injection of 50 μL (50 mg/mL) substrate D-luciferin (Sigma, #L9504). The mice 
were imaged with the IVIS 100 Bioluminescence Imaging scanner 10 minutes after luciferin 
administration. All mice were imaged in groups of five with 1-minute exposure time, and the 
images were acquired at low binning.  
Statistical Analyses. Data are presented as means ± SD with indicated biological replicates. 
Comparisons of two groups were calculated using indicated unpaired or paired two-tailed 
Student’s t-test and P values less than 0.05 were considered significant. For some experiments, 
generated mean normalized values (ratios from two groups, treated to untreated) were 
compared to the hypothetical value 1 (indicating equal values between treated and untreated), 
calculated using one-sample t-test, and P values less than 0.05 were considered significant. 
Comparisons of more than two groups were calculated using one-way ANOVA followed by 
Bonferroni’s multiple comparison tests, and P values less than 0.05/m, where m is the total 
number of possible comparisons, were considered significant. The Benjamini–Hochberg false 
discovery rate (FDR) method was used to adjust the P values for multiple testing in 
metabolomic and proteomic studies. An FDR q value ≤ 0.2 was used as a threshold for 
significance. All statistical analysis and generated graphs were performed either in R or 
Graphpad Prism 6.0h. 
The rates of dCTP incorporation into the DNA were determined using linear regression with 
procedure GLM in SAS (v. 9.4). DNA % label was transformed using a shifted log addition of 1 
due to the presence of zeros in the data set. Rates were calculated using the slope of the 
regression line for the log transformed data and are presented in the table with the associated 
standard errors, along with the ratio between the rate of incorporation into DNA by the de novo 
and salvage pathways (Table 1). 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RESULTS 
Inhibition of ATR and dCK impairs G1/S transition in T-ALL cells and alters substrate 
utilization for dCTP biosynthesis.  
Human T-ALL cells CCRF-CEM (subsequently referred to as “CEM”) express dCK and exhibit 
constitutive phosphorylation of the ATR effector kinase CHEK1 on Serine 345 (pS345, 
Supplementary Fig. 2a), a marker of replication stress34. CHEK1 pS345 levels are reduced 
following exposure to VE-822, a specific ATR inhibitor35 (Supplementary Fig. 2a). To investigate 
whether ATR inhibition increases the dependence of T-ALL cells on dCK activity at the G1/S 
transition, CEM cells were synchronized in G1 using Palbociclib, a CDK4/6 inhibitor36,37, and 
then released from G1 arrest into media containing VE-822 and/or DI-82, a high affinity 
competitive dCK inhibitor (dCKi) developed by our group38. At various time points following G1 
release, cells were pulsed for 1 h with 5’-ethynyl-2’-deoxyuridine (EdU) to analyze cell cycle 
kinetics by flow cytometry. Six hours after release from G1, ~25% of cells in the untreated and 
single drug treated groups advanced into early S-phase (designated as S1, in blue, Fig. 1a). In 
contrast, only 16% of cells treated with both VE-822 and dCKi entered S1. Twelve hours after 
release from G1 arrest, 16% fewer VE-822-treated cells entered the later part of S-phase 
(designated as S2, in red, Fig. 1b) compared to untreated cells. While at this time point dCK 
inhibition alone did not affect the number of cells that progressed beyond early S phase, 
progression to late S-phase was significantly impeded (Supplementary Fig. 2b). Co-inhibition of 
ATR and dCK decreased the percentage of cells that reached S2 by five-fold relative to 
untreated cells (Fig. 1b). The effects of ATR inhibition on cell cycle kinetics were partially 
rescued by nucleotide supplementation, in a dCK-dependent manner (Supplementary Fig. 2c 
and 2d).  
To further investigate the functions of dCK and ATR at the G1/S transition in CEM cells, a non-
targeted liquid chromatography mass spectrometry (LC-MS) assay was used to determine the 
utilization of labeled [13C6]glucose and [13C9,15N3]deoxycytidine, the main substrates for de novo 
and salvage nucleotide biosynthesis, respectively. Of the 166 metabolites identified in CEM cells 
treated with VE-822 and/or dCKi, 105 metabolites found in all four treatment groups contained 
glucose-derived 13C atoms. While ATR inhibition did not decrease glucose uptake and labeling 
of glycolytic intermediates (Supplementary Fig. 3), it significantly decreased glucose utilization 
for 29 other metabolites (Fig. 1c and Supplementary Table 1). These metabolites included 
intermediates such as rUTP, rCTP, and rCDP in the de novo dCTP biosynthesis (Fig. 1d). These 
data indicate that ATR inhibition impacts glucose utilization for de novo nucleotide biosynthesis. 
However, several deoxyribonucleotides, including dCTP, were below the limit of detection of the 
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non-targeted LC-MS approach, raising the concern that the sensitivity of this assay is not 
sufficient to measure the contribution of the salvage pathway or the ratio of de novo and salvage 
biosynthesis to these pools. To address this problem, a newly developed targeted mass 
spectrometric assay was developed (Fig. 1e and Supplementary Fig. 4). In this assay, samples 
containing either extracted dNTPs or hydrolyzed DNA from labeled cells are separated by liquid 
chromatography for detection by a triple quadrupole mass spectrometer (QQQ) using multiple 
reaction monitoring (LC-MS/MS-MRM). The first (Q1) and third (Q3) quadrupoles function as 
mass filters, while the second (Q2) quadrupole serves as a collision chamber (Fig. 1e). For 
instance, to profile the biosynthetic composition of deoxycytidine (dC) derived from hydrolyzed 
DNA or dCTP, an intact, protonated dC ion is selected in Q1, followed by fragmentation of the 
glycosidic bond, which releases in Q2 a protonated nucleobase, cytosine, that is filtered in Q3 
and detected to generate an ion chromatogram. The peak areas for the ion chromatograms of 
salvage [13C9,15N3]dC (red trace), de novo [13C5]dC (black trace, from [13C6]glucose) and 
unlabeled dC (gray trace) (Fig. 1e) are used to determine the relative contributions of the de 
novo and salvage routes both to dCTP pools and to dCTP incorporated into DNA.  
Since dCK phosphorylates not only dC but also dA and dG5, the targeted LC-MS/MS-MRM 
assay was first used to determine whether, in T-ALL cells, dCK mediates the salvage of multiple 
deoxyribonucleosides (dNs). However, salvaging of purine dNs via dCK occurred only if the 
catabolic enzymes which degrade these dNs, adenosine deaminase (ADA) and purine 
nucleoside phosphorylase (PNP), were inhibited pharmacologically (Supplementary Fig. 5 and 
6). Since inactivating mutations in ADA and PNP have been associated with severe combined 
immunodeficiency39, but not with cancer, we focused on examining the metabolic fate of dC as 
the most relevant dCK substrate in ATR-inhibited T-ALL cells for salvage biosynthesis. CEM 
cells were collected at multiple points after release from Palbociclib-induced G1 arrest into 
media containing VE-822 and/or dCKi, as well as substrates for the de novo and salvage 
pathways, [13C6]glucose and [13C9, 15N3]dC, respectively. At each of the examined time points, 
free dCTP pools in untreated cells were predominantly synthesized by the salvage pathway 
from [13C9,15N3]dC via dCK, with only a small contribution from [13C6]glucose via the de novo 
pathway (Fig. 1f). While ATR inhibition alone did not alter free dCTP levels or their biosynthetic 
origins (e.g. de novo vs. salvage), dCKi either alone or in combination with VE-822, nearly 
eliminated the contribution of the salvage pathway and reduced the amount of free dCTP by 
~50% at the 12 h time point.  
In contrast to the free dCTP pool, which was predominantly derived from the salvage pathway, 
dCTP incorporated into newly replicated DNA of CEM cells was produced in equal proportions 
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by the de novo and salvage pathways (Fig. 1g and Table 1). This observation is consistent with 
previous findings that de novo synthesized dCTP is more readily incorporated in DNA than is 
dCTP synthesized by the salvage pathway12. ATR inhibition reduced the DNA incorporation of 
both de novo and salvage produced dCTP, yielding a combined 30% reduction in overall DNA 
labeling compared to untreated cells at the 12 h time point (Fig. 1g and Table 1). This reduction 
is consistent with the literature showing replication fork collapse and delays in restarting DNA 
replication following ATR inhibition in other cell types40–43. dCK inhibition abolished the 
incorporation of salvage produced dCTP into newly replicated DNA and triggered a 
compensatory increase in the DNA incorporation of de novo generated dCTP. This 
compensatory response was suppressed in cells treated with both VE-822 and dCKi (Fig. 1g 
and Table 1).  
ATR inhibition alters protein and phosphorylation levels of de novo and salvage 
nucleotide biosynthetic enzymes.  
To investigate the molecular mechanisms underlying the metabolic consequences of ATR and 
dCK inhibition, global changes in protein expression were assessed in CEM cells using 
quantitative nano-liquid chromatography tandem mass spectrometry (nLC-MS/MS) (Fig. 2a). 
Chemical isotope coding following reductive dimethylation of peptide N-termini and lysine 
primary amines with differential stable isotopes (light:medium:heavy) was used to compare 
expression of experimental (VE-822, dCKi, and VE-822 + dCKi) samples to controls (untreated, 
NT) by mixing equal proportions for triplex nLC-MS/MS quantitative analyses. The proteomics 
dataset was filtered for proteins identified in all treatment groups in three independent 
experiments with coefficients of variation <20%. This yielded 1757 proteins with relative fold 
changes in treated vs. untreated cells ranging from 0.45 to 1.83. Of these, about 3% (46 
proteins) displayed statistically significant (as determined by one-way ANOVA and false 
discovery rate cut-offs) fold changes in expression (>20%) in at least one treatment group (Fig. 
2b and Supplementary Table 2). Protein levels of both RNR subunits, RRM1 and RRM2, as well 
as thymidylate synthase (TYMS) decreased by more than 20% following ATR inhibition (Fig. 2c). 
Changes in the expression of de novo enzymes observed in synchronous cells also occurred 
with ATR inhibition in asynchronous CEM cells (Fig. 2d, Supplementary Table 3), thereby 
arguing against the possibility of experimental artifacts introduced by Palbociclib-mediated cell 
cycle synchronization. The reduction in RRM2 protein levels induced by ATR inhibition was 
accompanied by an ~50% decrease in the phosphorylation of RRM2 on threonine 33 (pT33) 
(Fig. 2e), a phosphosite previously linked to the stability of the RRM2 subunit44.  
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ATR inhibition decreased dNTP levels in several solid tumor-derived cell lines and has been 
linked to reduced RRM2 levels26,45. However, it remains unclear to what degree RRM2 protein 
levels are rate-limiting for de novo dCTP biosynthesis. To further investigate the relationship 
between RRM2 protein levels and dCTP biosynthesis, we knocked down RRM2 in CEM cells 
using shRNA (Supplementary Fig. 7a). RRM2 levels in the CEM shRNARRM2 cells were reduced 
by 35–50%, as determined by quantitative nLC-MS/MS and intracellular flow cytometry 
analyses (Supplementary Fig. 7a and 7b). The CEM shRNARRM2 cells exhibited approximately 
30% lower incorporation of de novo synthesized dCTP into newly replicated DNA compared to 
control cells (Supplementary Fig. 7c); a response comparable with the effects of 
pharmacological ATR inhibition (Fig. 1g). These findings suggest that the RRM2 regulation by 
ATR is an important determinant of de novo dCTP biosynthesis in T-ALL cells. Since ATR 
inhibition reduced RRM2 levels by only 20%, it is likely that there are other mechanisms by 
which ATR regulates de novo dCTP biosynthesis. These additional mechanisms could include 
reduced levels of the large RNR subunit, RRM1 (Fig. 2c and 2d), and/or changes in yet to be 
identified regulatory PTMs in RRM1 and RRM2 that are modulated directly or indirectly by ATR 
signaling.  
In contrast to the reduced RRM1 and RRM2 levels in response to ATR inhibition, dCK protein 
levels were not affected (Fig. 2c and 2d). A recent study showed that ATR directly 
phosphorylates dCK on serine 74 (dCK pS74) to control its activity under replication stress28. 
We therefore quantified the effects of ATR inhibition on the biosynthetic output and 
phosphorylation status of dCK. Used as a positive control, the dCKi reduced dCK activity, as 
defined by contribution of labeled [13C9,15N3]dC to intracellular dCMP, by almost 90% (Fig. 2f, 
left panel). ATR inhibition in CEM cells reduced the dCK-labeled [13C9,15N3]dCMP pool by ~33% 
compared to untreated cells (Fig. 2f, left panel). The reduction in dCMP biosynthesis following 
ATR inhibition correlated with a ~36% decrease in dCK pS74 levels (Fig. 2f, right panel). 
Collectively, these data (summarized in Fig. 2g) show that, in T-ALL cells, ATR regulates de 
novo and salvage nucleotide biosynthetic pathways by diverse mechanisms involving alterations 
in total protein (ATR) and protein phosphorylation (dCK) levels. Nonetheless, both de novo and 
salvage pathways retain significant activity in ATR inhibited CEM cells and therefore, may allow 
these cells to survive therapeutic interventions that interfere with ATR signaling. 
Effects of the RNR inhibitor 3-AP on de novo and salvage dCTP biosynthesis in CEM 
cells.  
To identify the most potent clinically relevant RNR inhibitors that could be used to target the 
remaining de novo nucleotide biosynthetic activity in ATR inhibited CEM cells we evaluated four 
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compounds, each with a distinct mechanism of action: (3-AP)46,47, hydroxyurea (HU)48, gallium 
maltolate (GaM)49, and thymidine (dT)50 (Fig. 3a). Amongst these, 3-AP was the most potent, as 
indicated by its ability to induce S-phase arrest at concentrations as low as 0.5 µM (Fig. 3b and 
Supplementary Fig. 8). In contrast, 60 to 100-fold higher concentrations of HU, GaM, and dT 
were required to induce S-phase arrest. The effects of 3-AP on the utilization of [13C6]glucose 
and [13C5, 15N3]dC for nucleotide biosynthesis in CEM cells were investigated (Fig. 3c), using the 
targeted LC-MS/MS-MRM assay. 3-AP doubled the rCTP and rCDP pools, likely reflecting an 
inefficient conversion of these pools to dCDP via RNR. However, the most significant change in 
3-AP treated cells occurred downstream of RNR and involved a ~19-fold reduction in the 
incorporation of de novo produced dCTP into newly replicated DNA. Along with its effects on de 
novo biosynthesis, 3-AP triggered a compensatory upregulation of the salvage pathway. 
Salvage dC nucleotide pools doubled in size following 3-AP treatment, and the incorporation of 
salvage-produced dCTP into DNA increased by >1.5-fold, thereby providing a potential 
mechanism of resistance to RNR inhibition by 3-AP (Fig. 3c). 
Co-targeting ATR, RNR and dCK in CEM cells induces significant alterations in 
nucleotide metabolism followed by replication stress overload and caspase-8 mediated 
apoptosis.  
Having identified 3-AP as a clinically relevant and potent RNR inhibitor that can be used to 
directly target the remaining de novo activity in ATR treated T-ALL cells, we next quantified the 
impact of combined ATR, dCK and RNR inhibition on the de novo and salvage dCTP 
biosynthesis in asynchronous CEM cells (Fig. 4a and Supplementary Table 4). ATR inhibition 
decreased the [13C6]glucose labeling of the rCDP pool by 40% (Fig. 4a, rCDP panel), an effect 
similar to that observed in the synchronous model (Fig. 1d). In contrast, RNR inhibition 
increased the size of the rCDP pool (Fig. 4a, rCDP panel, 3-AP). While neither ATR nor RNR 
inhibition alone had a statistically significant impact on the de novo contributions to the dCDP, 
dCMP and dCTP pools, these pools were nearly abolished when both ATR and RNR were 
inhibited simultaneously. However, the salvage biosynthetic contributions to the dCMP, dCDP 
and dCTP pools remained substantial in the absence of the dCKi. In fact, RNR inhibition, alone 
or combined with ATR inhibition, increased the salvage contributions to the dCMP, dCDP, and 
dCTP pools by approximately two-fold, indicative of a compensatory mechanism. dCK inhibition 
abolished this adaptive mechanism to augment these deoxyribonucleotide pools. Consequently, 
the rate of dCTP incorporation into newly replicated DNA was lowest when all three enzymes 
were inhibited (Fig. 4a, DNA panel). 
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Persistent nucleotide insufficiency triggers replication stress characterized by the accumulation 
of single-stranded DNA (ssDNA) at stalled replication forks, which progresses to DNA double 
stranded breaks (DSBs)51. To investigate these events following ATR, dCK, and RNR inhibition, 
we used flow cytometry and antibodies against ssDNA52 as an indicator of replication stress, 
and phosphorylated histone H2A.X on serine 139 (pH2A.X) as an indicator of DNA damage 
(Fig. 4b). RNR inhibition by 3-AP increased the percentage of ssDNA+ cells by more than two-
fold as early as 0.5 h after treatment, and by greater than three-fold at the 4 h time point. 
Combined inhibition of ATR and dCK also increased the ssDNA+ and ssDNA+;pH2A.X+ cell 
populations at the 0.5 and 4 h time points. Addition of an RNR inhibitor resulted in a rapid and 
massive (>12-fold) expansion of ssDNA+ population at the 0.5 h time point compared to 
untreated cells, an effect which was further amplified at the later time point (Fig. 4b). Along with 
these changes, RNR inhibition triggered rapid induction of CHEK1 pS345, a direct downstream 
target of ATR (Fig. 4c). This PTM was abrogated by VE-822 treatment at the 0.5 h time point 
and partially inhibited at the 4 h time point. The rebound in CHEK1 pS345 expression at the 4 h 
time point was likely mediated by the ATR related kinase, ataxia telangiectasia mutated (ATM), 
which also phosphorylates CHEK1 on serine 34553. ATM was activated in cells treated with the 
triple combination therapy, as indicated by an increase in phosphorylation of CHEK2 on 
threonine 68 (pT68, Fig. 4c); a direct target of activated ATM. The induction of CHEK2 pT68 in 
cells treated with the triple combination therapy coincided with an increase in the pH2A.X+ 
population (Fig. 4b) and with cleavage of the apoptotic markers caspase 8 (but not caspase 9), 
caspase 3, and Poly (ADP-ribose) polymerase (PARP) (Fig. 4c). Consistent with these 
observations, co-targeting ATR, dCK, and RNR resulted in the highest percentage of apoptotic 
cells, as measured by Annexin V staining (Supplementary Fig. 9a). The cytotoxic effect of ATR 
inhibitors has been attributed to the induction of premature mitotic entry of cells undergoing DNA 
replication, an event that exacerbates the level of replication stress and DNA damage54,55. 
Consistent with this model, ATR inhibition increased the percentage of S-phase CEM cells with 
phosphorylation of histone 3 on serine 10 (H3 pS10), a marker for mitotic kinase activation. This 
effect was significantly amplified in the triple combination therapy and correlated with the 
induction of apoptosis (Supplementary Fig. 9b). 
ATR inhibition alone is marginally effective in a systemic primary B-ALL mouse model.  
To investigate the in vivo efficacy and tolerability of co-targeting alternative nucleotide 
biosynthetic pathways and ATR, we used a previously described primary BCR-ABL-expressing 
Arf-null pre-B (p185BCR-ABLArf–/–) model which is difficult-to-treat and thought to be representative 
of the human disease31,33. When compared with 31 cancer cell lines of different origins, 
p185BCR-ABLArf–/– cells were amongst the most sensitive to ATR inhibition by VE-822, with an IC50 
!22
value of ~300 nM (Fig. 5a). However, despite its high potency in culture against pre-B-ALL cells, 
VE-822 alone was only marginally efficacious in vivo. C57BL/6 mice inoculated with luciferase 
expressing p185BCR-ABLArf–/– cells succumbed to disease within 17 days; all VE-822 treated mice 
died of leukemia within 38 days after inoculation (Fig. 5b–d). We then investigated whether 
targeting the activities of de novo and salvage pathways can improve the efficacy of ATR 
inhibition in p185BCR-ABLArf–/– cells. Similar to the findings in the human T-ALL cells, targeting 
these biosynthetic pathways along with ATR was necessary to achieve maximal induction of cell 
death (Fig. 5e) and complete inhibition of cell growth (Supplementary Fig. 10a and 10b).  
Co-targeting ATR, dCK, and RNR is well-tolerated and promotes long-term survival in a 
systemic primary B-ALL mouse model.  
To translate the above cell culture findings into an in vivo setting, we first developed a new drug 
formulation consisting of PEG-200, Transcutol, Labrasol, and Tween-80 blended in a ratio of 
5:3:1:1 to solubilize three different drugs (3-AP, VE-822, and dCKi) and achieve therapeutically 
relevant plasma concentrations via oral delivery (Fig. 6a). Based on the observed plasma 
pharmacokinetic parameters, 3-AP and dCKi were administered twice/day while VE-822 was 
administered once/day (Fig. 6b). Treatment was initiated on day 7 post-inoculation of pre-B-ALL 
when all mice showed evidence of systemic disease, as indicated by whole body 
bioluminescence imaging (BLI, Fig. 6c, top row, right panel). While mice in the control group 
succumbed to disease within 17 days, mice in the combination treatment group had significantly 
lower disease burden on day 17 (Fig. 6c and 6d). All treated mice remained disease-free for 442 
days after treatment withdrawal, 42 days post-inoculation of pre-B-ALL (Fig. 6e). The 
combination therapy was well-tolerated, as indicated by maintenance of body weight during 
treatment (Fig. 6f) and long term survival (over 1 year and currently ongoing) without any 
detectable pathology. We also assessed the efficacy of the combination therapy when all 3 
components were administered once daily. Although this therapeutic scheme appeared to be 
slightly less efficacious than the twice/day schedule for 3-AP and dCKi, it was well tolerated and 
four out of five mice had no detectable disease 313 days after treatment withdrawal 
(Supplementary Fig. 11). Importantly, removing the dCKi from the combination therapy 
significantly reduced the therapeutic efficacy in vivo (Supplementary Fig. 12), a result consistent 
with cell culture findings (Fig. 4, Fig, 5e, Supplementary Fig. 9 and 10).  
While BCR-ABL tyrosine kinase inhibitors are becoming standard care for patients with 
Philadelphia chromosome positive ALL56, therapeutic resistance in pre-B-ALL is common and is 
caused by the rapid emergence of the T315I BCR-ABL kinase domain (“gatekeeper”) mutation 
which renders this class of kinase inhibitors ineffective32,56. To test the combination of VE-822, 
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dCKi, and 3-AP against kinase inhibitor resistant ALL we generated p185BCR-ABLArf–/– T315I 
mutant cells by exposing the leukemia bearing mice to dasatinib and harvesting drug-resistant 
cells from bone marrow (Supplementary Fig. 13a–c). Mice were inoculated with the T315I-
positive cells and treated with the combination therapy (Supplementary Fig. 13d–g). The 
combination therapy was effective against the highly aggressive dasatinib resistant in vivo pre-
B-ALL model with 13 of 20 mice being disease-free over 365 days post-inoculation of leukemia 
cells (Supplementary Fig. 13). To determine whether mice that did not achieve complete 
remissions harbor ALL cells that have acquired resistance to the triple combination, we 
harvested leukemia cells from the bone marrow of the moribund mice. These cells were then 
used to test the efficacy of the combination treatment in cell culture, and compare it with the 
original dasatinib-resistant p185BCR-ABLArf–/– pre-B-ALL cells. The harvested leukemia cells 
responded to the combination treatment as well as did the parental cells (Supplementary Fig. 
14). One potential reason for the incomplete response in some of the treated mice is the rapid 
engraftment of p185BCR-ABLArf–/– T315I+ pre-B-ALL cells in the brain coupled with the suboptimal 
penetrability of 3-AP and potentially, dCKi across the blood-brain-barrier. 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DISCUSSION 
Here we show that ATR inhibition in leukemia cells reduces the output of both de novo and 
salvage pathways. However, significant remaining activities of both pathways were sufficient to 
prevent ATR inhibition-induced DNA replication shutdown in cell culture, and were sufficient to 
permit disease-induced lethality in a systemic mouse model of pre-B-ALL. Combining ATR 
inhibition with specific inhibitors of de novo (RNR) and salvage (dCK) rate-limiting enzymes led 
to rapid accumulation of ssDNA, a hallmark of replication stress22, followed by extensive DNA 
damage, caspase-8 and PARP cleavage, and apoptosis. This synthetically lethal combination 
therapy was well-tolerated in vivo and promoted long-term disease free survival in mice with 
systemic p185BCR-ABLArf–/– pre-B-ALL, as well as in a mouse model of targeted-therapy 
(dasatinib) pre-B-ALL resistance. Collectively our results quantify the control exerted by ATR on 
convergent nucleotide biosynthetic routes, and provide the rationale to co-target both signaling 
(ATR) and metabolic (RNR and dCK) mechanisms in acute leukemia for optimal therapeutic 
efficacy. 
In mammalian cells dCTP and other dNTPs are present in low concentrations (1-50 pmol of 
dCTP/106 cells); amounts far below those required to complete one round of genome 
duplication (~1089 pmol of dCTP/106 cells)14,57. This apparent discrepancy between dNTP 
supply and demand can be explained by a model in which dNTP production is tightly coupled 
with utilization for DNA synthesis – an “on demand” model. A key prediction of this model is that 
even small disruptions of dNTP production could significantly impact DNA integrity, unless the 
demand for dNTPs is reduced by preventing new origin firing, a process regulated by ATR and 
its effector kinases43. This prediction is supported by the synthetic lethality observed with ATR 
inhibition and pharmacological targeting of the de novo and salvage pathways observed in cell 
culture (Fig. 5e, Supplementary Fig. 9, 10, and 14) and in vivo (Fig. 6c–f, Supplementary 11–
13). These findings also suggest that more accurate estimates of the nucleotide biosynthetic 
capacity of cancer cells should account both for alternative free nucleotide pools and for their 
potential differential accessibility for substrates that are incorporated into replicated DNA (Fig. 
1e–g, Fig. 3c, and Fig. 4a).  
To what extent are our findings of differential utilization of de novo and salvage pathways in 
leukemia applicable to solid tumors? An examination of three patient-derived primary cells point 
to significant nucleotide biosynthetic diversity in solid tumors (Supplementary Fig. 15a). HK-374 
glioblastoma multiforme (GBM) cells58 preferentially use the de novo pathways to generate most 
of their dATP, dGTP, and dCTP pools, with only the dTTP pool displaying a significant salvage 
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component. A distinct nucleotide biosynthetic profile is present in two melanoma patient-derived 
primary cells, M299 and M417 (Supplementary Fig. 15a). In M299 cells, the salvage contribution 
to all four dNTPs exceeds 50%. Except for dATP, a similarly increased reliance on salvage 
biosynthesis was evident in M417 cells (Supplementary Fig. 15a). In contrast, de novo 
pyrimidine biosynthesis is almost completely absent in M417 cells, with greater than 98% of the 
dTTP and dCTP pools originating from salvage pathways. Stable isotope labeling studies using 
[15N2]orotate show that both M417 and M229 patient-derived primary cells efficiently used this 
substrate to produce dCTP, thereby suggesting a block in de novo pyrimidine biosynthesis in 
M417 cells either at the level of carbamoylphosphate synthetase II (CAD) or at the level of 
dihydroorotate dehydrogenase (Supplementary Fig. 15b and 15c). Indeed, M417 cells were 
subsequently found to harbor a homozygous nonsense mutation (Q140*) in CAD 
(Supplementary Fig. 15d). Predictably, the defect in de novo pyrimidine biosynthesis rendered 
M417 cells hypersensitive to dCK inhibition (Supplementary Fig. 15e). Confirmation of these 
findings in larger panels of cell lines and patient derived primary samples would provide the 
rationale for developing new metabolically targeted therapies and clinically applicable 
biomarkers to define specific nucleotide biosynthetic subtypes (e.g. predominant de novo, 
predominant salvage, and both de novo and salvage) in solid tumors. Such biomarkers could be 
provided by Positron Emission Tomography (PET) imaging using new probes for nucleotide 
metabolism developed by us59,60 as well as by others61.  
Post-translational regulation and modifications (PTMs) can have profound and dynamic effects 
on the activity of metabolic networks62. Both dCK30 and RRM244,63 contain multiple PTMs. 
Among the four phosphorylation sites reported for dCK30, phosphorylation on serine 74 (pS74) 
is an important determinant of dCK substrate specificity and catalytic activity29. Both ATR and 
ATM have been reported to phosphorylate dCK on S74 in response to replication stress and 
DNA damage respectively28,64. Our data show that the ATR inhibitor VE-822 reduces dCK 
activity by ~33%, an effect likely attributed to a two-fold decrease in dCK pS74 (Fig. 2f). 
However, it remains unknown what kinases are responsible for the remaining dCK pS74 present 
in VE-822 treated leukemia cells. ATM is a potential candidate, given that phosphorylation of 
CHEK2 on T68 is detected in ATR inhibited cells (Fig. 4c). Further studies are needed to confirm 
this hypothesis. In this context, it may also be informative to analyze the activity of dCK 
following ATR inhibition in tumors harboring inactivating mutations in ATM65–67. Concerning RNR 
regulation, the observed consequences of ATR inhibition in T-ALL cells include the following: a 
decrease in RRM2 protein levels (Fig. 2c and 2d), reduced RRM1 protein levels (Fig. 2c and 
2d), and a significant reduction in RRM2 pT33 (Fig. 2e), a CDK-mediated phosphorylation event 
which promotes RRM2 proteasomal degradation via interactions with the SCFCyclin F ubiquitin 
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ligase complex44. It is currently unknown whether the reduction in RRM2 levels by ATR inhibition 
in leukemia cells occurs via a post-translational mechanism concerning protein stability and/or 
by a transcriptional mechanism downstream of E2F family members68,69. Moreover, further 
studies are needed to determine the significance of the observed reductions in RRM1 protein 
levels following ATR inhibition (Fig. 2c and 2d) and to identify the mechanism responsible for 
this effect. 
Our results provide quantitative insights into alterations of nucleotide biosynthetic pathways 
induced in leukemia cells by inhibiting ATR and rate-limiting de novo (RNR) and salvage (dCK) 
enzymes. These findings support a new therapeutic strategy that uses existing inhibitors to 
exploit the dependency of leukemia cells on intact de novo and salvage biosynthetic pathways 
and replication stress response mechanisms. This strategy fits within the concept of targeting 
non-oncogene addiction proposed by Elledge and colleagues13. Further refinements in this 
strategy and expanding its applicability beyond leukemia may come from follow-up studies to 
define clinically applicable companion biomarkers capable of delineating nucleotide biosynthetic 
and replication stress subtypes that are predictive of responses in human tumors. 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FIGURES 
Fig. 1.1. Effects of ATR and dCK inhibition on G1-S transition and substrate utilization for 
dCTP biosynthesis. (a and b) Flow cytometry analysis of EdU incorporation in CEM T-ALL 
cells treated with VE-822 (1 µM) and/or dCKi (DI-82,1 µM) for 6 (a) and 12 h (b) following 
release from G1 arrest, respectively. Bar graphs summarize the percentage of cell populations 
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Figure 1 | Effects of ATR and dCK inhibition on G1-S transition and substrate utilization for dCTP biosynthesis. (a and b) 
Flow cytometry analysis of EdU incorporation in CEM T-ALL cells treated with VE-822 (1 µM) and/or dCKi (DI-82,1 µM) for 6 (a) and 
12 h (b) following release from G1 arrest, respectively. Bar graphs summarize the percentage of cell populations in S1 (early S-
phase) and S2 (mid to late S-phase) at 6 and 12 h (mean ± s.d., n = 2, one-way ANOVA, Bonferroni corrected). Plots are 
representative of two independent experiments. (c) Comparison of metabolite labeling by [13C6]glucose in CEM T-ALL cells treated 
with VE-822 and/or dCKi for 12 h following release from G1 arrest. Number of metabolites exhibiting alterations in [13C6]glucose 
labeling greater than 15% with significance at a false discovery rate (FDR) ≤ 20% are indicated. (d) Percent glucose labeling of 
ribonucleotides intermediates in the de novo dCTP biosynthesis (mean ± s.d., n = 6, one-way ANOVA, Bonferroni corrected). (e) 
Workflow for targeted LC-MS/MS-MRM analysis of dCTP incorporated into newly replicated DNA using a triple quadrupole mass 
spectrometer (QQQ). See text for details and Supplementary Fig. 4 for the LC-MS/MS-MRM analysis of dCTP pools. (f and g) 
Contributions of the de novo and salvage pathways to dCTP pools (f) and dCTP incorporated into newly synthesized DNA (g) in 
CEM c lls treated with VE-822 and/or dCKi after rele se from G1 arrest ( e n ± s.d., n = 3). Results ar  repres ntative of two 
independent experiments. 
NT = Not treated, V = VE-822, D = dCKi, V+D = VE-822 + dCKi. 
* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. 
ATR ataxia telangiectasia and Rad3-related protein; EDU 5’-ethynyl-2’-deoxyuridine; FDR false discovery rate; RNR ribonucleotide 
reductase; CTPS1/2 CTP synthase 1/2; R5P ribose 5-phosphate; OMP orotidine monophosphate; rCDP cytidine diphosphate; CTP 
cytidine triphosphate; UTP uridine triphosphate; dCTP deoxycytidine triphosphate; LC-MS/MS-MRM liquid chromatography tandem 
mass spectrometry operating in multiple reaction monitoring.
in S1 (early S-phase) and S2 (mid to late S-phase) at 6 and 12 h (mean ± s.d., n = 2, one-way 
ANOVA, Bonferroni corrected). Plots are representative of two independent experiments. (c) 
Comparison of metabolite labeling by [13C6]glucose in CEM T-ALL cells treated with VE-822 
and/or dCKi for 12 h following release from G1 arrest. Number of metabolites exhibiting 
alterations in [13C6]glucose labeling greater than 15% with significance at a false discovery rate 
(FDR) ≤ 20% are indicated. (d) Percent glucose labeling of ribonucleotides intermediates in the 
de novo dCTP biosynthesis (mean ± s.d., n = 6, one-way ANOVA, Bonferroni corrected). (e) 
Workflow for targeted LC-MS/MS-MRM analysis of dCTP incorporated into newly replicated 
DNA using a triple quadrupole mass spectrometer (QQQ). See text for details and 
Supplementary Fig. 4 for the LC-MS/MS-MRM analysis of dCTP pools. (f and g) Contributions 
of the de novo and salvage pathways to dCTP pools (f) and dCTP incorporated into newly 
synthesized DNA (g) in CEM cells treated with VE-822 and/or dCKi after release from G1 arrest 
(mean ± s.d., n = 3). Results are representative of two independent experiments. 
NT = Not treated, V = VE-822, D = dCKi, V+D = VE-822 + dCKi. 
* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. 
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Fig. 1.2. Alterations in total protein and phosphoprotein levels following ATR and dCK 
inhibition. (a) Workflow for quantitative global proteomics using nLC-MS/MS. See text for 
details. (b) Comparison of protein levels in CEM cells treated with VE-822 and/or dCKi for 12 h 
following release from G1 arrest. Number of proteins exhibiting fold changes greater than 15% 
changes with significance at a false discovery rate (FDR) ≤ 20% are indicated. (c) Protein levels 
of nucleotide biosynthetic enzymes (mean ± s.d., n = 3, one-way ANOVA, Bonferroni corrected). 
(d) Protein levels in asynchronous CEM cells treated with VE-822 (1 µM) for 12 h (mean ± s.d., 
n = 3, one sample t-test to assess if the mean of the protein level normalized to untreated 
control is equal to one). (e) Relative level of RRM2 pT33 normalized to RRM2 protein level from 
(d), in asynchronous CEM cells treated with VE-822 (1 µM) for 12 h (mean ± s.d., n = 3, 
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Figure 2 | Alterations in total protein and phosphoprotein levels following ATR and dCK inhibition. (a) Workflow for 
quantitative global proteomics using nLC-MS/MS. See text for details. (b) Comparison of protein levels in CEM cells treated with 
VE-822 and/or dCKi for 12 h following release from G1 arrest. Number of proteins exhibiting fold changes greater than 15% changes 
with significance at a false discovery rate (FDR) ≤ 20% are indicated. (c) Protein levels of nucleotide biosynthetic enzymes (mean ± 
s.d., n = 3, one-way ANOVA, Bonferroni corrected). (d) Protein levels in asynchronous CEM cells treated with VE-822 (1 µM) for 12 h 
(mean ± s.d., n = 3, one sample t-test to assess if the mean of the protein level normalized to untreated control is equal to one). (e) 
Relative level of RRM2 pT33 normalized to RRM2 protein level from (d), in asynchronous CEM cells treated with VE-822 (1 µM) for 
12 h (mean ± s.d., n = 3, unpaired two-tailed Student’s t-test). (f, left panel) Salvage produced [13C9,15N3]dCMP in asynchronous 
CEM cells treated with VE-822 or dCKi for 12 h (mean ± s.d., n = 3, o e-way ANOVA, Bonferroni corrected). (f, right panel) Relative 
levels of dCK pS74, after normalized to dCK protein level from (d), in asynchronous CEM cells treated with VE-822 (1 µM) for 12 h 
(mean ± s.d., n = 3, unpaired two-tailed Student’s t-test). (g) Summary of the observed effects of ATR and dCK inhibition in CEM 
cells. ↓ partial decrease/inhibition, ↓↓↓ nearly complete inhibition, ↑ increase, ⟷ no change, nd not determined. 
NT = Not treated, V = VE-822, D = dCKi, V+D = VE-822 + dCKi. 
* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. 
nLC-MS/MS nano liquid chromatography tandem mass spectrometry; RRM1 ribonucleotide reductase subunit 1; RRM2 
ribonucleotide reductase subunit 2; TYMS thymidylate synthase; dCK deoxycytidine kinase; dCMP deoxycytidine monophosphate.
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unpaired two-tailed Student’s t-test). (f, left panel) Salvage produced [13C9,15N3]dCMP in 
asynchronous CEM cells treated with VE-822 or dCKi for 12 h (mean ± s.d., n = 3, one-way 
ANOVA, Bonferroni corrected). (f, right panel) Relative levels of dCK pS74, after normalized to 
dCK protein level from (d), in asynchronous CEM cells treated with VE-822 (1 µM) for 12 h 
(mean ± s.d., n = 3, unpaired two-tailed Student’s t-test). (g) Summary of the observed effects of 
ATR and dCK inhibition in CEM cells. ↓ partial decrease/inhibition, ↓↓↓ nearly complete 
inhibition, ↑ increase, ⟷ no change, nd not determined. 
NT = Not treated, V = VE-822, D = dCKi, V+D = VE-822 + dCKi. 
* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. 
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Fig. 1.3. 3-AP potently inhibits RNR and enhances salvage nucleotide biosynthesis. (a) 
Mechanisms of action of four RNR inhibitors. The two RNR subunits, RRM1 (α) and RRM2 (β) 
form a catalytically active α2β2 complex. Each RRM1 subunit contains two allosteric regulatory 
sites (the specificity and activity sites), as well as the active site, where nucleotide reduction 
!32
Specificity site
Activity site
Active site NDP
dNDP
RRM1
RRM2
3+Fe
Y–O
Y–OH Y–OH Y–OH
HU
Y–O
dTTP
dT 
GDP, ADP
dGDP, dADP
3-AP GaM
3+GaMet-β2 Apo-β2
Figure 3 | 3-AP potently inhibits RNR and enhances salvage nucleotide biosynthesis. (a) Mechanisms of action of four RNR 
inhibitors. The two RNR subunits, RRM1 (α) and RRM2 (β) form  catalytically active α2β2 complex. Each RRM1 subunit contains 
two allosteric regulatory sites (the specificity and activity sites), as well as the active site, where nucleotide reduction occurs. The 
active form of the RRM2 dimer (holo-β2) houses the di-iron cofactor and the tyrosyl radical (Y-O•). 3-AP forms a complex with Fe2+ 
which interferes with the regenerati n of the tyrosyl radical in RRM2 therefore promoting the formation of an in ctive met-β small 
subunit which retains its di-iron center7. Hydroxyurea (HU) scavenges the RRM2 tyrosyl radical and depletes the di-iron center to 
form an inactive apo-β form. Gallium maltolate (GaM) releases Ga3+ which mimics Fe3+ and disrupts the RRM2 di-iron center. 
Thymidine (dT) is converted via the salvage pathway to thymidine triphosphate (dTTP) which binds to the allosteric specificity site on 
RRM1 to favor GDP reduction over pyrimidine (CDP and UDP) reduction, thereby resulting in dCTP insufficiency. (b) Effects of RNR 
inhibitors on cell cycle progression. CEM cells were incubated for 24 h with indicated concentrations of RNR inhibitors followed by 
cell cycle analyses using flow cytometry. Shown in bold red are the concentrations of each RNR inhibitor required to induce a greater 
than 45% increase in the S-phase population, indicative of S-phase arrest due to nucleotide insufficiency. Cell cycle plots are 
representative of two independent experiments. See Supplementary Fig. 8 for quantification. (c) LC-MS/MS-MRM analysis of dCTP 
biosynthesis in CEM cells treated with 500 nM 3-AP for 12 h (mean ± s.d., n = 3).  
NT: not treated. 
CMPK1 uridine-cytidine monophosphate kinase 1; NME1/2 nucleoside diphosphate kinase 1/2; dC 2’-deoxycytidine; dCMP 
deoxycytidine monophosphate; dCDP deoxycytidine diphosphate.
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occurs. The active form of the RRM2 dimer (holo-β2) houses the di-iron cofactor and the tyrosyl 
radical (Y-O•). 3-AP forms a complex with Fe2+ which interferes with the regeneration of the 
tyrosyl radical in RRM2 therefore promoting the formation of an inactive met-β small subunit 
which retains its di-iron center7. Hydroxyurea (HU) scavenges the RRM2 tyrosyl radical and 
depletes the di-iron center to form an inactive apo-β form. Gallium maltolate (GaM) releases 
Ga3+ which mimics Fe3+ and disrupts the RRM2 di-iron center. Thymidine (dT) is converted via 
the salvage pathway to thymidine triphosphate (dTTP) which binds to the allosteric specificity 
site on RRM1 to favor GDP reduction over pyrimidine (CDP and UDP) reduction, thereby 
resulting in dCTP insufficiency. (b) Effects of RNR inhibitors on cell cycle progression. CEM 
cells were incubated for 24 h with indicated concentrations of RNR inhibitors followed by cell 
cycle analyses using flow cytometry. Shown in bold red are the concentrations of each RNR 
inhibitor required to induce a greater than 45% increase in the S-phase population, indicative of 
S-phase arrest due to nucleotide insufficiency. Cell cycle plots are representative of two 
independent experiments. See Supplementary Fig. 8 for quantification. (c) LC-MS/MS-MRM 
analysis of dCTP biosynthesis in CEM cells treated with 500 nM 3-AP for 12 h (mean ± s.d., n = 
3). NT: not treated. 
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Fig. 1.4. Synthetic lethality induced by combined inhibition of ATR, dCK and RNR. (a) LC-
MS/MS-MRM analysis of dCTP biosynthesis in CEM cells treated as indicated in the text for 12 
h (mean ± s.d., n = 3). Results are representative of two independent experiments. (b, left 
panels) Flow cytometry analyses of ssDNA (F7-26) and pH2A.X levels in CEM cells treated as 
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Figure 4 | Synthetic lethality induced by combined inhibition of ATR, dCK and RNR. (a) LC-MS/MS-MRM analysis of dCTP 
biosynthesis in CEM cells treated as indicated in the text for 12 h (mean ± s.d., n = 3). Results are representative of two independent 
experiments. (b, left panels) Flow cytometry analyses of ssDNA (F7-26) and pH2A.X levels in CEM cells treated as indicated for 0.5 
and 4 h. (b, right panels) Bar gr phs summarizing the percentage of ssDNA+ and ssDNA+;pH2A.X+ cells at 0.5 and 4 h, respectively 
(mean ± s.d., n = 2, one-way ANOVA, Bonferroni corrected). ssDNA-pH2A.X plots are representative two independent experiments. 
(c) Representative immunoblots of CEM cells treated as indicated in the text for 0.5 and 4 h. 
* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. 
ssDNA single-stranded DNA; DSB double-stranded breaks; PARP Poly (ADP-ribose) polymerase.
pH
2A
.X
indicated for 0.5 and 4 h. (b, right panels) Bar graphs summarizing the percentage of ssDNA+ 
and ssDNA+;pH2A.X+ cells at 0.5 and 4 h, respectively (mean ± s.d., n = 2, one-way ANOVA, 
Bonferroni corrected). ssDNA-pH2A.X plots are representative two independent experiments. 
(c) Representative immunoblots of CEM cells treated as indicated in the text for 0.5 and 4 h. 
* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. 
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Fig. 1.5. ATR inhibition alone is effective but not sufficient to achieve disease-free 
survival in a systemic primary B-ALL model. (a) IC50 values of VE-822 in a panel of cancer 
cell lines and patient-derived samples (CellTiter-Glo assay at 72 h, mean ± s.d., n = 3). (b and 
c) Bioluminescence images (b) and quantification of whole-body radiance (c) of leukemia 
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Figure 5 | ATR inhibition alone is effective but not sufficient to achieve disease-free survival in a systemic primary B-ALL 
model. (a) IC50 values of VE-822 in a panel of cancer cell lines and patient-derived samples (CellTiter-Glo assay at 72 h, mean ± 
s.d., n = 3). (b and c) Bioluminescence images (b) and quantification of whole-body radiance (c) of leukemia bearing mice treated 
with 40 mg/kg VE-822 (n = 6) or vehicle (control, n = 6). VE-822 was administered once daily. (d) Kaplan-Meier survival analysis of 
C57BL/6 mice bearing p185BCR-ABLArf–/– systemic pre-B-ALL treated with 40 mg/kg/day VE-822 (n = 6) or vehicle (control, n = 6). 
Median survival for the control group was 15 days after treatment initiation and 32.5 days for the VE-822 group (Mantel-Cox test). (e) 
Apoptosis induction in p185BCR-ABLArf–/– pre-B-ALL cells treated as indicated (350 nM 3-AP, 100 nM VE-822, and 1 µM dCKi) for 72 h 
using flow cytometry for A nexin V an  PI staining (mean ± s.d., n = 2, one-w y ANOVA, Bonferroni corrected). 
* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. 
HCC hepatocellular carcinoma; PDAC pancreatic ductal adenocarcinoma.
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bearing mice treated with 40 mg/kg VE-822 (n = 6) or vehicle (control, n = 6). VE-822 was 
administered once daily. (d) Kaplan-Meier survival analysis of C57BL/6 mice bearing p185BCR-
ABLArf–/– systemic pre-B-ALL treated with 40 mg/kg/day VE-822 (n = 6) or vehicle (control, n = 6). 
Median survival for the control group was 15 days after treatment initiation and 32.5 days for the 
VE-822 group (Mantel-Cox test). (e) Apoptosis induction in p185BCR-ABLArf–/– pre-B-ALL cells 
treated as indicated (350 nM 3-AP, 100 nM VE-822, and 1 µM dCKi) for 72 h using flow 
cytometry for Annexin V and PI staining (mean ± s.d., n = 2, one-way ANOVA, Bonferroni 
corrected). 
* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. 
HCC hepatocellular carcinoma; PDAC pancreatic ductal adenocarcinoma. 
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Fig. 1.6. The triple combination therapy is effective and well-tolerated in a systemic 
primary B-ALL model. (a) Plasma pharmacokinetic parameters for 3-AP (15 mg/kg), VE-822 
(40 mg/kg) and dCKi (50 mg/kg) in C57BL/6 mice (n ≥ 3) after single dose oral co-administration 
(mean ± s.d., n ≥ 3). (b) Doses and schedules for the triple combination therapy of leukemia 
bearing mice. (c and d) Bioluminescence images (c) and quantification of whole body radiance 
(d) of leukemia bearing mice treated with the combination therapy (treated, n = 5) or vehicle 
(control, n = 5) at indicated days after tumor inoculation. See also Supplementary Fig. 11–13. (e 
and f) Kaplan-Meier survival analysis (e) and body weight measurements (f) of leukemia 
bearing mice treated with the combination therapy (treated, n = 5) or vehicle (control, n = 5). 
Median survival for the control group was 14 days after treatment initiation, whereas median 
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Figure 6 | The triple combination therapy is effective and well-tolerated in a systemic primary B-ALL model. (a) Plasma 
pharmacokinetic parameters for 3-AP (15 mg/kg), VE-822 (40 mg/kg) and dCKi (50 mg/kg) in C57BL/6 mice (n ≥ 3) after single dose 
oral co-administration (mean ± s.d., n ≥ 3). (b) Doses and schedules for the triple combination therapy of leukemia bearing mice. (c 
and d) Bioluminescence images (c) and quantification of whole body radiance (d) of leukemia bearing mice treated with the 
combination therapy (treated, n = 5) or vehicle (control, n = 5) at indicated days after tumor inoculation. See also Supplementary Fig. 
11–13. (e and f) Kaplan-Meier survival analysis (e) and body weight measurements (f) of leukemia bearing mice treated with the 
combination therapy (treated, n = 5) or vehicle (control, n = 5). Median survival for the control group was 14 days after treatment 
initiation, whereas median survival for the treated group remains undefined (Mantel-Cox test). 
* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. 
q.d. once/day; b.i.d. twice/day.
survival for the treated group remains undefined (Mantel-Cox test).* P < 0.05; ** P < 0.01; *** P 
< 0.001; **** P < 0.0001. q.d. once/day; b.i.d. twice/day. 
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Fig. S1.1. Constitutive ATR activation in CEM T-ALL cells and its role in cell cycle 
progression. (a) Representative pS345 CHEK1 immunoblots of CEM cells ± VE-822 (1 µM) for 
24 h. (b) Flow cytometry analysis of EdU incorporation in CEM T-ALL cells treated with VE-822 
(1 µM) and/or dCKi (DI-82,1 µM) for 12 h following release from G1 arrest. Bar graphs 
!40
Supplementary Figure 1 | Constitutive ATR activation in CEM T-ALL cells and its role in cell cycle progression. (a) 
Representative pS345 CHEK1 immunoblots of CEM cells ± VE-822 (1 µM) for 24 h. (b) Flow cytometry analysis of EdU incorporation 
in CEM T-ALL cells treated with VE-822 (1 µM) and/or dCKi (DI-82,1 µM) for 12 h following release from G1 arrest. Bar graphs 
summarize the percentage of cell populations in S3 (late S-phase) 12 h (mean ± s.d., n = 2, one-way ANOVA, Bonferroni corrected). 
Plots are representative of wo independent experiments. (c) Cell cycle analyses of synchronous CEM T-ALL cells treated with 
VE-822 (1 µM) and/or dCKi (DI-82,1 µM) in the presence or absence of 10 µM dNTPs for 12 h following release from G1 arrest. (d) 
Cell cycle analyses of asynchronous CEM T-ALL cells treated with VE-822 (1 µM) and/or dCKi (DI-82,1 µM) in the presence or 
absence of 10 µM dNTPs for 12 h. Bar graph summarize the percentage of cell p pulations in S-phase at 12 h (mean ± s.d., n = 2, 
one-way ANOVA, Bonferroni corrected).
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summarize the percentage of cell populations in S3 (late S-phase) 12 h (mean ± s.d., n = 2, 
one-way ANOVA, Bonferroni corrected). Plots are representative of two independent 
experiments. (c) Cell cycle analyses of synchronous CEM T-ALL cells treated with VE-822 (1 
µM) and/or dCKi (DI-82,1 µM) in the presence or absence of 10 µM dNTPs for 12 h following 
release from G1 arrest. (d) Cell cycle analyses of asynchronous CEM T-ALL cells treated with 
VE-822 (1 µM) and/or dCKi (DI-82,1 µM) in the presence or absence of 10 µM dNTPs for 12 h. 
Bar graph summarize the percentage of cell populations in S-phase at 12 h (mean ± s.d., n = 2, 
one-way ANOVA, Bonferroni corrected). 
 
Fig. S1.2. ATR inhibition minimally impacts glucose labeling in the glycolysis of CEM T-
ALL cells. Percent glucose labeling of glycolytic metabolites (mean ± s.d., n = 6, one-way 
ANOVA). 
Glc glucose; G6P/F6P glucose 6-phosphate/fructose 6-phosphate; F1,6BP fructose 1,6-
bisphosphate; DHAP dihydroacetone phosphate; G3P glyceraldehyde 3-phosphate; 3PG 3-
phosphoglycerate; PEP phosphoenolpyruvate; Pyr pyruvate; Lac lactate. 
* P < 0.05; ** P < 0.01; *** P < 0.001. 
!41
Supplementary Figure 2 | ATR inhibition minimally impacts glucose labeling in the glycolysis of CEM T-ALL cells. Percent 
glucose labeling of glycolytic metabolites (mean ± s.d., n = 6, one-way ANOVA). 
Glc glucose; G6P/F6P glucose 6-phosphate/fructose 6-phosphate; F1,6BP fructose 1,6-bisphosphate; DHAP dihydroacetone 
phosphate; G3P glyceraldehyde 3-phosphate; 3PG 3-phosphoglycerate; PEP phosphoenolpyruvate; Pyr pyruvate; Lac lactate. 
* P < 0.05; ** P < 0.01; *** P < 0.001.
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 Fig. S1.3. Workflow for the targeted mass spectrometric analysis used in Fig. 2 to 
measure dCTP pools. Optimally, nucleotides should be monitored in the positive mode to 
precisely measure the labeled atoms on the nucleobase and sugar moieties. To enable such 
measurements, we expanded on the work by Cohen and colleagues1 who reported the use of 
ion pairing reagents. With the addition of diethylamine (DEA) in the mobile phase, nucleotides 
have their negative charge phosphate group masked by DEA and their nucleobase becomes 
protonated. Under these conditions, nucleotides with the DEA adduct were monitored in the 
positive mode as [NTP−DEA−H]+ and the fragmentation of the adduct nucleotide ions resulted 
in protonated nucleobases. 
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Supplementary Figure 3 | Workflow for the targeted mass spectrometric analysis used in Fig. 2 to measure dCTP pools. 
Optimally, nucleotides should be monitored in the positive mode to precisely measure the labeled atoms on the nucleobase and 
sugar moieties. To enable such measurements, we expanded on the work by Cohen and colleagues1 who reported the use of ion 
pairing reagents. With the addition of diethylamine (DEA) in the mobile phase, nucleotides have their negative charge phosphate 
group masked by DEA and their nucleobase becomes protonated. Under these conditions, nucleotides with the DEA adduct were 
monitored in the positive mode as [NTP−DEA−H]+ and the fragmentation of the adduct nucleotide ions resulted in protonated 
nucleobases.
Fig. S1.4. dCK-dependent dATP production from dA requires ADA inhibition (companion 
for Fig. 1). (a) Schematic representation and the 13C and 15N labeling pattern of the de novo 
and salvage dATP biosynthetic pathways. dA can be salvaged as a nucleobase through the 
actions of ADA, PNP, and HPRT or as an intact deoxyribonucleoside via dCK. The former 
salvage pathway is blocked by Pentostatin (dCF), a specific adenosine deaminase (ADA) 
inhibitor; the latter salvage pathway is blocked by DI-82, a dCK inhibitor (dCKi). (b–d) Jurkat 
cells were treated with dCF (10 µM) ± dCKi (1 µM) in culture media containing 11 mM 
[13C6]glucose and 5 µM [15N5]dA for 18 h. (b) [15N5]dA levels in the cell culture media 18 h after 
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Supplementary Figure 4 | dCK-dependent dATP production from dA requires ADA inhibition (companion for Fig. 1). (a) 
Schematic representation and the 13C and 15N labeling pattern of the de novo and salvage dATP biosynthetic pathways. dA can be 
salvaged as a nucleobase through the actions of ADA, PNP, and HPRT or as an intact deoxyribonucleoside via dCK. The former 
salvage pathway is blocked by Pentostatin (dCF), a specific adenosine deaminase (ADA) inhibitor; the latter salvage pathway is 
blocked by DI-82, a dCK inhibitor (dCKi). (b–d) Jurkat cells were treated with dCF (10 µM) ± dCKi (1 µM) in culture media containing 
11 mM [13C6]glucose and 5 µM [15N5]dA for 18 h. (b) [15N5]dA levels in the cell culture media 18 h after treatment initiation (mean ± 
s.d., n = 3, one-way ANOVA, Bonferroni corrected). (c) Biosynthetic routes to produce free dATP and dATP incorporated into newly 
replicated DNA 18 h after treatme  initiation: de novo from [13C6]glucose vi  RNR, [15N5]dA salvage via dCK catalyzed 
phosphorylation, and HPRT mediated salvage of [15N5]hypoxanthine (Hx) produced from [15N5]dA following deamination, and 
glycosidic bond cleavage catalyzed by ADA and PNP, respectively (mean ± s.d., n = 3). (d) Fold changes in total dNTP levels 18 h 
after treatment initiation (mean ± s.d., n = 3, one-way ANOVA, Bonferroni corrected). (e) Cell cycle analyses of Jurkat cells treated as 
indicated for 24 h. (f) Quantification of cells in S (left panel) and G2/M (right panel) after the indicated treatments for 24 h (mean ± 
s.d., n = 2). (g) Representative immunoblots of CHEK1, CHEK2 and H2A.X phosphorylation; cells were treated as indicated for 24 
h.  
* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. 
dCF Pentostatin; ADA adenosine deaminase; PNP purine phosphorylase; Hx hypoxanthine; HPRT hypoxanthine 
phosphoribosyltransferase.
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treatment initiation (mean ± s.d., n = 3, one-way ANOVA, Bonferroni corrected). (c) Biosynthetic 
routes to produce free dATP and dATP incorporated into newly replicated DNA 18 h after 
treatment initiation: de novo from [13C6]glucose via RNR, [15N5]dA salvage via dCK catalyzed 
phosphorylation, and HPRT mediated salvage of [15N5]hypoxanthine (Hx) produced from 
[15N5]dA following deamination, and glycosidic bond cleavage catalyzed by ADA and PNP, 
respectively (mean ± s.d., n = 3). (d) Fold changes in total dNTP levels 18 h after treatment 
initiation (mean ± s.d., n = 3, one-way ANOVA, Bonferroni corrected). (e) Cell cycle analyses of 
Jurkat cells treated as indicated for 24 h. (f) Quantification of cells in S (left panel) and G2/M 
(right panel) after the indicated treatments for 24 h (mean ± s.d., n = 2). (g) Representative 
immunoblots of CHEK1, CHEK2 and H2A.X phosphorylation; cells were treated as indicated for 
24 h.  
* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. 
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Fig. S1.5. dCK-dependent production from dG requires PNP inhibition (companion for 
Fig. 1). (a) Schematic representation and the 13C and 15N labeling pattern of the de novo and 
salvage dGTP biosynthetic pathways. dG can be salvaged as a nucleobase through the actions 
of PNP and HPRT or as an intact deoxyribonucleoside via dCK. The former salvage pathway is 
blocked by BCX-1777, a specific inhibitor of PNP; the latter salvage pathway is blocked by 
DI-82, a dCK inhibitor (dCKi). (b–d) Jurkat cells were treated with BCX-1777 (100 nM) ± dCKi (1 
µM) in culture media containing 11 mM [13C6]glucose and 5 µM [15N5]dA for 18 h. (b) [15N5]dG 
concentration in the cell culture media 18 h after treatment initiation (mean ± SD, n = 3, one-way 
ANOVA, Bonferroni corrected). (c) Biosynthetic routes to produce free dGTP and dGTP 
incorporated into newly replicated DNA 18 h after treatment initiation: de novo from 
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Supplementary Figure 5 | dCK-dependent production from dG requires PNP inhibition (companion for Fig. 1). (a) Schematic 
representation and the 13C and 15N labeling pattern of the de novo and salvage dGTP biosynthetic pathways. dG can be salvaged as 
a nucleobase through the actions of PNP and HPRT or as an intact deoxyribonucleoside via dCK. The former salvage pathway is 
blocked by BCX-1777, a specific inhibitor of PNP; the latter salvage pathway is blocked by DI-82, a dCK inhibitor (dCKi). (b–d) 
Jurkat cells were treated with BCX-1777 (100 nM) ± dCKi (1 µM) in culture media containing 11 mM [13C6]glucose and 5 µM [15N5]dA 
for 18 h. (b) [15N5]dG concentration in the cell culture media 18 h after treatment initiation (mean ± s.d., n = 3, one-way ANOVA, 
Bonferroni corrected). (c) Biosynthetic routes to produce free dGTP and dGTP incorporated into newly replicated DNA 18 h after 
treatment initiation: de novo from [13C6]glucose via RNR, [15N5]dG salvage via dCK catalyzed phosphorylation, and HPRT mediated 
salvage of [15N5]G produced from [15N5]dG following glycosidic bond cleavage catalyzed by PNP (mean ± s.d., n = 3). (d) Fold 
changes in total dNTP levels 18 h after treatment initiation (mean ± s.d., n = 3, one-way ANOVA, Bonferroni corrected). (e) Cell cycle 
analyses of Jurkat cells treated as indicated for 24 h. (f) Quantification of cells in the S (left panel) and G2/M (right panel) after the 
indicated treatments for 24 h (mean ± s.d., n = 2, one-way ANOVA, Bonferroni corrected). (g) Representative immunoblots of 
CHEK1, CHEK2 and H2A.X phosphorylation; cells were treated as indicated for 24 h  
* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. 
PNP purine phosphorylase; Hx hypoxanthine; HPRT hypoxanthine phosphoribosyltransferase.
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[13C6]glucose via RNR, [15N5]dG salvage via dCK catalyzed phosphorylation, and HPRT 
mediated salvage of [15N5]G produced from [15N5]dG following glycosidic bond cleavage 
catalyzed by PNP (mean ± SD, n = 3). (d) Fold changes in total dNTP levels 18 h after 
treatment initiation (mean ± SD, n = 3, one-way ANOVA, Bonferroni corrected). (e) Cell cycle 
analyses of Jurkat cells treated as indicated for 24 h. (f) Quantification of cells in the S (left 
panel) and G2/M (right panel) after the indicated treatments for 24 h (mean ± SD, n = 2, one-
way ANOVA, Bonferroni corrected). (g) Representative immunoblots of CHEK1, CHEK2 and 
H2A.X phosphorylation; cells were treated as indicated for 24 h  
* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. 
PNP purine phosphorylase; Hx hypoxanthine; HPRT hypoxanthine phosphoribosyltransferase. 
 
Fig. S1.6. Effects of knocking down RRM2 using shRNA on RRM2 protein levels and 
RNR-produced dCTP incorporated into newly replicated DNA of CEM T-ALL cells. (a) 
Protein levels in CEM shRNARRM2 cells as determined by nLC-MS/MS (mean ± SD, n = 3, one 
sample t-test to assess if the mean of the protein level normalized to parental CEM is equal to 
one). (b) Mean fluorescence intensity (MFI) of RRM2 levels in S-phase parental CEM cells 
treated with 1 µM VE-822 for 12 h (V) and CEM shRNARRM2 cells (mean ± SD, n = 2, one-way 
ANOVA, Bonferroni corrected). (c) Contributions of the de novo and salvage pathways to dCTP 
incorporated into newly replicated DNA in parental CEM and CEM shRNARRM2 cells (mean ± 
SD, n = 3, two-way ANOVA, Bonferroni corrected, comparing de novo contribution between 
parental CEM and CEM shRNARRM2).  
* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.  
RRM1 ribonucleotide reductase subunit 1; RRM2 ribonucleotide reductase subunit 2; TYMS 
thymidylate synthase; dCK deoxycytidine kinase. 
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Supplementary Figure 6 | Effects of knocking down RRM2 using shRNA on RRM2 protein levels and RNR-produced dCTP 
incorporated into newly replicated DNA of CEM T-ALL cells. (a) Protein levels in CEM shRNARRM2 cells as determined by nLC-
MS/MS (mean ± s.d., n = 3, one sample t-test to assess if the mean of the protein level normalized to parental CEM is equal to one). 
(b) Mean fluorescence intensity (MFI) of RRM2 levels in S-phase parental CEM cells treated with 1 µM VE-822 for 12 h (V) and CEM 
shRNARRM2 cells (mean ± s.d., n = 2, one-way ANOVA, Bonferroni corrected). (c) Contributions of the de novo and salvage pathways 
to dCTP incorporated into newly replicated DNA in parental CEM and CEM shRNARRM2 cells (mean ± s.d., n = 3, two-way ANOVA, 
Bonferroni corrected, comparing de novo contribution between parental CEM and CEM shRNARRM2).  
* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.  
RRM1 ribonucleotide reductase subunit 1; RRM2 ribonucleotide reductase subunit 2; TYMS thymidylate synthase; dCK 
deoxycytidine kinase.
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Fig. S1.7. IC50 values and minimal concentrations of RNR inhibitors required to cause S-
phase arrest (see in Fig. 3b and main text for details). (a) IC50 values of dT, HU, GaM, and 3-
AP in CEM cells (CellTiter-Glo assay at 72 h, mean ± SD, n = 3). (b) Minimal concentrations of 
the four RNR inhibitors required for the induction of S-phase arrest observed in Fig. 3b (see 
main text for details, mean ± SD, n = 2, one-way ANOVA, P < 0.0001).  
dT thymidine; HU hydroxyurea; GaM gallium maltolate. 
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Supplementary Figure 7 | IC50 values and minimal concentrations of RNR inhibitors required to cause S-phase arrest (see in 
Fig. 3b and main text for details). (a) IC50 values of dT, HU, GaM, and 3-AP in CEM cells (CellTiter-Glo assay at 72 h, mean ± s.d., 
n = 3). (b) Minimal concentrations of the four RNR inhibitors required for the induction of S-phase arrest observed in Fig. 3b (see 
main text for details, mean ± s.d., n = 2, o e-way ANOVA, P < 0.0001).  
dT thymidine; HU hydroxyurea; GaM gallium maltolate.
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Fig. S1.8. Analyses of apoptosis induction and premature mitotic entry in CEM cells 
treated with ATR, dCK and RNR inhibitors as indicated in Fig. 4. (a) Apoptosis induction in 
CEM cells treated as indicated (500 nM 3-AP, 1 µM VE-822, and 1 µM dCKi) for 24 h using flow 
cytometry for Annexin V and PI staining (mean ± SD, n = 2, one-way ANOVA, Bonferroni 
corrected). (b) Phosphorylated H3 on serine 10 (pS10 H3) levels in CEM cells treated as 
indicated (500 nM 3-AP, 1 µM VE-822, and 1 µM dCKi) for 24 h using flow cytometry (mean ± 
SD, n = 2, one-way ANOVA, Bonferroni corrected). 
NT: not treated control, V: VE-822, D: dCKi. 
* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. 
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Supplementary Figure 8 | Analyses of apoptosis induction and premature mitotic entry in CEM cells treated with ATR, dCK 
and RNR inhibitors as indicated in Fig. 4. (a) Apoptosis induction in CEM cells treated as indicated (500 nM 3-AP, 1 µM VE-822, 
and 1 µM dCKi) for 24 h using flow cytometry for Annexin V and PI staining (mean ± s.d., n = 2, one-way ANOVA, Bonferroni 
corrected). (b) Phosphorylated H3 on serine 10 (pS10 H3) levels in CEM cells treated as indicated (500 nM 3-AP, 1 µM VE-822, and 
1 µM dCKi) for 24 h using flow cytometry (mean ± s.d., n = 2, one-way ANOVA, Bonferroni corrected). 
NT: not treated control, V: VE-822, D: dCKi. 
* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.
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Fig. S1.9. Optimal therapeutic efficacy against p185BCR-ABLArf –/– pre-B-ALL cells in culture 
requires combined inhibition of ATR, RNR and dCK (companion for Fig. 5). (a and b) 
Treatment scheme (a) and growth curves (b) of p185BCR-ABLArf–/– pre-B-ALL treated as indicated 
(mean ± SD, n = 2, unpaired two-tailed Student’s t-test comparing 3-AP+V and 3-AP+V+D at 
day 8).  
NT: not treated control, V: VE-822, D: dCKi. 
*** P < 0.001. 
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Supplementary Figure 9 | Optimal therapeutic efficacy against p185BCR-ABLArf –/– pre-B-ALL cells in culture requires 
combined inhibition of ATR, RNR and dCK (companion for Fig. 5). (a and b) Treatment scheme (a) and growth curves (b) of 
p185BCR-ABLArf–/– pre-B-ALL treated as indicated (mean ± s.d., n = 2, unpaired two-tailed Student’s t-test comparing 3-AP+V and 3-
AP+V+D at day 8).  
NT: not treated control, V: VE-822, D: dCKi. 
*** P < 0.001.
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Fig. S1.10. Co-targeting ATR, dCK and RNR is effective and well-tolerated in a systemic 
primary B-ALL model (companion for Fig. 6). (a, b, c) Schematic representation of the 
therapeutic regimen (a), bioluminescence images (b), and quantification of whole-body radiance 
(c) of leukemia bearing mice treated with a slight modification of the therapeutic regime shown 
in Fig. 6b (3-AP, 30 mg/kg q.d., treated, n = 5). (d and e) Kaplan-Meier survival analysis (d) and 
body weight measurements (e) of leukemia bearing mice treated with the combination therapy 
(treated, n = 5) or vehicle (control from Fig. 6c, n = 5). Median survival for the control group is 
14 days after treatment initiation, whereas median survival for the treated group remains 
undefined (Mantel-Cox test). 
** P < 0.01. 
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Supplementary Figure 10 | Co-targeting ATR, dCK and RNR is effective and well-tolerated in a systemic primary B-ALL 
model (companion for Fig. 6). (a, b, c) Schematic representation of the therapeutic regimen (a), bioluminescence images (b), and 
quantification of whole-body radiance (c) of leukemia bearing mice treated with a slight modification of the therapeutic regime shown 
in Fig. 6b (3-AP, 30 mg/kg q.d., treated, n = 5). (d and e) Kaplan-Meier survival analysis (d) and body weight measurements (e) of 
leukemia bearing mice treated with the combination therapy (treated, n = 5) or vehicle (control from Fig. 6c, n = 5). Median survival 
for the control group is 14 days after treatment initiation, whereas median survival for the treated group remains undefined (Mantel-
Cox test). 
** P < 0.01.
 
Fig. S1.11. Optimal therapeutic efficacy against p185BCR-ABLArf –/– pre-B-ALL cells in vivo 
requires combined inhibition of ATR, RNR and dCK (companion for Fig. 6). (a) Schematic 
representation of the therapeutic regimen; (b) bioluminescence images (c), and quantification of 
whole-body radiance of leukemia bearing mice treated with 15 mg/kg 3-AP + 40 mg/kg VE-822 
(3-AP+V, n = 8), 15 mg/kg 3-AP + 40 mg/kg VE-822 + 50 mg/kg dCKi (3-AP+V+D, n = 8), and 
vehicle (control, n = 4). Drugs were formulated in PEG-200, Transcutol, Labrasol, and Tween-80 
blended in a ratio of 5:3:1:1 and were administered orally. One-way ANOVA, Bonferroni 
corrected for the BLI comparisons among three groups at day 16 and unpaired two-tailed 
Student’s t-test for the BLI comparison of 3-AP+V and 3-AP+V+D at day 19. Mice from control 
group were sacrificed before day 19 due to high leukemic burden.  
* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. 
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Supplementary Figure 11 | Optimal therapeutic efficacy against p185BCR-ABLArf –/– pre-B-ALL cells in vivo requires combined 
inhibition of ATR, RNR and dCK (companion for Fig. 6). (a) Schematic representation of the therapeutic regimen; (b) 
bioluminescence images (c), and quantification of whole-body radiance of leukemia bearing mice treated with 15 mg/kg 3-AP + 40 
mg/kg VE-822 (3-AP+V, n = 8), 15 mg/kg 3-AP + 40 mg/kg VE-822 + 50 mg/kg dCKi (3-AP+V+D, n = 8), and vehicle (control, n = 4). 
Drugs w re formulated in PEG-200, Transcutol, Labrasol, and Tween-80 blended in a ratio f 5:3:1:1 and were administer d orally. 
One-way ANOVA, Bonferroni corrected for the BLI comparisons among three groups at day 16 and unpaired two-tailed Student’s t-
t st for the BLI c mparison of 3-AP+V and 3-AP+V+D at day 19. Mice from control group were sacrificed before day 19 due o high 
leukemic burden.  
* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.
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Fig. S1.12. The combination therapy is efficacious against a dasatinib-resistant pre-B-
ALL mouse model. (a) Generation of dasatinib-resistant p185BCR-ABLArf–/– pre-B-ALL cells. 
Leukemia bearing C57BL/6 mice, were treated with 10 mg/kg dasatinib q.d. (once/day) for 20 
days. Upon presentation of resistance, leukemia cells were harvested from the bone marrow. 
(b) Sequencing of ABL kinase domain of dasatinib-resistant p185BCR-ABLArf–/– pre-B-ALL cells 
showed the T315I gate-keeper mutation. (c) Apoptosis induction in p185BCR-ABLArf–/– pre-B-ALL 
parental and resistant cells treated as indicated (dasatinib, 1 nM) for 24 h using flow cytometry 
for Annexin V and PI staining. (d) Doses and schedule of the combination treatment (3-AP, dCKi 
and VE-822) against dasatinib-resistant leukemia bearing mice. (e and f) Bioluminescence 
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Supplementary Figure 12 | The combination therapy is efficacious against a dasatinib-resistant pre-B-ALL mouse model. (a) Generation 
of dasatinib-resistant p185BCR-ABLArf–/– pre-B-ALL cells. Leukemia bearing C57BL/6 mice, were treated with 10 mg/kg dasatinib q.d. (once/day) for 
20 days. Upon presentation of resistance, leukemia cells were harvested from the bone marrow. (b) Sequencing of ABL ki ase domain of 
dasatinib-resistant p185BCR-ABLArf–/– pre-B-ALL cells showed the T315I gate-keeper mutation. (c) Apoptosis induction in p185BCR-ABLArf–/– pre-B-
ALL parental and resistant cells treated as indicated (dasatinib, 1 nM) for 24 h using flow cytometry for nnexin V and PI staining. (d) Doses and 
schedule of the combination treatment (3-AP, dCKi and VE-822) against dasatinib-resistant leukemia bearing mice. (e and f) Bioluminescence 
images (e) and quantification of whole body radiance (f) of dasatinib-resistant leukemia bearing mice treated with the combination therapy 
(treated, n = 20) or vehicle (control, n = 5) at indicated days after tumor inoculation. 10 representative mice are shown for the treated group. (g) 
Kaplan-Meier survival analysis of dasatinib-resistant leukemia bearing mice treated with the combination therapy (treated, n = 20) or vehicle 
(control, n = 5). Median survival for the control group is 14 days after treatment initiation, whereas median survival for the treated group remains 
undefined (Mantel-Cox test). 
**** P < 0.0001.
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images (e) and quantification of whole body radiance (f) of dasatinib-resistant leukemia bearing 
mice treated with the combination therapy (treated, n = 20) or vehicle (control, n = 5) at 
indicated days after tumor inoculation. 10 representative mice are shown for the treated group. 
(g) Kaplan-Meier survival analysis of dasatinib-resistant leukemia bearing mice treated with the 
combination therapy (treated, n = 20) or vehicle (control, n = 5). Median survival for the control 
group is 14 days after treatment initiation, whereas median survival for the treated group 
remains undefined (Mantel-Cox test). 
**** P < 0.0001. 
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Fig. S1.13. Dasatinib resistant pre-B-ALL cells recovered from a leukemic mouse which 
was treated with the triple combination therapy and eventually succumbed to disease 
retain sensitivity to the triple combination therapy. (a) Apoptosis induction of dasatinib-
resistant p185BCR-ABLArf–/– pre-B-ALL cells, prior to inoculation in mice, treated as indicated (350 
nM 3-AP, 100 nM VE-822, and 1 µM dCKi) for 72 h using flow cytometry for Annexin V and PI 
staining. (b) Apoptosis induction of dasatinib-resistant p185BCR-ABLArf–/– pre-B-ALL cells, 
harvested from bone marrow of a leukemic mouse treated with the triple combination therapy 
and eventually succumbed to disease from Supplementary Fig. 13, treated as indicated (350 nM 
3-AP, 100 nM VE-822, and 1 µM dCKi) for 72 h using flow cytometry for Annexin V and PI 
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Supplementary Figure 13 | Dasatinib resistant pre-B-ALL cells recovered from a leukemic mouse which was treated with the 
triple combination therapy and eventually succumbed to disease retain sensitivity to the triple combination therapy. (a) 
Apoptosis induction of dasatinib-resistant p185BCR-ABLArf–/– pre-B-ALL cells, prior to inoculation in mice, treated as indicated (350 nM 
3-AP, 100 nM VE-822, and 1 µM dCKi) for 72 h using flow cytometry for Annexin V and PI staining. (b) Apoptosis induction of 
dasatinib-resistant p185BCR-ABLArf–/– pre-B-ALL cells, harvested from bone marrow of a leukemic mouse treated with the triple 
combination therapy and eventually succumbed to disease from Supplementary Fig. 13, treated as indicated (350 nM 3-AP, 100 nM 
VE-822, and 1 µM dCKi) for 72 h using flow cytometry for Annexin V and PI staining. (c) Bar graph summarizes the percentage of 
Annexin V+ cell population from (a) and (b) (mean ± s.d., n = 2, one-way ANOVA, Bonferroni corrected). 
ns not significant.
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Fig. S1.14. Nucleotide biosynthetic diversity in patient-derived samples. (a) Profiling the 
differential contributions of the de novo and salvage pathways to newly replicated DNA in 
patient-derived primary glioblastoma (HK374) and melanoma (M299 and M417) cells (mean ± 
SD, n = 3). Cells were incubated in culture media containing 11 mM [13C6]glucose and 5 µM 
each of the following labeled nucleosides: [13C9,15N3]dC, [13C10,15N2]dT, [13C10,15N5]dA, [15N5]dG. 
(b) [15N2]orotate enrichment in dCTP incorporated into newly replicated DNA in M299 and M417 
cells at 18 h (mean ± SD, n = 3). Cells were incubated in culture media containing 11 mM 
[13C6]glucose with indicated varying concentration of [15N2]orotate. (c) Schematic representation 
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Supplementary Figure 14 | Nucleotide biosynthetic diversity in patient-derived samples. (a) Profiling the differential 
contributions of the de novo and salvage pathways to newly replicated DNA in patient-derived primary glioblastoma (HK374) and 
melanoma (M299 and M417) cells (mean ± s.d., n = 3). Cells were incubated in culture media containing 11 mM [13C6]glucose and 5 
µM each of the following labeled nucleosides: [13C9,15N3]dC, [13C10,15N2]dT, [13C10,15N5]dA, [15N5]dG. (b) [15N2]orotate enrichment in 
dCTP incorporated into newly replicated DNA in M299 and M417 cells at 18 h (mean ± s.d., n = 3). Cells were incubated in culture 
media containing 11 mM [13C6]glucose with indicated varying concentration of [15N2]orotate. (c) Schematic representation of the de 
novo and salvage nucleotide pathway involving CAD, DHODH, and UMPS to newly replicated DNA. (d) IGV plot from exome 
sequ cing of M417 showing homozygou  CAD mutation (Q140*), present in 104 out of 108 re ds. Results for M299 shown as 
negative reference. (e) Growth curves for M299 and M417 treated with vehicle or 1 µM dCKi (mean ± s.d., n = 2). 
* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. 
CAD carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase; DHODH dihydroorotate dehydrogenase; 
UMPS uridine m nophosphate synthase; PRPP 5’-pho phoribosyl pyrophosphate; UMP uridine monophosphate. 
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of the de novo and salvage nucleotide pathway involving CAD, DHODH, and UMPS to newly 
replicated DNA. (d) IGV plot from exome sequencing of M417 showing homozygous CAD 
mutation (Q140*), present in 104 out of 108 reads. Results for M299 shown as negative 
reference. (e) Growth curves for M299 and M417 treated with vehicle or 1 µM dCKi (mean ± SD, 
n = 2). 
* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. 
CAD carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase; 
DHODH dihydroorotate dehydrogenase; UMPS uridine monophosphate synthase; PRPP 5’-
phosphoribosyl pyrophosphate; UMP uridine monophosphate.  
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CHAPTER 2 
Development and preclinical pharmacology of a novel dCK 
inhibitor, DI-87 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ABSTRACT 
Introduction: Deoxycytidine kinase (dCK) is essential for DNA synthesis through salvage 
pathways and DI-87 is a novel dCK inhibitor in preclinical development.  
Methods: Following synthesis, DI-87 was tested in cell culture to determine in vitro IC50 and 
protein binding. Oral DI-87 was administered to NSG mice with plasma and tumor PK assessed 
over 24 hrs by mass spectrometry. NSG mice with CEM tumors were administered varying 
doses of DI-87 followed by the [18F]CFA PET probe and PET imaging. NSG mice with CEM 
tumors were administered oral DI-87 and intraperitoneal thymidine concurrently and tumor 
growth monitored.  
Results: The R-enantiomer had an in vitro EC50 of 10.2 nM with relatively low protein binding 
and was used for subsequent studies. Peak DI-87 plasma concentrations were observed 
between 1-3 hr and 3-9hr in plasma and tumor, respectively. Tumor concentrations were less 
than one third of plasma concentrations. Full dCK inhibition by PET imaging occurred between 
10 and 25 mg/kg and decreasing doses led to faster recovery of activity. Full recovery of 
enzyme activity occurred by 36 hr with full inhibition being maintained at the 12 hr time point at 
the 25 mg/kg dose. Maximal growth inhibition occurred with full dCK inhibition over the dosing 
range (25 mg/kg BID) when DI-87 was given in combination therapy with thymidine; thus 
increased doses led to more persistent dCK inhibition with predictable increased growth 
inhibition.   
Conclusions: DI-87 is a promising new compound for combination therapy for tumors 
expressing DCK.  
  
!64
INTRODUCTION 
Nucleotide biosynthesis is essential for growing tumors and consists of redundant and 
convergent biosynthesis pathways. Deoxyribonucelotide triphosphates (dNTPs) are required for 
DNA replication and repair. They can be synthesized either de novo or via salvage pathways. 
The de novo pathway produces dNTPs from glucose and amino acids. It is dependent on 
ribonucleotide reductase (RNR) which is the rate limiting step in this pathway (1). Therapeutics 
have been developed to block RNR such as 3-aminopyridine-2-carboxaldehyde 
thiosemicarbazone (3AP) (2), however tumors develop resistance through upregulation of 
salvage pathways which produce dNTPs from preformed deoxyribonucelosides in the 
extracellular environment. Deoxycytidine kinase (dCK) is an enzyme important in the production 
of deoxycytidine triphosphate (dCTP). DI-39, a reversible high-affinity dCK inhibitor, has 
previously been shown to inhibit tumor growth when given in combination therapy with 
thymidine to mice with acute lymphoblastic leukemia (ALL) xenografts (3). DI-87 is novel small 
molecule dCK inhibitor developed to be more soluble and metabolically stable than DI-39.   
Positron emission tomography (PET) scanning and tracers can assist in assessing drug 
effects on target pathways. [18F]Clofarabine ([18F]CFA) has previously been developed as a PET 
probe for dCK inhibition (4) and has higher specificity for human dCK compared to previous 
generation PET probes. This probe is a purine analog which is phosphorylated by dCK to form 
CFA-PO4 and retained in cells thereby generating PET detectable signal. Such tracers can help 
determine dose-response relationships by directly interrogating the target pathway being altered 
by the drug. As a salvage pathway important for nucleotide synthesis in healthy tissue, it is 
important to characterize dose-response relationships for dCK inhibition to determine the 
optimal inhibition necessary to maximally suppress tumor growth without leading to excess 
toxicity. 
The aim of the current study is to provide a better understanding of preclinical 
pharmacokinetics and dose-response relationships of the prototype dCK inhibitor, DI-87. The 
study utilizes PET imaging to measure dCK inhibition and PK-PD modeling to quantify 
relationships between drug levels in tissue and plasma with dCK activity and tumor shrinkage. 
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METHODS AND MATERIALS 
General chemical methods: Unless otherwise noted, reactions were carried out in oven-dried 
glassware under an atmosphere of nitrogen using commercially available anhydrous solvents. 
Solvents used for extractions and chromatography were not anhydrous. 4,6-diamino-2-
mercaptopyrimidine was obtained from drying the hydrate over dynamic vacuum at 110 °C for 
20 h. All other reagents obtained from commercial suppliers were reagent grade and used 
without further purification unless specified. Reactions and chromatography fractions were 
analyzed by thin-layer chromatography (TLC) using Merck precoated silica gel 60 F254 glass 
plates (250 µm). Visualization was carried out with ultraviolet light, vanillin stain, permanganate 
stain, or p-anisaldehyde stain. Flash column chromatography was performed using E. Merck 
silica gel 60 (230−400 mesh) with compressed air. All compounds were characterized by 1H 
and 13C NMR recorded on ARX500 (500 MHz) or Avance500 (500 MHz) spectrometers, and 
electrospray mass spectrometry data were collected with a Waters LCT Premier XE time-of-
flight instrument controlled by MassLynx 4.1 software. Samples were dissolved in methanol and 
infused using direct loop injection from a Waters Acquity UPLC into the Multi-Mode Ionization 
source. The purity of all final compounds was determined to be >95%. Analytical HPLC analysis 
was performed on a Knauer Smartline HPLC system with a Phenomenex reverse-phase Luna 
column (5 µm, 4.6 × 250 mm) with inline Knauer UV (254 nm) detector. Mobile phase: A: 0.1% 
TFA in H2O, B: 0.1% TFA in MeCN.  
Synthesis of 4-methoxy-3-(2-morpholinoethoxy)benzonitrile (1). To a solution 
containing 4-methoxy-3-hydroxybenzonitrile and Cs2CO3 (1.5 eq) was added 4-(2-
chloroethyl)morpholine hydrochloride (1.5 eq). The reaction solution was stirred at 70 °C for 12 
hours, quenched with DI water, extracted with ethyl acetate and purified by flash 
chromatography.  
Synthesis of 4-methoxy-3-(2-morpholinoethoxy)benzothioamide (2). To a solution of 
1 in pyridine was added Et3N (1.1 eq) and ammonium sulfide solution (20 wt% in water, 3.0 eq). 
Reaction solution was stirred for 12 hours at 60 °C, concentrated en vacuo, and the resulting 
residue was taken up in ethyl acetate and washed with DI water and brine. The organic layer 
was concentrated and purified by flash chromatography.  
Synthesis of 1-(2-(4-methoxy-3-(2-morpholinoethoxy)phenyl)-5-methylthiazol-4-
yl)ethan-1-one (3). To a solution of 2 in ethanol was added 4-bromopentane-2,3-dione (1.5 eq) 
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and reaction solution heated to reflux for 4 hours. The reaction solution was then concentrated 
en vacuo, and the resulting residue was purified by flash chromatography.  
Synthesis of (S)-1-(2-(4-methoxy-3-(2-morpholinoethoxy)phenyl)-5-methylthiazol-4- 
yl)ethan-1-ol (4). To a solution of (R)-(+)-2-methyl-CBS-oxazaborolidine (9.0 eq) in THF at -78 
°C was added borane–THF complex (1.0M solution in THF, 6.0 eq), followed by a solution of 3 
(1.0 eq) in THF. Upon completion, reaction was quenched with DI water and concentrated en 
vacuo. The resulting residue was concentrated by flash chromatography.  
Synthesis of (S)-1-(2-(4-methoxy-3-(2-morpholinoethoxy)phenyl)-5-methylthiazol-4- 
yl)ethyl 2,2,2-trifluoroacetate (5). To a solution of 4 in DCM at 0 °C was added trifluoroacetic 
anhydride (TFAA, 5.0 eq) dropwise and stirred for 30 minutes. Reaction solution then allowed to 
room temperature prior to quenching with a saturated aqueous solution of sodium bicarbonate, 
which was extracted with ethyl acetate. Organic layer washed with brine, concentrated, and 
used directly in next step due to instability of the trifluoroacetate.   
Synthesis of (R)-2-((1-(2-(4-methoxy-3-(2-morpholinoethoxy)phenyl)-5-
methylthiazol-4-yl)ethyl)thio)pyrimidine-4,6-diamine (6, (R)-DI-87). To a solution of 5 in DMF 
was added 4,6-diamino-2-mercaptopyrimidine (1.5 eq) and reaction solution stirred at 80 °C. 
Upon completion, reaction solution was concentrated en vacuo and purified by flash 
chromatography. Additional purification by chiral reverse-phase liquid chromatography afforded 
(R)-DI-87 in >99% ee.  
[MOVE DETAILS OF SYNTHESIS TO APPENDIX??] – Shall we make a new section?  
dCK Uptake Assay Performed in Cell Culture: Cells were seeded at a density of 50,000 cells/
well in Millipore MultiScreen GV 96 well plates. 0.25 µCi of 3 H-dC (Moravek Biochemicals) 
were added to the cells simultaneously with concentrations of dCK inhibitor at a final volume of 
100 µL/well. After 1 h at 37 °C, cells were washed four times with ice cold phosphate-buffered 
saline (PBS) using the Millipore Vacuum Manifold. The amount of incorporated probe was 
measured by scintillation counting with the PerkinElmer Microbeta. 
Cell proliferation assay: Cells were plated at 1x103 cells / well in at 50 µl / well in white opaque 
384-well plates and treated as described. Following incubation with 10 nM Gemcitabine ± 1 µM 
(R)-DI-87 for 72 hours, 50 µl of CellTiter-Glo reagent (Diluted 1:5 in dH2O) was added to each 
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well, plates incubated at room temperature for 5 m and luminescence was measured using a 
BioTek microplate luminescence reader.  
  
Animals: Animal studies were conducted under the approval of the UCLA Animal Research 
Committee and were performed in accordance with the guidelines from the Division of 
Laboratory Animal Medicine at UCLA. All NOD scid gamma (NSG) mice were purchased from 
the UCLA Radiation Oncology breeding colony. 
Mouse xenograft tumor models and treatments: Mice had three separate evaluation 
protocols which included pharmacokinetics, dCK activity, and growth inhibition studies. The 
human cell line CCRF-CEM (CEM) was purchased from American Type Culture Collection 
(ATCC). The cell line was maintained in 10% FBS in RPMI-1640 and were grown at 37°C, 20% 
O2, and 5% CO2. CEM tumor xenografts were developed in 8-12 week-old male or female NSG 
mice by implanting 2 × 106 CEM cells in 100 µL of a 50/50 (vol/vol) mixture of PBS and matrigel 
(BD Biosciences) for subcutaneous injections in left shoulders (for imaging and PK studies) or 
both shoulders (for growth inhibition studies). (R)-DI-87 (dCKi, Sundia Pharmaceuticals) was 
administered by oral gavage to recipient animals. For oral administration of (R)-DI-87, the drug 
was solubilized in the formulation containing PEG-200: Transcutol: Labrasol: Tween-80 mixed in 
5:3:1:1 ratio. For imaging studies, the mice were treated with indicated doses of (R)-DI-87 after 
the tumor size reached 250 mm3. For growth inhibition and pharmacokinetic studies, treatments 
were started after the tumors reached 50 mm3.  
Pharmacokinetic studies of (R)-DI-87 in mice: (R)-DI-87 plasma and tumor concentrations 
were assessed at 1, 3, 6, 9 and 24 h following oral administration of 10, 25, or 50 mg/kg of (R)-
DI-87 to female NSG mice with CEM tumors (N=5 mice per time point). At each time point, a 
cohort of mice was sacrificed by cervical dislocation; thus, a single plasma and tumor 
concentration were obtained from each mouse. Blood samples were collected in heparin-EDTA 
tubes by the retro-orbital technique and spun at 6000 x g for 15 min prior to collecting the 
plasma supernatants. All plasma samples were frozen down at –20ºC before sample 
processing. The stock solutions of (R)-DI-87 and DI-82 (internal standard) were prepared by 
dissolving the appropriate amount of each drug in a known volume of dimethyl sulfoxide 
(DMSO) to a 10 mM concentration and were stored at –20ºC before use. DI-82 (internal 
standard) was diluted to 200 nM in methanol to make the internal solution. The calibration 
standards were prepared by spiking working stock solutions of (R)-DI-87 in plasma from 
untreated mice to give 0.01-10 pmol/µL range. Each 20 µL calibration standard sample was 
mixed with 60 µL of internal solution (methanol with 200 nM internal standard) and vortexed for 
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30 s. Following centrifugation at 15,000 x g for 10 min, approximately 60 µL of sample was 
carefully transferred into HPLC injector vials for LC-MS/MS-MRM analysis. Plasma samples 
were processed the same way as the calibration standard samples. 20 µL samples were 
injected onto a reverse phase column, (Thermo Scientific Hypersil GOLD column 3.0 µm; 2.1 x 
100 mm) equilibrated in 0.1% water/formic acid, and eluted (200 µL/min) with an increasing 
concentration of solvent B (acetonitrile/formic acid, 100/0.1, v/v: min/% acetonitrile; 0/0, 5/0, 
15/60, 16/100, 19/100, 20/0, and 25/0). The effluent from the column was directed to the Agilent 
Jet Stream ion source connected to the triple quadrupole mass spectrometer (Agilent 6460) 
operating in the multiple reaction monitoring (MRM) mode using previously optimized settings. 
The following drug precursor→fragment ion transitions were used: DI-82 (511→369), (R)-
DI-87(503→361). The peak areas for each drug (precursor→fragment ion transitions) at 
predetermined retention times were recorded using the software supplied by the instrument 
manufacturer (Agilent MassHunter) (5).  
Tumors were harvested after dissection of mice, weighed, and snap-frozen in liquid 
nitrogen. PBS containing internal standard (200 µL for 50 mg tumor) was added to the excised 
tumor and homogenized using a bead beater (BioSpec). The samples were spun down to 
collect supernatants. The supernatant was further diluted 5 times in PBS (with internal 
standard), and four parts of methanol (with internal standard) was added and incubated -80ºC 
overnight to precipitate proteins. The samples were spun at maximum speed (16000g) at 4ºC, 
and supernatant collected. Twenty microliter samples were injected onto a reverse phase 
column equilibrated in water 0.1% formic acid for LC-MS/MS-MRM analysis in positive ion mode 
as above and compared to calibration standards. 
DCK activity with MicroPET/CT: DCK activity was evaluated following oral administration of 5, 
10, or 25 mg/kg of DI-87 to male NSG mice implanted with CEM tumors (N=4 mice per time 
point). The NSG mice were anesthetized 3 hours prior to imaging and intravenously 
administered 740 kBq of [18F]CFA PET probe (4). Thus each mouse was representative of a 
single time point and concentration. MicroPET/CT experiments were conducted using G8 
microPET/CT system (6,7). The mice were then positioned in an imaging chamber and data was 
acquired with the G8 microPET/CT system (Sofie Biosciences). MicroPET data was acquired for 
10 min and reconstructed with a statistical maximum a posteriori probability algorithm (MAP) 
into multiple frames. The spatial resolution of PET is ∼1.5 mm with 0.4 mm voxel size. CT 
images are a low-dose 400 µm resolution acquisition with 200 µm voxel size. MicroPET and CT 
images were co-registered and then quantified by manually drawing three-dimensional regions 
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of interest using Osirix software. The color scale was proportional to tissue concentration, with 
red being the highest and yellow, green and blue corresponding to the lower values. 
Growth inhibition studies: Male NSG mice implanted with CEM tumors as above were used 
for the growth inhibition studies. Combination therapy with DI-87 and thymidine were used 
Treatments of (R)-DI-87 and/or thymidine were started after the tumors reached 50 mm3. (R)-
DI-87 was administered at varying doses orally once a day (QD) or twice a day (BID) for 16-18 
days while thymidine (2 g/kg) solubilized in saline was administered intraperitoneally BID after 
start of treatment (3). Control mice received either thymidine intraperitoneal saline (i.p.) 
injections alone, oral (R)-DI-87 with i.p saline injections, or i.p. thymidine alone. Tumor growth 
CT measurements were compared among different treatment groups (n=5 mice or 10 tumors/
group). Tumor growth was monitored daily by caliper measurements ([(length × width2)/2]) and 
bi-weekly by CT measurements.   
Pharmacokinetic and pharmacodynamic modeling: Using the computer program NONMEM 
(version 7.3) with a GNU Fortran G77 Compiler, DI-87 concentration-time data were modeled 
using first-order conditional estimation method (FOCE) with interaction. Plasma concentrations 
were assessed with standard PK models which included a depot compartment representing the 
gut. Tumor concentrations were evaluated with the additional of a separate tumor compartment 
once plasma concentrations had been characterized (ADVAN6, TRANS1 subroutine). An 
exponential-normal distribution error model was used for inter-subject variability. 
A combined pharmacokinetic-pharmacodynamic (PK-PD) model was developed using the final 
DI87 plasma-tumor PK parameter estimates (Figure 1). The effect compartment (DCK inhibition 
or growth inhibition) was linked to the tumor concentrations. Linear (slope), Emax, and sigmoid 
Emax models were tested to determine which were the best fits to the data (see equations 
below) (8). The final model was used to simulate DCK inhibition and growth inhibition from a 
representative mouse for each of the tested DI-87 concentrations. 
PD models: 
A. Linear (Slope): SLOPE*CONC 
B. Emax: Emax*CONC/(EC50+CONC) 
C. Sigmoid Emax: Emax*(CONCEXP)/(EC50EXP+CONCEXP) 
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RESULTS 
Development of a highly potent, orally bioavailable dCK inhibitor, (R)-DI-87 
(R)-DI-87 (Figure 2A) was synthesized as follows: an SN2 reaction between 4-methoxy-3-
hydroxybenzonitrile and 4-(2-chloroethyl) morpholine furnished 1. Heating with an aqueous 
solution of ammonium sulfide gave thioamide 2, which was subjected to Hantzsch thioazole 
formation conditions to yield thiazole 3. Asymmetric Corey-Bakshi-Shibata (CBS) reduction of 
the ketone resulted in the S-alcohol 4, which was converted into the trifluoroacetate 5 and 
displaced via SN2 reaction by 4,6-diamino-2-mercaptopyrimidine to furnish (R)-DI-87 (6) (Figure 
2B). The IC50 values for each enantiomer of DI-87 were determined using a dC uptake assay in 
CEM cells. (S)-DI-87 exhibited a much higher IC50 value (468±2.1 nM) relative to (R)-DI-87 
(3.15±1.2 nM) (Figure 2C). (R)-DI-87 treatment rescued CEM cells from the anti-proliferative 
effects of gemcitabine, a dCK-dependent nucleoside analog prodrug, with an EC50 of 10.2 nM 
(Figure 2D). Additionally, we observed that protein binding of (R)-DI-87 is comparatively lower 
than its predecessor, (R)-DI-82, as measured by IC50 of the respective dCK inhibitor in 
presence of bovine serum albumin (BSA) (Figure 2E). 
Pharmacokinetics of DI-87 
DI-87 concentrations in plasma and tumor were determined for 3 dose levels (10, 25, and 50 
mg/kg) (Figure 3). Plasma and tumor concentrations were obtained at a single time point from 
each mouse. Plasma DI-87 concentrations exhibited linear PK and increased proportionally with 
higher doses. Plasma concentrations peaked between 1 and 3 hours. Tumor concentrations 
were lower than plasma concentrations and had a later, more sustained peak at 3-9 hours. 
Tumor concentrations varied with tumor size, but overall exhibited linear pharmacokinetics. In 
particular, the 50 mg/kg dose was administered to mice with larger tumors (>1.5 cm3), so 
although the tumor concentrations were similar to the 25 mg/kg dose, the total drug amount in 
the tumors was higher for the 50 mg/kg dose. Plasma and tumor PK was also evaluated in male 
mice at the 10 mg/kg dose with essentially identical results to that seen in female mice (data not 
shown). 
A population PK model was initially developed for plasma concentrations. A one compartment 
structural model fit the data well. An additional compartment was added to model tumor 
concentrations. The parameter estimates for the combined tumor and plasma population PK 
model are shown in Table 1. KA was fixed to the parameter estimate obtained from the plasma 
PK model. The typical value of clearance was 0.46 L/hr/kg and plasma volume of distribution 
was 2.78 L/kg. Actual tumor volumes were used for the tumor volume in the model. Plasma 
concentrations were over 3.5 fold higher than tumor concentrations.  
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DCK inhibition studies 
DI-87 was administered to mice in three separate doses (25 mg/kg, 10 mg/kg and 5 mg/kg) to 
establish a dose response curve. The [18F]CFA PET probe was administered 3 hours prior to 
imaging. Representative mice at each time point and concentration are shown in Figure 4A. The 
data from all mice is represented graphically in Figure 4B. The dose of 25 mg/kg exhibits full 
DCK inhibition until 27 hrs after the dose and activity fully recovers at 36 hrs. The 10 mg/kg 
dose results in full inhibition with recovery initiating at the 12 hr time point. The 5 mg/kg dose 
results in minimal DCK inhibition with rapid recovery. 
 The PET signal intensity quantitative data was used in a combined population PK-PD 
model. PK parameters from the final combined plasma-tumor model were fixed and PD 
parameters were estimated in NONMEM. A sigmoid Emax indirect response PD model (9) was 
found to fit the DCK inhibition data the best: 
DA/DT=Kin *(1- Sigmoid Emax) - Kout*A 
Final parameter estimates from the model are shown in Table 1f. Emax was 1.20 and EC50 was 
0.31 mcg/mL. The Hill coefficient was 58.6 consistent with the full DCKi seen at the 6 hr time 
point for the 25 and 10 mg/kg doses and represents that DCK inhibition is essentially a step 
function at higher concentrations with the transition from no inhibition to full inhibition being 
achieved over a relatively narrow range of concentrations. Figure 4C is a simulation of the final 
model to demonstrate PET signal intensity and the dose response curve for DCK inhibition seen 
with the 5, 10, and 25 mg/kg doses. 
Growth inhibition studies 
Based on the results of the DCK inhibition experiments, we predicted close to full DCK inhibition 
with 25 mg/kg DI-87 and performed growth inhibition studies with 25 mg/kg daily of DI-87 in 
combination with a fixed dose of i.p. thymidine since DI-87 alone exhibits minimal growth 
inhibition. DI-87 at 10 mg/kg (oral) was given in combination with i.p. thymidine to demonstrate a 
dose-response relationship with reduced DCKi inhibition. Control mice received either 
intraperitoneal (i.p.) saline injections alone, oral DI-87 with i.p saline injections, or thymidine 
alone. A second experiment was performed to validate the results and explore full DCK 
inhibition throughout the dosing interval with 25 mg/kg BID of DI-87 administered in combination 
with a fixed dose of thymidine. DI-87 at 10 mg/kg was again given in combination with i.p. 
thymidine to demonstrate a dose-response relationship with reduced DCKi inhibition and the 
same controls were used as experiment 1. Tumor size was measured every 3 days after the 
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initiation of drug administration. Mice administered thymidine alone or DI-87 alone had similar 
tumor growth curves to the control (data not shown). Increasing DI-87 doses resulted in reduced 
cell growth in both experiments consistent with the DCK inhibition seen in the PET scans 
(Figure 5A).  
The tumor sizes from both experiments were used in a combined PK-PD model. PK parameters 
from the final combined plasma-tumor model were fixed and PD parameters were estimated in 
NONMEM. A superexponential function was found to describe the growth of the control data the 
best: Growth(t)=exp(k1*tk2). An Emax indirect response PD model (9) was found fit the growth 
inhibition data the best:  
DA/DT=KIN - KOUT * (1 + Emax)-(56*k1*k2*(TIME**(k2-1))))*A 
Final parameter estimates from the model are shown in Table 1. Emax was 1.06 and EC50 was 
3.63 mcg/mL. The final model was used for simulations of the three concentrations tests (10 
mg/kg daily, 25 mg/kg daily, 25 mg/kg BID). Figure 5B demonstrates that the final model fit the 
experimental data well. Thus, more growth inhibition results from maximal DCK inhibition over 
the 24 hr dosing period consistent with the 25 mg/kg BID dose.  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DISCUSSION 
Restricting the amount of dNTPs available for incorporation into newly synthesized DNA leads 
to replication stress, which can be therapeutically leveraged against rapidly replicating 
malignant cells. Cancer cells can utilize either de novo and salvage biosynthesis of dNTPs, 
meaning that any therapeutic strategy attempting to restrict their supply must simultaneously 
inhibit both pathways – this may explain the limited clinical efficacy of inhibiting RNR, a key 
enzyme in the de novo pathway. We therefore developed pharmacological inhibitors of dCK, the 
rate-limiting enzyme in the salvage pathway biosynthesis of dCTP, to be used in combination 
with RNR inhibition. We have previously reported the development of DI-39 (3) and DI-82 
(Nomme et al., 2014), potent inhibitors of dCK (dCKi) which had poor solubility and sub-optimal 
drug-like properties. To address these shortcomings, we developed (R)-DI-87, a potent, specific, 
soluble, and bioavailable dCK inhibitor which has recently gained FDA IND approval and will be 
evaluated in clinical trials shortly.  
In line with our previous studies, we determined that the R-enantiomer of DI-87 had a 
significantly higher affinity for dCK when compared with the S-enantiomer. The affinity of DI-87 
for dCK was further confirmed through a rescue assay in which the growth of CEM cells treated 
with gemcitabine with and without DI-87 supplementation was monitored. Supplementation with 
DI-87 led to a complete rescue of growth, indicating that the activity of dCK, the key enzyme 
responsible for the cytotoxic effects of gemcitabine, was being blocked. Previous generations of 
reversible dCK inhibitors developed by our group had comparable potency, but did not have 
optimal biochemical properties. In particular, DI-82 was an effective dCK inhibitor but was 
heavily protein bound. By comparison, DI-87 was significantly more potent in the presence of 
bovine serum albumin.  
  
We evaluated the preclinical pharmacology of DI-87. Plasma and tumor concentrations of DI-87 
exhibited linear PK. Plasma concentrations peaked 3 hours after administration, while tumor 
concentrations remained at peak levels between hours 3 and 9. Thus, the tumor-to-plasma 
concentration ratio changed depending upon sampling time. Tumor concentrations were 
significantly lower than plasma concentrations for all concentrations observed. The PET probe 
[18F]CFA was used to quantify dCK activity in tumors and thus effects on the target pathway. 
Given the differential peaks in plasma and tumor concentrations, linking DI-87 tumor 
concentrations to dCK inhibition provided a more physiologic and mechanistic approach. Our 
population PK-PD modeling allowed us to describe limited tumor data and link these 
concentrations to dCK inhibition. Full dCK inhibition was observed over a range of 
concentrations and decreasing doses led to faster recovery of activity. At the highest dose 
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tested, full recovery of enzyme activity occurred by 36 hours with full inhibition being maintained 
at the 12 hour time point. Our PK-PD model suggested a threshold or rapid switching on-off 
effect. Maximal growth inhibition occurred with full dCK inhibition over the dosing range when 
DI-87 was given in combination therapy with thymidine, and lower doses led to diminished dCK 
inhibition with predictable decrease in growth inhibition.  
dCK is an intriguing target in anti-cancer therapy, as it is a rate limiting enzyme within the 
salvage pathway of dNTP biosynthesis, and multiple cell lines in the Cancer Cell Line 
Encyclopedia and tumor samples from The Cancer Genome Atlas express this enzyme at 
higher levels when compared to normal tissues (10). Among the listed cancers, leukemias and 
lymphomas are most prominently featured. While targeting the salvage pathway of dNTP 
biosynthesis through dCK inhibition is a relatively new approach, the key enzyme of the parallel 
de novo pathway, ribonucleotide reductase (RNR), has been an important target in anticancer 
therapies for decades. The RNR inhibitor hydroxyurea (HU) has been used in clinics worldwide 
and continues to progress to clinical phase studies, as Triapine (3-AP). While these compounds 
are able to inhibit RNR, they each possess dose-limiting toxicity and limited efficacy. A major 
resistance mechanism to RNR inhibition therapy is presence of an active dCK-mediated salvage 
pathway, which may explain the failure of RNR inhibitors such as 3-AP in clinical trials. In an 
effort to circumvent this resistance mechanism, we developed inhibitors of dCK and 
demonstrated that combined administration with RNR inhibitors significantly improved their 
therapeutic efficacy.  
While the previously developed DI-39 and DI-82 had suboptimal pharmacologic properties, they 
remained effective dCK inhibitors. DI-87 improves upon these properties while maintaining low-
nM affinity for dCK. When evaluated as single agents, these dCK inhibitors were well tolerated 
at higher doses in preclinical studies, but had essentially no ability to inhibit growth (data not 
shown). By blocking dCK, the kinase required for the metabolic switch to nucleotide salvage 
pathway dCTP synthesis, in combination with blockade of the de novo pathway using thymidine 
as an inhibitor of RNR, we were able to achieve growth inhibition at higher doses of combination 
therapy over the course of the growth inhibition study. The current study evaluated an ALL 
xenograft, the CEM cell line, however dCK has been shown to be active in a wide variety of 
tumors cells including lymphomas, colon cancer, and gastric cancer (11,12). DI-87 thus appears 
to have potential as a cancer therapeutic in combination therapy. 
Pre-clinical studies are used to guide first-in-human phase I clinical trials, and several 
algorithms are used for determining the appropriate dose of a therapeutic agent. One approach 
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utilizes one-tenth of the dose that results in 10% lethality (LD10) in mice as a starting dose. 
However, if toxicology studies in non-rodent species show significant toxicity or limited lethality, 
one sixth to one third of the lowest dose that results in toxicity, the toxic dose low (TDL), is used 
as the starting dose (13). While these guidelines have been used for cytotoxic chemotherapy, 
appropriate rules and models to use for first-in-human studies of molecularly targeted agents 
are less clear (14) and use in combination further complicates choosing the initial first dose in 
humans. Molecularly targeted therapies can often result in significantly lower toxicity compared 
with cytotoxic chemotherapy, thus the use of LD10 may result in a very high recommended first 
dose since effective doses may be much lower than the maximum tolerable dose due to 
maximal target engagement and receptor occupancy (15). The dosing schedule will also require 
optimization based on maintaining inhibition rather than recovery from toxicity. Thus 
understanding and optimizing dosing based on mechanisms of action for molecularly targeted 
therapies is essential in preclinical and clinical drug development (16).  
The PET probe used in the current study is a tool to help provide mechanistically driven rational 
dosing of DI-87 and similar compounds prior to clinical trials. The use of non-invasive PET 
probes and scans can greatly aid in drug development. Imaging studies in early phase 
development can confirm that molecules reach the target tissue, do not accumulate in target 
sites, determine dose-target occupancy, and help critically evaluate similar drug candidates 
based on responses (17). Our group developed [18F]FAC (1-(2’-deoxy-2’-[18F]fluoro-β-D-
arabinofuranosyl)cytosine) as the first dCK specific PET probe (6). This compound has been 
used in preclinical drug development of small molecule dCK inhibitors (18). We subsequently 
developed a more specific probe, [18F]CFA, which was used in the current study to evaluate 
dCK activity in tumors when given a small molecule dCK inhibitor. This probe is also being 
studied in a clinical trial to evaluate changes in dCK activity with cancer immunotherapy at our 
institution (19). PET probes in preclinical and clinical studies can aid in understanding how drug 
distribution in target tissues and response on the target pathway is modified in the presence of 
multiple drugs as compared to single agent therapy. They can help evaluate the degree of 
synergy, appropriate timing of therapies, and dosing amount. Our growth inhibition studies 
utilized a fixed dose of thymidine with varying doses of DI-87 and dual inhibition led to effective 
growth inhibition when full dCK inhibition was achieved throughout the dosing interval. 
The current study was limited in that each time point represented a separate mouse since the 
half-life of the probe did not allow for multiple images within the same mouse. The probe 
required time for optimal diffusion in the tumor, thus we were unable to quantify dCK inhibition at 
very early time points. PK in the tumor was evaluated in separate mice rather than using a 
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probe to follow drug levels over time. However similar results were obtained between replicate 
experiments and results between mice were similar at each time point, thus this was unlikely to 
be a major limitation. While a fixed dose of intraperitoneal thymidine was used for growth 
inhibition in the current study, either an IV or oral RNR inhibitor will be necessary for 
combination therapy in further clinical development. 
In summary, the current study describes the preclinical development and pharmacology of a 
novel dCK inhibitor, DI-87. It provides additional evidence for the value of PET probes in 
assisting with preclinical drug development. By using a probe specific for dCK activity, we were 
able to find a DI-87 dose that resulted in maximal dCK inhibition throughout the dosing interval 
and accurately predict appropriate dosing for growth inhibition studies. We have developed PK-
PD models for both dCK inhibition and growth inhibition and both can be used to optimize 
dosing schedules for preclinical studies. Thus, DI-87 is a promising new compound for 
combination therapy in tumors expressing DCK.  
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Table 1: PK-PD modeling parameter estimates 
Plasma-Tumor PK model parameters
Parameter 
Estimate
Standard 
Error
CL (L/hr/kg) 0.46 0.03
V (L/kg) 2.78 0.22
KA (hr) 0.66 (FIXED) .
Q (L/hr/kg) 0.0045 0.0013
Scalar 3.69 0.40
Eta1 (Scalar) 34.6% 0.08
Proportional Error 49.9% 0.04
DCK inhibition PK-PD model
Kout 0.12 0.00011
Emax 1.20 0.00200
EC50 0.31 0.00009
Gamma (Hill coefficient) 58.60 0.18500
Kin 0.76 0.00078
Additive Error 0.88 0.00025
Growth Inhibition PK-PD Model
Kout 0.372 0.0973
Emax 1.06 0.2030
Growth Function Exp 1 0.00498 0.0011
Growth Function Exp 2 1.47 0.0399
EC50 3.63 1.19
Intersubject Variability (Emax) 14.1% 2.65%
Additive Error 0.20 0.02
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FIGURES 
 
Fig. 2.1. Schematic of population PK-PD model. DI-87 is an oral drug which is absorbed from 
the gut with an absorption constant (KA). It distributes between the plasma volume (Vp) and 
tumor volume (Vt) with an intercompartmental clearance Q and is eventually cleared from the 
plasma compartment (CL). Tumor DI-87 concentrations lead to drug effect (DCK inhibition or 
growth inhibition). DCK inhibition with modeled with a sigmoid Emax indirect response model 
while growth inhibition was modeled with an Emax indirect response model. 
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Gut
DI-87 oral
VP
(Plasma)
VT
(Tumor)
Q • dCK
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 Fig. 2.2. Synthesis and in vitro activity of DI-87. (A) Structure of DI87. (B) Synthetic route of 
DI-87. (C) IC50 values determined using 3H-dC uptake assay in CEM T-ALL cells to measure 
inhibition of dCK activity. (D) Dose response of DI-87 in CEM T-ALL cells treated with 10 nM 
Gemcitabine (n=4; mean±SD) for 72h determined using Cell Titer Glo. (E) Protein binding of 
DI-87 and (R)DI-82 assessed by comparing IC50 of the compounds in presence of 25 and 50 
mg/mL BSA (n=2; mean±SD). 
!80
0 6 12 18 24
Time (hr)
0.05
0.1
1
10
50
D
I8
7 
C
on
co
nc
en
tr
at
io
n 
(æ
g/
m
L)
50 mg /kg
25 mg /kg
10 mg /kg
OMe
O
NS
TFAO
N
O
OMe
O
NS
HO
N
O
CN
OMe
OH
OMe
O
CN
N
O
OMe
O
N
O
S NH2
OMe
O
N
O
NS
O
OMe
O
N
O
NS
S
N
N
H2N
NH2
N
O
Cl
Cs2CO3 
DMF 
70 °C
(NH4)2S (20%)
Et3N 
Pyridine 
60 °C
Br
O
O
Ethanol 
Reflux
TFAA
0°C 
DCM
N
NHS NH2
NH2
Cs2CO3 
80 °C 
DMF
(R)-CBS
BH3–THF complex 
THF 
-78 °C
1 2 3
4 5 6
OMe
O
N
O
NS
S
N
N
H2N
NH2
(R)
A
0 1 2 3 4 5
0
25
50
75
100
125
log[Gem] nM
%
 c
on
tro
l g
ro
wt
h
+ (R)DI-87
- (R)DI-87
-2 0 2 4
0
50
100
150
dCKi log10 (nM)
[3
H]
-d
C 
up
ta
ke
 
(%
 c
on
tro
l)
(S)DI-87
(R)DI-87
0 25 50
0
10
20
30
40
50
BSA [mg/mL]
IC
50
 (n
M
)
(R)-DI-82
(R)-DI-87
C D E
 Fig. 2.3. Plasma and tumor concentrations. Each data point represents the plasma and 
tumor concentrations from a single mouse (n=5 per time point). Plasma concentrations are 
higher than tumor concentrations and have an earlier peak. Plasma and tumor PK was linear 
over the range of concentrations studied. Tumor sizes for the 50 mg/kg dose were larger than 
those for the 25 mg/kg dose resulting in similar mcg/mL concentrations despite more overall 
drug in the 50 mg/kg dosage tumors.  
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Fig. 2.4. dCK inhibition studies. A. dCK activity in tumors. DI-87 was administered as 
a single dose to mice and PET scans were completed following drug administration. 
dCK activity from representative mice over time is shown for 25 mg/kg, 10mg/kg, and 5 
mg/kg. B. dCK activity as measured by PET scans. dCK inhibition was prolonged with 
higher doses of drug (25 mg/kg vs. 10 mg/kg). Minimal inhibition was seen at 5 mg/kg. 
C. Simulation of dCK activity for three doses of DI-87. 
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Experiment 1 Experiment 2
 Fig. 2.5. Growth inhibition experiments. A. Scheme of treatment study of dT+DI-87, DI87 was 
administered as multiple doses in combination with thymidine to mice. Experiment compared 10 
mg/kg daily to 25 mg/kg daily dosing of DI-87. B. Representative tumors after 1 week of 
treatment with agents as indicated. C. Quantification of tumor volume after 1 week of treatment 
with agents as indicated. Data represent the mean and standard deviation of 5 mice. D. Growth 
inhibition model simulations. Solid lines represent simulations from final PK-PD model and 
symbols represent data from: Experiments 1 and 2. Overall the model represents data well.  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CHAPTER 3 
Evaluation of potent isoquinoline-based 
thiosemicarbazone antiproliferatives against solid tumor 
models  
!88
ABSTRACT 
A potent class of isoquinoline-based ⍺-N-heterocyclic carboxaldehyde thiosemicarbazone (HCT) 
compounds has been re-discovered; based on this scaffold we have synthesized three series of 
antiproliferative agents through iterative rounds of methylation and fluorination modifications. 
Synergy between isoquinoline fluorination and 4’ amine methylation was identified, and 
incubation of the compounds with physiologically relevant levels of CuCl2 was shown to further 
potentiate their activity. The lead compound, HCT-13, was highly potent against a panel of 
pancreatic, small cell lung carcinoma, and prostate cancer models, with IC90 values in the low-
to-mid nanomolar range. We show that the cytotoxicity of HCT-13 is copper-dependent, that it 
acts as a copper ionophore, induces production of reactive oxygen species (ROS), and 
promotes mitochondrial dysfunction and S-phase arrest. Lastly, DNA damage response/
replication stress response (DDR/RSR) pathways, specifically Ataxia-Telangiectasia Mutated 
(ATM) and Rad3-related protein kinase (ATR), were identified as actionable adaptive resistance 
mechanisms following HCT-13 treatment. Taken together, HCT-13 is potent against solid tumor 
models and warrants in vivo evaluation against aggressive tumor models, either as a single 
agent or as part of a combination therapy.    
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INTRODUCTION 
The diverse therapeutic potential of ⍺-N-heterocyclic carboxaldehyde thiosemicarbazones 
(HCTs) have been investigated since the 1940s, with tuberculostatic activity being first observed 
in vivo as early as 1946.1 This class of compounds was subsequently shown to possess 
antitumor, antiviral, antibacterial, and antifungal activities, prompting decades of research and 
development.2–7 In particular, isoquinoline-based HCTs such as IQ-1 (HCT-1)3 were the subject 
of early interest due to their efficacy, particularly in terms of 50-day survival rates of tumor-
bearing mice (Figure 1).5 The research groups of Sartorelli and French spent decades 
developing isoquinoline HCTs and investigating other HCT scaffolds, eventually turning their 
attention to pyridyl-based HCT analogs. Notably, in 1992 Sartorelli and coworkers developed 3-
aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, also known as Triapine), a pyridyl-
based HCT. It has since undergone multiple clinical trials for the treatment of various cancers, 
and it is widely accepted to inhibit ribonucleotide reductase (RNR), a critical enzyme for rapidly 
proliferating cells such as bacteria and cancer cells.8–14 Two other HCT compounds, namely 
di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC) hydrochloride and 4-(2-
pyridinyl)-2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide-1-piperazinecarbothioic acid 
(COTI-2)15,16, have been investigated in the clinic. However, despite the early promise, no HCT 
compounds have yet advanced beyond phase II clinical trials.13 
While the mechanisms of action of HCTs are multi-modal and have not yet been fully 
defined17–25, their biological activities generally stem from the ability to chelate transition metals 
through their heterocyclic nitrogen, Schiff base nitrogen, and thiosemicarbazone sulfur. The 
resulting HCT-metal complexes can undergo redox cycles, a property that generates cytotoxic 
reactive oxygen species (ROS) through Fenton and/or Haber-Weiss processes.26 HCTs are 
particularly adept at binding copper27, which can be either detrimental or beneficial to the 
compound’s biological activity. For instance, physiological concentrations of copper in human 
plasma (11-18 µM)28,29 strongly interfere with the RNR-inhibitory activity of 3-AP27, while the 
cytotoxicities of Dp44mT30,31 and NSC-31972632 against glioblastoma and other cancer models 
are potentiated by copper. Binding of this transition metal is intriguing from an anticancer 
therapy standpoint, as cancers rely upon higher intracellular levels of copper, relative to healthy 
cells, to promote angiogenesis, tumor growth, and metastasis.33,34 Indeed, several therapeutic 
strategies have employed small molecules to disrupt copper homeostasis in cancers, either 
through chelation-mediated copper sequestration, or by increasing intracellular copper to 
cytotoxic levels through ionophoric modalities.32,35 
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The antiproliferative effects of HCTs coupled with their ability to bind copper make them a 
compelling scaffold from which to develop copper-mediated therapeutics. We have identified 
isoquinoline-based HCTs as a viable scaffold for this purpose, as previously reported analogs 
demonstrated both in vitro and in vivo efficacy. Additionally, studies investigating the isoquinoline 
HCT chemical space have not emerged for years, as focus shifted away from this scaffold 
following the report of 3-AP.3,5,6 Therefore, we aimed to develop novel isoquinoline-based HCTs 
which leverage copper against malignancies. Herein, the design and synthesis of such a series 
of molecules is reported, with identification of a lead compound (HCT-13) which inhibits 
proliferation of pancreatic ductal adenocarcinoma (PDAC), small cell lung carcinoma (SCLC), 
and prostate cancer (PC) models at nanomolar concentrations in the presence of physiologically 
relevant levels of copper. We further demonstrate that HCT-13 increases intracellular copper 
levels, generates reactive oxygen species (ROS), and interferes with the mitochondrial electron 
transport chain. Additionally, we have identified actionable adaptive resistance mechanisms 
which could be exploited in combination therapies. 
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METHODS AND MATERIALS 
Cell culture and culture conditions 
Pancreatic adenocarcinoma cell lines: PATU8988T, MIAPACA2, SU8686, PSN1, HPAC, 
BXPC3, DANG, SUIT2, A13A, CAPAN2, T3M4, A2.1, HUPT4, XWR200, L36PL, YAPC, 
PANC0327, PANC1, PATU8902, HPAF11, ASPC1, PANC0813, PANC0203, HS766T, SW1990, 
and CFPAC1; prostate cancer cell lines: 22Rv1, LNCaP, RM1 and C4-2; and small cell lung 
carcinoma cell lines: NCI-H526, NCI-H146, and NCI-H1963 were obtained from American Type 
Culture Collection (ATCC). 143 BTK WT and 143 BTK ρ0, BJ WT and BJ ρ0 cells were gifts from 
Prof. Michael Teitell in UCLA. Murine Prostate cancer cell lines MyC CaP was a kind gift from 
Prof. DLJ Thorek at WUSTL. Murine Pancreatic cancer cells KP4662 was kind gift from Prof. 
Robert Vonderheide at UPenn. With a few exceptions, cell lines were cultured in DMEM 
(Corning) or RPMI (Corning) containing 10% fetal bovine serum (FBS, Omega Scientific) and 
were grown at 37 °C, 20% O2 and 5% CO2. All cultured cells were incubated in antibiotic free 
media and were regularly tested for mycoplasma contamination using MycoAlert kit (Lonza) 
following the manufacturer’s instructions, except that the reagents were diluted 1:4 from their 
recommended amount. 
Proliferation assay 
Cells were plated in 384-well plates (500 cells/well for adherent cell lines in 30 µl volume). Drugs 
were serially diluted to the desired concentrations and an equivalent volume of DMSO was 
added to vehicle control. Following 72 h incubation, ATP content was measured using CellTiter-
Glo reagent according to manufacturer’s instructions (Promega, CellTiter-Glo Luminescent Cell 
Viability Assay), and analyzed by SpectraMax luminometer (Molecular Devices). IC50  and IC90 
values, concentrations required to inhibit proliferation by 50% and 90% respectively compared 
to DMSO treated cells, were calculated using Prism 6.0 h (Graphpad Software). 
Western blot 
Cells were lysed using RIPA buffer supplemented with protease (ThermoFisher, 78,430) and 
phosphatase (ThermoFisher, 78,420) inhibitors, scraped, sonicated, and centrifuged (20,000 × g 
at 4 °C). Protein concentrations in the supernatant were determined using the Micro BCA 
Protein Assay kit (Thermo), and equal amounts of protein were resolved on pre-made Bis-Tris 
polyacrylamide gels (Life Technologies). Primary antibodies: pAMPKT172 (Cell signaling, #2535, 
1:1000), HO-1 (Cell signaling, #5061S, 1:1000), pS345 CHEK1(Cell signaling, #2348L, 1:1000), 
pT68 CHEK2 (Cell signaling, #2197 S, 1:1000), pS139 H2A.X (Millipore, 05-636, 1:1000), clvd. 
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Casp3 (Cell signaling, #9662, 1:1000), and anti-actin (Cell Signaling Technology, 9470, 
1:10,000). Primary antibodies were stored in 5% BSA (Sigma-Aldrich) and 0.1% NaN3 in TBST 
solution. Anti-rabbit IgG HRP-linked (Cell Signaling Technology, 7074, 1:2500) and anti-mouse 
IgG HRP-linked (Cell Signaling Technology, 7076, 1:2500) were used as secondary antibodies. 
Chemiluminescent substrates (ThermoFisher Scientific, 34,077 and 34,095) and 
autoradiography film (Denville) were used for detection. 
Viability/Apoptosis assay 
Viable cells were measured by Trypan blue staining using vi-cell counter (Beckman Coulter, CA, 
USA). Apoptosis and cell death were assayed using Annexin V-FITC and PI according to 
manufacturer’s instructions (FITC Annexin V Apoptosis Detection Kit, BD Sciences, #556570). 
Cell cycle 
Cell cycle was assessed using Propidium iodide staining at indicated timepoints. Cells were 
pulsed with EdU 1 h before collection at different time points. Cells were fixed 4% 
paraformaldehyde, permeabilized with perm/wash reagent (Invitrogen), stained with Azide-
AF647 (using click-chemistry, Invitrogen; Click-iT EdU Flow cytometry kit, #C10634) and 
FxCycle-Violet (Invitrogen), and then analyzed by flow cytometry (a detailed description is 
available in the Supplementary Information). 
ROS Measurements 
Cellular ROS measurement was assayed with CM-H2DCFDA staining after treatment according 
to manufacturer’s instructions (Reactive Oxygen Species (ROS) Detection Reagents, Invitrogen, 
#D399). The cells were then incubated with 5 µM of CM-H2DCFDA for 30 min, spun down at 
450 x g for 4 mins, and the supernatant was replaced with fresh media containing lethal 
compounds and/or Cu(II). Then, the cells were incubated for 30 mins, spun down, and the 
supernatant was replaced with PBS. The samples were analyzed using flow cytometry. 
Mitochondrial ROS was measured using MitoSOX staining according to manufacturer’s 
instructions (MitoSOX, Invitrogen, #M36008). Cells were treated with HCT-13, washed and 
treated with MitoSOX. Cells were then incubated for 30 minutes at 37°C. After incubation, media 
is aspirated and cells are washed with PBS and analyzed by flow cytometry. 
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Mito Stress Test and Electron Flow Assay 
All oxygen consumption rate (OCR) was measured using a XF24 Analyzer (Agilent) and 
normalized per µg protein. For cellular OCR, cells were incubated in unbuffered DMEM 
containing 25 mM glucose, 1 mM pyruvate and 2 mM glutamine. OCR was measured before 
(total respiration) and after the sequential injection of 1 µM oligomycin (complex V inhibitor), 
0.75 µM FCCP (uncoupler), and 1 µM of rotenone and myxothiazol (complex I and III inhibitors, 
respectively), as described previously (1). Mitochondrial respiration was calculated by 
subtracting the non-mitochondrial respiration left after rotenone and myxothiazol injection. 
Oligomycin-sensitive respiration represents ATP-linked respiration (coupled respiration).  
To measure electron transport chain complex activity from cells, cells were incubated in MAS 
buffer with 10 mM pyruvate (complex I substrate), 2 mM malate, 4 µM FCCP, 4 mM ADP, and 1 
nM of XF Plasma Membrane Permeabilizer (PMP) reagent (Agilent). OCR was measured 
before and after the sequential injection of 2 µM rotenone, 10 mM succinate (complex II 
substrate), 4 µM antimycin A (complex III inhibitor), and a mix of 10 mM ascorbate and 100 µM 
TMPD (complex IV substrates), as described previously (2). Antimycin A-sensitive respiration 
represents the complex III respiration. 
To measure OCR directly from mitochondria, mitochondria were isolated from fresh mouse liver 
by dual centrifugation at 800g and 8000g and seeded by centrifugation (2). Mitochondria were 
incubated with 1 mM pyruvate (complex I), 2 mM malate, 4 µM FCCP in MAS buffer, as well as 
the “corresponding drugs” for 30 min at 37ºC. OCR was measured before and after the 
sequential injections described in the previous paragraph.  
Intracellular Cu(II) measurement 
Cells were plated in 6-well plates and cultured for one day. Vehicle of HCT-13 were added to the 
cells the following day and incubated for 24 hours. The plates were then washed 2 times with 
PBS containing 1 mM EDTA and 2 times with PBS alone. The concentration of Cu(II) was 
measured using Inductive Coupled Plasma Mass Spectrometry (ICP-MS) using standard 
procedure.  
DHODH activity 
Recombinant protein was incubated in an aqueous solution (total volume, 1.0 mL) containing 
500 µM DHO (Sigma, D1728), 200 mM K2CO3-HCl (pH 8.0), 0.2% triton x-100, and 100 µM 
coenzyme Q10 (Sigma, C9538) at 37 °C for 0, 15, 30, 45, or 60 min. An aliquot (100 µL) of the 
mixture of enzyme reaction mixture or cell/tissue lysate was mixed with 100 µL of 0, 0.5, or 1.0 
µM orotic acid, 50 µL of H2O, 250 µL of 4.0 mM 4-TFMBAO (Sigma, 422231), 250 µL of 8.0 mM 
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K3[Fe(CN)6] (Sigma, 244023), and 250 µL of 80 mM K2CO3 (Sigma, P5833) and then heated at 
80 °C for 4.0 min. The reaction was stopped by cooling in an ice-water bath and the absorbance 
was measured with a spectrofluorometer (FP-6300 Jasco, Tokyo, Japan): excitation and 
emission wavelengths were 340 nm and 460 nm, respectively. 
FACS analyses 
All flow cytometry data were acquired on a five-laser LSRII cytometer (BD), and analyzed using 
the FlowJo software (Tree Star). 
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RESULTS 
Synthesis of isoquinoline-based ⍺-N-heterocyclic carboxaldehyde thiosemicarbazone 
(HCT) compounds 
Among the previously reported isoquinoline HCTs, the 5-, 7-, and 8-fluoro analogs of HCT-1 
were of particular interest to our group. These compounds varied in terms of potency and 
toxicity5, demonstrating that the effects of fluorination were dependent upon the position of 
isoquinoline substitution. The benefits that fluorination endows upon small-molecule drugs are 
well documented36,37, and are also reflected in the marketplace, since approximately 20% of all 
pharmaceuticals are fluorinated.38 Therefore, it was important to investigate how the previously 
unreported 4- and 6-fluoro analogs of HCT-1 would perform in antiproliferative assays against 
cancer models. Additionally, we were intrigued as to whether fluorination at these positions 
would synergize with 4’ amine alkylation, as Kowol et al. discovered that 4’ amine alkylation 
potentiated the cytotoxicity of 3-AP analogs.39 
A total of 15 isoquinoline-based HCTs – four known compounds (HCT-1, HCT-4, HCT-5, HCT-6) 
and 11 novel compounds – were synthesized and tested for antiproliferative potency against 
cancer models (Scheme 1, Table 1). The synthetic approach began with methylation of the 
appropriate isoquinoline 1 to generate 2 (Scheme 1). Depending upon the desired 5-position 
substituent, 2 was then subjected to either Route A (5-hydrido), Route B (5-amino), or Route C 
(5-methylamino). Syntheses of HCTs 1-3, HCTs 6-8, and HCTs 11-13 were carried out by Route 
A, wherein the methyl substituent of 2 was oxidized using selenium dioxide (SeO2) to furnish the 
carboxaldehyde 3. Condensation with the appropriate thiosemicarbazide under acidic conditions 
yielded the desired HCT. HCT-5 and HCT-10 were synthesized via Route B, which began with 
nitration of 2 followed by an iron-mediated reduction to the amine, which was subsequently Boc-
protected and oxidized to produce carboxaldehyde 4. This intermediate was then 
simultaneously Boc-deprotected and condensed with the appropriate thiosemicarbazide under 
acidic conditions to furnish the target HCT. Syntheses of HCT-4, HCT-9, HCT-14, and HCT-15 
via Route C proceeded from 2 with installation of a nitro group, subsequent conversion to the 
mono-Boc-methylamine, and SeO2-mediated oxidation to furnish 5. Concurrent Boc-
deprotection and thiosemicarbazide condensation were again achieved under acidic conditions 
to provide the desired HCT compound. While characterizing the HCTs, we occasionally 
observed the presence of a minor Z-isomeric product, particularly for HCTs 11-15. This isomer 
arose from an intramolecular hydrogen bond between the 2’ amine of the thiosemicarbazone 
and the heterocyclic isoquinoline nitrogen, forming a stable 6-membered hydrogen bonded 
species.40 The E and Z isomers were inseparable by reversed-phase HPLC purification and 
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were used as a mixture in vitro, as previous studies reported no significant difference in potency.
40 
Fluorination and dimethylation display synergistic effects further potentiated by copper 
supplementation 
IC90 values against MIAPACA2 cells for all compounds were first determined in normal cell 
culture conditions (DMEM media and 10% FBS) (Figure 2). Compounds were separated into 
three series – 4’ primary amines, 4’ secondary amines, and 4’ tertiary amines – to reflect the 
relative degrees of 4’ amine methylation. A series of non-methylated 4’ primary amine 
compounds was first synthesized, with known compounds HCT-1, HCT-4, and HCT-5 included 
to gauge whether fluorination of the isoquinoline proved beneficial for biological activity.41,42 
Within the 4’ primary amine series, fluorination at the isoquinoline 4-position (HCT-2) did not 
show an increase in potency relative to unsubstituted analog HCT-1. However, fluorination at 
the 6-position (HCT-3) showed a 3-fold increase in potency, demonstrating that the fluorine 
position impacts the potency of these compounds. 
In the 4’ secondary amine series, synergistic effect was observed when combining isoquinoline 
fluorination with 4’ amine methylation. The 4-fluorine substituted HCT-7 and the 6-fluorine 
substituted HCT-8 were each significantly more potent than their non-fluorinated analog HCT-6, 
as well more potent than their 4’ primary amine analogs (HCT-2 and HCT-3, respectively). The 
trend of isoquinoline substitution and 4’ secondary amine combining to enhance potency held 
for 5-methylamino substituted HCT-9 and 5-amino substituted HCT-10. Taken together, these 
results suggested that combining isoquinoline substitution, particularly 4- or 6-fluorination, with 
4’ amine methylation produced synergistic antiproliferative effects when compared with either 
modification alone. 
The effects of fluorine substitution became significantly more pronounced for the di-methylated 
4’-tertiary amine compounds HCT-12 and HCT-13, whose IC90 values were in the nM range and 
were roughly 110- and 270-fold more potent, respectively, when compared to their non-
fluorinated analog HCT-11. Fluorination at the 6-position (HCT-13) was found to be a superior 
modification when compared to fluorination at the 4-position (HCT-12), a trend which also held 
for the fluorine-substituted 5-methylamino compounds HCT-14 and HCT-15. 
HCT compounds are known to be copper chelators, and a recent publication by Stockwell and 
coworkers demonstrated that the activity of a known 4’ tertiary amine HCT (NSC-319726) was 
significantly potentiated by the addition of copper.32 To test whether our compounds were 
similarly potentiated, IC90 (+Cu IC90) values were determined against MIAPACA2 cells in media 
supplemented with physiologically relevant levels of copper (DMEM media + 10% FBS + 20 µM 
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CuCl2) (Fig. 2). While the activity of HCT-5 was attenuated, all other compounds displayed a 
significant increase in potency under copper-supplemented conditions. For non-fluorinated 
isoquinoline compounds HCT-1, HCT-6, and HCT-11, the +Cu IC90 values improved as the 
degree of methylation at the 4’ amine increased (10-fold, 60-fold, and 400-fold increase in 
potency, respectively, versus non-copper-supplemented IC90 values). Copper supplementation 
was similarly beneficial for fluorinated isoquinolines – all such compounds displayed significant 
improvements in antiproliferative potency in presence of copper, and fluorine substitution led to 
greater potency when compared with corresponding non-fluorinated analogs. Compounds 
bearing 4’ tertiary amines were the most active, achieving +Cu IC90 values as low as 21.6 nM 
(HCT-13). The results demonstrated that physiologically relevant levels of copper potentiated 
the activity of isoquinoline HCTs, and that 4’ amine methylation synergized with fluorine 
substitution. Due to its potency and straightforward synthesis, we chose HCT-13 as a lead 
compound for in-depth mechanism of action studies.  
HCT-13 highly potent against a panel of solid tumor models and induces copper-
dependent cytotoxicity 
Serum copper levels are elevated (>20 µM) in individuals with solid tumor types such as 
pancreatic ductal adenocarcinoma (PDAC), small cell lung carcinoma (SCLC), and prostate 
cancer (PC).43–48 These cancers rely upon elevated copper levels to sustain growth, making this 
transition metal a viable target for therapeutic modulation.34 In a panel of PDAC, SCLC, and PC 
cancer models cultured in media supplemented with physiologically relevant levels of copper 
(20 µM CuCl2), HCT-13 was a highly potent growth inhibitor, with +Cu IC90 values ranging from 1 
nM to 200 nM (Figure 3a). The MIAPACA2 cell line, a well-characterized PDAC model that was 
highly sensitive to HCT-13 treatment, was used to further investigate the mechanism of action of 
the lead compound. 
MIAPACA2 proliferation was measured in response to HCT-13 in the presence and absence of 
20 µM CuCl2 (Cu(II)), as well as in response to 20 µM Cu(II) alone (Figure 3b). The potency of 
HCT-13 improved by greater than 5-fold under Cu(II) supplemented conditions, with its IC90 
decreasing from 110 nM to 21 nM. Importantly, Cu(II) supplementation alone did not affect 
proliferation at all. To probe whether HCT-13 was acting as an ionophore, intracellular copper 
levels were measured using inductively coupled plasma mass spectrometry (ICP-MS). In the 
presence of HCT-13, intracellular copper levels increased both with and without Cu(II) 
supplementation (Figure 3c). Additionally, treatment with bathocuproine disulfonate (BCPS), a 
membrane impermeable Cu(II) chelator, abrogated the cytotoxicity of HCT-13 in the presence of 
Cu(II), suggesting that the growth inhibitory effect of our lead compound is largely dependent 
upon the availability of copper (Figure 3d). Collectively, this data suggests that HCT-13 is a 
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Cu(II) ionophore which increases intracellular copper concentration, and whose cytotoxicity is 
copper-dependent. 
HCT-13 induces oxidative stress and ROS production 
While HCT-13 in the presence of Cu(II) exhibited nanomolar potency against a panel of solid 
cancer models, the underlying reasons remained unknown as the canonical mechanism of HCT 
cytotoxicity is poorly defined in the literature. Cu(II)-supplemented MIAPACA2 cells treated with 
HCT-13 showed induction of AMPK phosphorylation (T172) at 24 h, demonstrating suppression 
of mitochondrial oxidative phosphorylation (Figure 4a). Further, HCT-13 treatment increased 
heme oxygenase-1 (HO-1) levels in MIAPACA2 cells, indicative of ROS induction (Figure 4a). 
Based on the immunoblot results, we set out to determine whether HCT-13 treatment was 
leading to ROS generation. We found that treatment with our lead compound induced ROS 
generation detectable by CM-H2DCFDA staining (Figure 4b). Interestingly, ROS generation 
resulting from HCT-13 treatment of MIAPACA2 cells was also observed in the mitochondria, as 
measured by mitochondria-specific dye MitoSOX (Figure 4c). 
HCT-13 induces mitochondrial dysfunction and displays mitochondria-dependent 
cytotoxicity 
Considering the canonical role AMPK plays in energy homeostasis, and the implication that 
AMPK activation may signal mitochondrial dysfunction49, we compared the metabolic status of 
MIAPACA2 cells treated with HCT-13 for 24 hr with and without 20 µM Cu(II) using a Seahorse 
Bioscience XFe24 analyzer. In the presence of Cu(II), HCT-13 significantly reduced both the 
basal respiration and maximum respiratory capacities of MIAPACA2 cells, indicating 
mitochondrial electron transport chain (mtETC) impairment (Figure 5a). In vitro mitochondrial 
complex activity following HCT-13 treatment was dissected by an electron flow assay in isolated 
mitochondria, which showed decreased activity of complexes I and II (Figure 5b). 
These findings suggested that HCT-13 inhibited mtETC activity but did not indicate whether the 
lead compound’s cytotoxicity stemmed from effects independent of mitochondrial function. 
Another HCT compound, Dp44mT, was reported to increase AMPK expression and induce 
ROS, although its cytotoxicity was not attributed to the functionality of the mitochondria.50 To 
determine whether the cytotoxicity of HCT-13 was mitochondria-dependent, its effects upon 143 
BTK ρ0, an mtDNA-deficient fibroblast cell line, were examined. Both 143 BTK ρ0 and parental 
(wild type, WT) cells were treated with HCT-13 + 20 µM Cu(II) for 48 h, after which cell viability 
was determined through trypan blue staining (Figure 5c). Compared to WT, the ρ0 cells were 
significantly less sensitive to the treatment. The cytotoxicity of HCT-13 was partially abolished 
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by supplementation with uridine (rU) but not by pyruvate, suggesting disruption to the supply of 
pyrimidine nucleotides in addition to impaired mitochondria (Supplementary Figure S2a). 
Proper mitochondrial function is necessary for the action of dihydroorotate dehydrogenase, an 
enzyme critical for the de novo production of pyrimidine nucleotides, and one for which HCT-13 
did not demonstrate affinity (Supplementary Figure S2b). Additionally, cell cycle analysis 
revealed marked S-phase arrest in 143 BTK WT cells but not in 143 BTK ρ0 (Figure 5d). Taken 
together, these results indicate that the cytotoxic effects of HCT-13 are mitochondria-dependent 
and suggest that HCT-13 may be indirectly targeting DHODH, and thus de novo pyrimidine 
nucleotide production, through induction of mitochondrial dysfunction. 
Small molecule kinase inhibitor screen with HCT-13 identifies the DNA-damage pathway 
as a resistance mechanism 
To identify potential resistance mechanisms and synergistic interactions with HCT-13, we 
performed an unbiased pharmacological inhibition screen using a chemical genomics platform 
consisting of 430 kinase inhibitors (Selleckchem, Cat. L1200). MIAPACA2 cells were treated 
with the 430-member library, covering a 7-point concentration range spanning between 6.5 nM 
and 5 µM, with and without 25 nM HCT-13 in presence of 20 µM CuCl2. After 72 h of incubation, 
ATP content was measured using CellTiter-Glo (Figure 6a). A composite synergy score was 
calculated for each combination, defined as the sum of the Bliss Additivity Score (% proliferation 
inhibition observed - % proliferation inhibition expected). A positive synergy score indicates 
greater-than-additive interaction, and a negative score indicates less-than-additive interaction 
i.e. antagonism. 
The ten highest scoring compounds were kinase inhibitors contained in the DNA damage 
response/replication stress response (DDR/RSR) module, with the ATM/ATR/CHK pathway 
featuring as the most prominent codependency (Figure 6b, 6c). All six ATM, ATR and CHEK1 
inhibitors included in the library scored positively in the screen, indicating synergy with our lead 
compound. Upon HCT-13 + Cu(II) treatment, we consistently observed phosphorylation of the 
downstream targets of ATR and ATM, CHEK1 and CHEK2, respectively, indicating activation of 
this pathway as an adaptive resistance mechanism. This phosphorylation was accompanied by 
induction of DNA damage marker pH2AX and by cleavage of apoptotic marker caspase 3 
(Figure 6d). The synergistic interaction between HCT-13 and ATR inhibition was further 
validated using cell death assays measured by Annexin V/PI and Trypan Blue Viability Staining 
in PDAC (MIAPACA2, CFPAC-1) and PC (C4-2) cell lines (Figure 6E, 6F, and Supplementary 
Figure S3b, S3c).  
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DISCUSSION 
We primarily focused on two modifications of the HCT-1 (IQ-1) scaffold during our synthetic 
planning: fluorination of the isoquinoline ring, and sequential methylation of the 4’ amine. 
Though the 5-, 7-, and 8-fluoro-substituted analogs of HCT-1 were previously reported, and 
while it was apparent that fluorine position could influence a compound’s toxicity and produce 
differential antiproliferative effects upon various cell lines, no trends had previously emerged 
regarding the effects of fluorine position.5 Additionally, multiple groups have shown that 4’ amine 
methylation potentiates the activity HCTs such as pyridine 2-carboxyaldehyde 
thiosemicarbazones and 2-acetylpyridine thiosemicarbazones.24,39,40 We therefore sought to 
synthesize the novel 4- and 6-fluoro analogs of HCT-1 and investigate what effects sequential 4’ 
amine methylation had upon antiproliferative activity. Following our isoquinoline HCT synthetic 
campaign, analysis of the antiproliferative data revealed several trends. Without copper 
supplementation, fluorination at either the 4- or 6-position of the isoquinoline ring led to an 
increase in potency for five out of six compounds, when compared with their corresponding non-
fluorinated analogs (Figure 2). In some cases, the change was dramatic – for example, the IC90 
of HCT-13 was nearly 270-fold lower than its non-fluorinated analog HCT-11. Secondly, 4’ amine 
methylation in the absence of isoquinoline substitution or copper supplementation was 
detrimental to activity, as demonstrated by the decrease in potencies for HCTs 6 and 11 when 
compared with 4’ primary amine HCT-1 (Figure 2). However, combining 4’ amine methylation 
and isoquinoline substitution in a single compound, as in HCTs 7-10, 12 and 13, produced 
synergistic antiproliferative effects when compared with either their 4’ primary amine or 
unsubstituted isoquinoline analogs. HCT-13 again exemplified this trend, with potency nearly 
270-fold greater than its non-substituted isoquinoline analog HCT-11 and nearly 50-fold greater 
than its non-methylated analog HCT-3 (Figure 2). The underlying mechanisms responsible for 
this synergy remain under study by our group. Finally, the antiproliferative activities of all but 
one of our isoquinoline HCTs were potentiated by supplementation with physiologically relevant 
levels of copper, with HCT-5 being the exception.  
The observed trends culminated with identification of our lead compound as HCT-13, which was 
uncomplicated in its synthesis and potent both in the absence and presence of copper 
supplementation.  
The potency of HCT-13 is highlighted by its nanomolar IC90 values against a panel of PDAC, 
SCLC, and PC cancer models in the presence of physiologically relevant levels of copper 
(Figure 3a). The use of copper-chelating small molecules in anticancer therapy is an 
established strategy which is executed either through sequestration of copper from tumor tissue, 
or through increasing intracellular copper to cytotoxic levels.51 HCT-13 behaved as an ionophore 
and increased intracellular levels of copper, both in the presence and absence of copper 
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supplementation. This property is essential for the cytotoxicity of HCT-13, as sequestration of 
copper via BCPS-chelation negated our lead compound’s growth inhibitory effects (Figure 3d). 
We further demonstrated that HCT-13 leverages copper to effect its cytotoxicity in a 
mitochondria-dependent manner. Specifically, the data indicate that HCT-13 induces 
mitochondrial dysfunction and mitochondria-dependent S-phase arrest, and generates ROS and 
oxidative stress in different cancer models. Strikingly, mitochondria-deficient 143 BTK ρ0 cells 
were significantly less sensitive to HCT-13 in the presence of copper compared to their parental 
143 BTK WT counterpart, providing further evidence of mitochondria-dependent cytotoxicity 
(Fig 5c). It is possible that the observed S-phase arrest results from disruption of the de novo 
pathway (DNP) for pyrimidine nucleotide biosynthesis, which supplies cells with the pyrimidine 
nucleotides necessary for replication. The lone oxidation step of the pyrimidine DNP is carried 
out by dihydroorotate dehydrogenase (DHODH), an enzyme located in the inner mitochondrial 
membrane, which utilizes ubiquinone as a redox partner. Without a properly functioning 
mitochondrial ETC, DHODH does not have access to the levels of ubiquinone necessary for the 
oxidative enzyme to adequately turn-over, leading to shortages in pyrimidine nucleotides and 
corresponding S-phase arrest.52–57  
In general, cancer cells exhibit higher levels of ROS and higher baseline oxidative stress than 
healthy cells, which may imbue our lead compound with selectivity towards them. The ROS and 
mitochondrial dysfunction produced in MIAPACA2 cells by HCT-13 lead to an increase in DNA 
damage marker pH2AX, which may explain why our compound synergized with inhibitors of 
ATR (Ataxia-Telangiectasia Mutated (ATM) and Rad3-related protein kinase), the most upstream 
kinase in the DNA-damage response/replication stress response (DDR/RSR) pathway. Synergy 
with DDR/RSR inhibitors may increase the therapeutic window of our lead compound, should it 
be administered in combination therapy. The observed mechanisms of action of HCT-13 
suggest that it may also synergize with radiotherapy, as therapeutic ionizing radiation increases 
ROS, thereby increasing oxidative stress and DNA damage in the targeted area(s). Therefore, 
HCT-13 could also function as a radiosensitizer by further increasing the load of ROS, oxidative 
stress, and DNA damage when administered in combination with radiation therapy. Taken 
together, the potency of HCT-13 as a single-agent therapeutic against aggressive solid tumor 
models, its mechanism of action, and the observed synergy with ATR inhibitors warrant further 
testing in vivo.  
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CONCLUSION 
A class of isoquinoline-based HCTs has been expanded upon to produce a set of novel 
antiproliferative compounds. The synergistic effects of combining 4’ amine methylation with 
isoquinoline substitution were demonstrated, and HCT-13 was identified as a highly potent 
antiproliferative which is active against a panel of PDAC, SCLC, and PC cancer models. The 
presence of physiologically-relevant levels of Cu(II) greatly potentiated our lead compound’s 
activity, and subsequent investigation into HCT-13’s mechanism of action revealed that it acts as 
a copper ionophore and requires copper to effect its cytotoxicity. Furthermore, HCT-13 induces 
ROS production, oxidative stress, S-phase arrest, and mitochondrial dysfunction which may 
contribute to indirect inhibition of DHODH. Lastly, a high-throughput phenotypic screen of 
protein kinase inhibitors was used to identify actionable adaptive resistance mechanisms of 
HCT-13-treated cells, and the DDR/RSR pathways were revealed as actionable vulnerabilities. 
Specifically, we show that ATR inhibition synergizes with HCT-13 in presence of physiologically-
relevant levels of Cu(II). Taken together, this study demonstrates the potential of HCT-13 for use 
in anti-cancer therapy, either as a single agent or as part of a larger combination therapy. 
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FIGURES, SCHEMES AND TABLES 
Fig. 3.1. Structures of ⍺-N-heterocyclic carboxaldehyde thiosemicarbazone (HCT) 
compounds of clinical and research significance. 
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Figure 1
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Scheme 3.1. Synthesis HCT compounds 1-15 from simple isoquinolinesa,b 
a(a) allyl chloroformate, MeMgBr, THF; (b) Pd(PPh3)4, morpholine; DDQ, CH2Cl2; (c) SeO2, 
1,4-dioxane, 60 °C; (d) appropriate thiosemicarbazide, HCl, EtOH, reflux or microwave 50 °C; 
(e) KNO3, H2SO4; (f) Fe, HCl, MeOH, reflux; (g) Boc2O, DMAP, TEA, THF; (h) Boc2O, DMAP, 
TEA, THF; NaHCO3, MeOH, reflux or K2CO3, MeOH, reflux; (i) NaH, THF; MeI. bHCTs 1-3, 6-8, 
and 11-13 synthesized through Route A; HCTs 5 and 10 synthesized through Route B; HCTs 4, 
9, 14, and 15 synthesized through Route C. See Supporting Information for full synthetic details. 
Table 3.1. Substitution patterns of HCTs 1-15a 
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Scheme 1 and Table 1 
HCT-1 HCT-2 HCT-3 HCT-4 HCT-5 HCT-6 HCT-7 HCT-8 HCT-9 HCT-10 HCT-11 HCT-12 HCT-13 HCT-14 HCT-15
R1 H F H H H H F H H H H F H H F
R2 H H F H H H H F H H H H F F H
R3 H H H H H Me Me Me Me Me Me Me Me Me Me
R4 H H H H H H H H H H Me Me Me Me Me
5-Pos H H H NHMe NH2 H H H NH2 NHMe H H H NHMe NHMe
HCTs 1-15
1 2
3
4
5
a, b
d
d
d
c
Route A
e, f, g, c
Route B
e, f, h, i, c
Route C
a(a) allyl chloroformate, MeMgBr, THF; (b) Pd(PPh3)4, morpholine; DDQ, CH2Cl2; (c) SeO2, 1,4-dioxane, 60 °C; (d) appropriate 
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Route C. See Supporting Information for full synthetic details.
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Fig. 3.2. Cu(II) supplementation potentiates the activity of isoquinoline HCTs. MIAPACA2 
cells were treated with the indicated HCT ± 20 µM Cu(II) for 72 h, then cell viability was 
measured with CellTiter-Glo to determine IC90 values. 
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Figure 2
Fig. 2 | Cu(II) supplementation alters the po ency of a subset f HCT compounds. ACA2 
cells were treated with the indicated HCT ± 20 µM Cu(II) for 72 h, then cell viability was measured 
with CellTiter-Glo to determine IC90 values. 
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Fig. 3.3. Copper potentiates HCT-13 toxicity against a panel of cancer models. (a) IC90 in a 
panel of human and mouse prostate cancer (PC), small cell lung carcinoma (SCLC) and 
pancreatic ductal adenocarcinoma (PDAC) models treated with HCT-13 + Cu(II) (20 µM) for 72h 
measured by CellTiterGlo. (b) Proliferation rate of MIAPACA2 PDAC cells measured by 
CellTiterGlo following HCT-13 treatment for 72h ± Cu(II) (20 µM), and with Cu(II) alone. (c) 
Intracellular concentrations of copper measured by inductively coupled plasma mass 
spectrometry (ICP-MS) in MIAPACA2 PDAC cells treated with HCT-13 (25nM) for 24h ± Cu(II) 
(20 µM). (d) Inhibition of proliferation of MIAPACA2 cells treated with HCT-13 (25nM) + Cu(II) 
(20 µM) for 24h ± bathocuproine disulfonate (BCPS, 300 µM) measured by trypan blue 
exclusion.  
(mean ± SD, n = 2, one-way ANOVA corrected for multiple comparisons by Bonferroni 
adjustment, * P < 0.05; ** P < 0.01; *** P < 0.001). 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Fig. 3 | Copper potentiates HCT-13 toxicity against a panel of cancer models. (a) IC90 in a panel of human and mouse 
prostate cancer (PC), small cell lung carcinoma (SCLC) and pancreatic ductal adenocarcinoma (PDAC) models treated with 
HCT-13 + Cu(II) (20 µM) for 72h measured by CellTiterGlo. (b) Proliferation rate of MIAPACA2 PDAC cells measured by 
CellTiterGlo following HCT-13 treatment for 72h ± Cu(II) (20 µM). (c) Intracellular concentrations of copper measured by 
inductively coupled plasma mass spectrometry (ICP-MS) in MIAPACA2 PDAC cells treated with HCT-13 (25nM) for 24h ± Cu(II) 
(20 µM). (d) Inhibition of proliferation of MIAPACA2 cells treated with HCT-13 (25nM) + Cu(II) (20 µM) for 24h ± bathocuproine 
disulfonate (BCPS, 300 µM) measured by trypan blue exclusion.  
(mean ± SD, n = 2, one-way ANOVA corrected for multiple comparisons by Bonferroni adjustment, * P < 0.05; ** P < 0.01; *** P < 
0.001).
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 Fig. 3.4. Induction of ROS by HCT-13. (a) Representative immunoblots of MIAPACA2 PDAC 
cells treated as indicated for 24h. (b) Reactive oxygen species (ROS) measurement using CM-
H2DCFDA staining after HCT-13 (25nM) + Cu(II) (20 µM) treatment for 24h. (c) Mitochondrial 
ROS detection using MitoSOX staining in MIAPACA2 PDAC cells treated with HCT-13 (25 nM) 
+ Cu(II) (20 µM) for 24h. 
(mean ± SD, n = 2, Student t-test, ***P < 0.001). 
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Fig. 4 | HCT-13 induces oxidative stress in cancer cells (a) Representative immunoblots of MIAPACA2 PDAC cells treated as 
indicated for 24h. (b) Reactive oxygen species (ROS) measurement using CM-H2DCFDA staining after HCT-13 (25nM) + Cu(II) (20 
µM) treatment for 24h. (c) Mitochondrial ROS detection using MitoSOX staining in MIAPACA2 PDAC cells treated with HCT-13 (25 nM) 
+ Cu(II) (20 µM) for 24h. 
(mean ± SD, n = 2, Student t-test, ***P < 0.001).
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Fig. 4 | HCT-13 induces oxidative stress in cancer cells (a) Representative immunoblots of MIAPACA2 PDAC cells treated as 
indicated for 24h. (b) Reactive oxygen species (ROS) measurement using CM-H2DCFDA staining after HCT-13 (25nM) + Cu(II) (20 
µM) treatment for 24h. (c) Mitochondrial ROS detection using MitoSOX staining in MIAPACA2 PDAC cells treated with HCT-13 (25 nM) 
+ Cu(II) (20 µM) for 24h. 
(mean ± SD, n = 2, Student t-test, ***P < 0.001).
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Fig. 3.5. HCT-13 alters cellular energetics through inhibition of electron transport chain 
and has selective mitochondrial toxicity. (a) Mito Stress Test of MIAPACA2 PDAC cells 
treated with HCT-13 (25 nM) + Cu(II) (20 µM) for 24h. (b) Electron flow assay in isolated 
mitochondria treated with HCT-13 (100 nM) + Cu(II) (20 µM) for 1h. (c) Viability of 143 BTK 
parental (wild type, WT) and ρ0 cells after 48h of the indicated HCT-13 concentration + Cu(II) 
(20 µM) treatment, assessed with Trypan Blue Staining. (d) 48h cell cycle histogram and plots of 
S-phase arrest plots in 143 BTK WT and 143 BTK ρ0 cells at 24, 48 and 72h following treatment 
with indicated concentrations of HCT-13 + Cu(II) (20 µM). 
(mean ± SD, n = 2, one-way ANOVA corrected for multiple comparisons by Bonferroni 
adjustment, * P < 0.05; ** P < 0.01; *** P < 0.001). 
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Figure 5 
Fig. 5 | HCT-13 alters cellular energetics through inhibition of electron transport chain and has selective mitochondrial 
toxicity.  (a) Mito Stress Test of MIAPACA2 PDAC cells treated with HCT-13 (25 nM) + Cu(II) (20 µM) for 24h. (b) Electron flow assay 
in isolated mitochondria treated with HCT-13 (100 nM) + Cu(II) (20 µM) for 1h. (c) Viability of 143 BTK parental (wild type, WT) and ρ0 
cells after 48h of the indicated HCT-13 concentration + Cu(II) (20 µM) treatment, assessed with Trypan Blue Staining. (d) 48h cell cycle 
histogram and plots of S-phase arrest plots in 143 BTK WT and 143 BTK ρ0 cells at 24, 48 and 72h following treatment with indicated 
concentrations of HCT-13 + Cu(II) (20 µM). 
(mean ± SD, n = 2, one-way ANOVA corrected for multiple comparisons by Bonferroni adjustment, * P < 0.05; ** P < 0.01; *** P < 
0.001).
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Fig. 3.6. A chemical genomics screen identifies the replication stress response pathway 
as an actionable co-dependency of HCT-13-treated cells. (a) Experimental design of a 
synthetic lethality screen using a library of protein kinase inhibitors against HCT-13-treated cells 
in the presence of Cu(II) (20 µM). (b) Radar plot of screen results. (c) z-score values for kinase 
inhibitors within the DNA damage response/replication stress response (DDR/RSR) pathway 
module. (d) Representative immunoblot of replication stress and cell death biomarkers in 
MIAPACA2 PDAC cells treated with HCT-13 (10 nM) + Cu(II) (20 µM). (e) Annexin V/PI staining 
in MIAPACA2 cells to validate the synergistic interaction of HCT-13 (25nM) + Cu(II) (20 µM) with 
ATRi (250nM VE-822) treated for 72h. (f) Trypan Blue Viability staining in MIAPACA2 cells to 
validate the synergistic interaction of HCT-13 (25nM) with ATRi (250nM VE-822) treated for 72h 
in presence of Cu(II) (20 µM). 
(mean ± SD, n = 2, one-way ANOVA corrected for multiple comparisons by Bonferroni 
adjustment, * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001).F 
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Figure 6
a b c
Fig. 6 | A chemical genomics screen identifies the replication stress response pathway as an actionable co-dependency 
of HCT-13-treated cells. (a) Experimental design of a synthetic lethality screen using a library of protein kinase inhibitors against 
HCT-13-treated cells in the presence of Cu(II) (20 µM). (b) Radar plot of screen results. (c) z-score values for kinase inhibitors 
within the DNA damage response/replication stress response (DDR/RSR) pathway module. (d) Representative immunoblot of 
replication stress and cell death biomarkers in MIAPACA2 PDAC cells treated with HCT-13 (10 nM) + Cu(II) (20 µM). (e) Annexin 
V/PI staining in MIAPACA2 cells to validate the synergistic interaction of HCT-13 (25nM) + Cu(II) (20 µM) with ATRi (250nM 
VE-822) treated for 72h. (f) Trypan Blue Viability staining in MIAPACA2 cells to validate the synergistic interaction of HCT-13 
(25nM) with ATRi (250nM VE-822) treated for 72h in presence of Cu(II) (20 µM). 
(mean ± SD, n = 2, one-way ANOVA corrected for multiple comparisons by Bonferroni adjustment, * P < 0.05; ** P < 0.01; *** P < 
0.001; **** P < 0.0001).
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Fig. S3.1. Summary of HCT compound dose response curves. Viability curves measured 
with CellTiterGlo in MIAPACA2 cells treated with each HCT ± Cu(II) (20 µM) for 72h. 
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Supplementary data for Figure 2
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Fig. S1 | Summary of HCT compound dose response curves. Viability curves measured with CellTiterGlo in MIAPACA2 
cells treated with each HCT ± Cu(II) (20 µM) for 72h. 
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 Fig. S3.2. Cell proliferation inhibition induced by HCT-13 is partially rescued by uridine 
supplementation. (a) Rescue of HCT-13 (25 nM)-induced cell death by Uridine (rU) (200 µM), 
Pyruvate (1 mM), or both following 48h of treatment (b) Measurement of DHODH activity using 
recombinant DHODH assay following treatment with indicated perturbations for 2 min. DHODH 
inhibitor used: NITD-982 - 1 µM; HCT-13 - 100 nM, 1 µM, (100 nM data shown); Cu(II) - 20 µM.  
(mean ± SD, n = 2, Student t-test, * P < 0.05). 
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Fig. S2 | Cell proliferation inhibition induced by HCT-13 is partially rescued by uridine supplementation. (a) Rescue of 
HCT-13 (25 nM)-induced cell death by Uridine (rU) (200 µM), Pyruvate (1 mM), or both following 48h of treatment (b) 
Measurement of DHODH activity using recombinant DHODH assay following treatment with indicated perturbations for 2 min. 
DHODH inhibitor used: NITD-982 - 1 µM; HCT-13 - 100 nM, 1 µM, (100 nM data shown); Cu(II) - 20 µM.  
(mean ± SD, n = 2, Student t-test, * P < 0.05).
Figure S2
It is unclear what we mean by “HCT-13 affects de novo pyrimidine biosynthesis indirectly” 
The legend for panel b seems to be wrong. The gray likely corresponds to untreated cells 
while the blue corresponds to DHODHi. We should identify the DHODH inhibitor used in this 
assay. And we should write down the concentrations of both compounds.  
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Fig. S3.3. Identification of resistance mechanisms to HCT-13 using a synthetic lethality 
screen (a) Assay quality, as measured by Z-factor (Z’) scores (b and c) Annexin V/PI staining 
and Trypan Blue staining in CFPAC-1 PDAC cells and C4-2 PC cells to validate the synergistic 
interaction of HCT-13 with ATRi (250 nM VE-822) treated for 72h in presence of Cu(II) (20 µM).  
(mean ± SD, n = 2, one-way ANOVA corrected for multiple comparisons by Bonferroni 
adjustment, * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001). 
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Fig. S3 | Identification of resistance mechanisms to HCT-13 using a synthetic lethality screen (a) Assay quality, as measured by 
Z-factor (Z’) scores (b and c) Annexin V/PI staining and Trypan Blue staining in CFPAC-1 PDAC cells and C4-2 PC cells to validate the 
synergistic interaction of HCT-13 with ATRi (250 nM VE-822) treated for 72h in presence of Cu(II) (20 µM).  
(mean ± SD, n = 2, one-way ANOVA corrected for multiple comparisons by Bonferroni adjustment, * P < 0.05; ** P < 0.01; *** P < 
0.001; **** P < 0.0001).
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CHAPTER 4 
Metabolic modifier screen reveals secondary targets of 
protein kinase inhibitors within nucleotide metabolism  
!120
ABSTRACT 
A cell-based metabolic modifier screening platform for the discovery of modulators of 
convergent pyrimidine nucleotide biosynthetic pathways was designed and implemented. In 
screening a library of protein kinase inhibitors, multiple compounds were shown to possess 
previously uncharacterized metabolism modifying activity. The JNK inhibitor JNK-IN-8 was found 
to be a potent inhibitor of nucleoside transport, a property which was confirmed using 
nucleoside-analog PET imaging in mice. The PDK1 inhibitor OSU-03012 (also known as AR-12) 
and the RAF inhibitor TAK-632 were shown to inhibit the therapeutically relevant enzyme 
dihydroorotate dehydrogenase (DHODH) and their affinity unambiguously confirmed through in 
vitro assays and co-crystallization with human DHODH.  
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INTRODUCTION 
The redundant and plastic nature of metabolic networks represents a significant obstacle in the 
targeting of cancer metabolism. This hurdle manifests in two ways, the first being redundancy in 
enzymes performing identical biochemical reactions, such as the hexokinase isozymes which 
phosphorylate glucose(Xu et al., 2018). The second is the presence of convergent, parallel 
metabolic pathways producing a common metabolite from unique precursors, usually consisting 
of scavenging and de novo arms. Convergent metabolic nodes have been noted in 
nucleotide(Le et al., 2017), lipid (cholesterol)(York et al., 2015) and amino acid (aspartate) 
metabolism (Garcia-Bermudez et al., 2018). 
Despite these difficulties, the development of metabolism modifiers remains a robust area of 
research. One such therapeutically relevant target is pyrimidine nucleotide biosynthesis which 
consists of nucleoside scavenging (NSP) and de novo (DNP) pathways which both generate 
uridine monophosphate (UMP), the common precursor for all pyrimidine nucleotides (Okesli, 
Khosla, & Bassik, 2017). The NSP scavenges preformed nucleosides from the extracellular 
environment, shuttling them into the cell via nucleoside transporters where they are 
phosphorylated by uridine-cytidine kinases (UCKs) to produce UMP. It is thought that UCK2 is 
the primary NSP kinase, given its 20-fold higher catalytic efficiency compared with isozyme 
UCK1(An R. Van Rompay, Karin Linden, Magnus Johansson, Anna Karlsson, 2001). The DNP 
consists of a six-step process that utilizes glutamine, aspartate and bicarbonate to produce 
UMP through the action of the trifunctional enzyme CAD, electron transport chain-linked 
dihydroorotate dehydrogenase (DHODH), and bifunctional UMP synthase (UMPS). Amongst 
these proteins, DHODH in particular has been the subject of significant research interest in 
anticancer settings(Madak, Bankhead, Cuthbertson, Showalter, & Neamati, 2019; Sykes et al., 
2016), including pancreatic ductal adenocarcinoma (PDAC)(Santana-Codina et al., 2018). This 
interest is complemented by over 90 patent applications involving DHODH inhibition in the last 
decade(Lolli et al., 2018). 
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In this study, we show that the pyrimidine NSP and DNP are interchangeable in their ability to 
sustain cancer cell proliferation and that a synthetic lethal phenotype can be achieved through 
their simultaneous inhibition. With this knowledge, we construct a metabolic modifier screen for 
identifying selective modulators of NSP and DNP pathways. In screening a library of protein 
kinase inhibitors, we found that the c-Jun N-terminal kinase (JNK) inhibitor JNK-IN-8 is a potent 
inhibitor of nucleoside transporters vital for NSP function, and that the 3-phosphoinositide-
dependent protein kinase 1 (PDK1) inhibitor OSU-03012 (also known as AR-12) and the pan-
RAF inhibitor TAK-632 both bind and inhibit the pyrimidine DNP enzyme DHODH. 
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METHODS AND MATERIALS 
Data Availability 
Full kinase inhibitor library phenotypic screen results are included as Supplemental Table 1. 
The accession numbers for the protein structure data reported are 6OC0 (OSU-03012:DHODH) 
and 6OC1B (TAK-632:DHODH). 
Cell culture 
All cell cultures were between passages 3 and 20 and maintained in antibiotic free DMEM or 
RPMI +10% dialyzed FBS, at 37ºC in 5% CO2. We routinely monitored for mycoplasma 
contamination using the PCR-based Venor Mycoplasma kit. PDAC cell lines were acquired 
either from a commercial vendor (ATCC, DSMZ) or from collaborators. Cell line identity was 
independently authenticated by PCR. 
Drugs 
Drug stocks were prepared in DMSO or H2O and diluted fresh in cell culture media for 
treatments. NITD-982 was synthesized as previously described by Dr. Daniel Sun and Ethan 
Rosser (UCLA)(Bonavia et al., 2011). 
In vivo mouse studies 
All animal studies were approved by the UCLA Animal Research Committee (ARC). 4-6 week-
old female NSG mice, obtained from UCLA Radiation Oncology, were injected subcutaneously 
on bilateral flanks with 0.5x106 CCRF-CEM cells suspended 1:1 in PBS:matrigel. 20 d post-
inoculation treatment was initiated. JNK-IN-8 was suspended in 2% ethanol and 5% Tween-80 
in PBS and administered by intraperitoneal (i.p.) injection at 25 mg/kg. 
Protein kinase inhibitor phenotypic screen 
A library of 430 protein kinase inhibitors was arrayed in polypropylene 384-well plates at 200x 
concentrations covering a 7-point concentration range (corresponding to 1x concentrations: 
5µM, 1.65µM, 550nM, 185nM, 61.5nM, 20.6nM, 6.85nM). 25µl per well of condition-specific 
growth media (DNP+NSP: media +10 µM rU; DNP: media alone; NSP: media +10 µM rU + 1 
µM NITD-982) was plated in opaque-white 384-well plates using a BioTek multidrop liquid 
handler. Protein kinase inhibitors were added by 250 nL pin-tool transfer (BioMek FX, Beckman-
Coulter) and inhibitor/media mixtures were incubated at room temperature for 30 m. 25 µL of a 
40,000 cells/mL MIAPACA2 suspension (for 1000 cells / well) was subsequently added to each 
well. After 72 h, 50 µL of CellTiter-Glo reagent diluted 1:4 in dH2O was added to each well and 
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luminescence was measured using a Wallac plate reader (Perkin Elmer). Each condition was 
assayed in duplicate (n=2) and % proliferation values were calculated by normalizing 
experimental wells to plate negative controls and averaging replicate values. Composite 
pathway selectivity synergy scores for each test compound were defined as the sum of the 
excess over Bliss additivity scores (% proliferation inhibition observed - % proliferation inhibition 
expected) between individual protein kinase inhibitor concentrations across the 7-point 
concentration range. Z factor scores for individual assay plates were calculated using eight 
positive and eight negative control wells on each plate as previously described(Ji-Hu Zhang, 
1999). All plates gave a Z factor > 0.5 (Figure S3C). 
3H-rU and 3H-dC uptake assays 
Radioactive probe uptake assays were conducted as previously described (Campbell et al., 
2011). Briefly, 5 ×105 CCRF-CEM cells were resuspended in 1 mL of media per well in 12-well 
plates. After 1 h, cells were incubated with the indicated amounts of tritiated probe ± JNK-IN-8 
for an additional hour. Cells were then harvested and washed twice with ice-cold PBS. 
Radioactivity was measured using a beta-counter (Perkin-Elmer). 
Positron Emission Tomography (PET) imaging 
MicroPET/CT experiments were conducted as previously described (Shu et al., 2010). Briefly, 
prewarmed and anesthetized NSG mice were injected with [18F]CFA, and PET and CT images 
were acquired using the G8 PET/CT scanner (Sofie Biosciences) 4 h after i.p. administration of 
JNK-IN-8 or its vehicle and 3 h after the injection of 740 kBq of [18F]CFA. 
Radiochemical Synthesis of [18F]-Labeled Probes. 
The syntheses of [18F]CFA was performed as previously described (Shu et al., 2010). 
Flow cytometry 
All flow cytometry data were acquired on five-laser BD LSRII, and analyzed using FlowJo 
software (Tree Star). 
AnnexinV/PI: Treated PDAC cells were washed with PBS and incubated with AnnexinV and 
propidium iodide diluted in 1x Annexin binding buffer. 20,000 events were collected per sample. 
Propidium iodide cell cycle analysis: Treated PDAC cells were washed with PBS and 
suspended in propidium iodide cell cycle staining solution (100 µg/ml propidium iodide; 20 µg/ml 
Ribonuclease A). 10,000 events were collected per sample. 
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Viability analysis 
For CellTiter-Glo analysis cells were plated at 1x103 cells / well in at 50 µl / well in white opaque 
384-well plates and treated as described. Following incubation 50 µl of CellTiter-Glo reagent 
(Diluted 1:5 in dH2O) was added to each well, plates incubated at room temperature for 5 m and 
luminescence was measured using a BioTek microplate luminescence reader. Proliferation rate 
normalized growth inhibition was calculated using the previously described GR metric (Hafner et 
al., 2016). 
For crystal violet staining, PDAC cells were plated in 6-well cell culture plates at 1x104 cells/well 
and treated as described. Following treatment cells were fixed by incubating in 4% PFA in PBS 
for 15 m at room temperature. Plates were subsequently washed with PBS and stained with 
0.1% crystal violet in H2O for 15 m at room temperature.  
Gene cloning, protein expression, and purification of DHODH in E.coli cells 
Primers were ordered to add NdeI 
(AGAGAACAGATTGGTGGTCATATGATGGCCACGGGAGATGAG) upstream of residue 29 
(after the mitochondrial membrane associated loop) and BamHI 
(TCGGGCTTTGTTAGCAGCCGGATCCTTACCTCCGATGATCTGCTCC) after the stop codon to 
insert into N-terminal His-Sumo pET 14b vector. This clone, His-Sumo-DHODH 29-395 
(subsequently referred to as DHODH) was successfully inserted into the vector in XL1-blue cells 
for vector propagation. 
The vector was transformed into C41(DE3) cells for productions. Cells were grown at 37 °C in 
2xYT medium supplemented with 100 µg/mL ampicillin (Amp), treated with 0.1 mM isopropyl β-
D-1-thiogalactopyranoside (IPTG) at an OD600 nm of 0.6-0.8, and then cultured for an 
additional 18h at 18 °C.  Cells were harvested by centrifugation, washed with 200 mM NaCl and 
25 mM Tris pH 7.5, and pelleted at 5000 rpm for 20 minutes before storage at -20°C. 6.7g/L of 
cell pellet was obtained. 
DHODH was purified according to known purification conditions(Baumgartner et al., 2006). Cell 
pellet was resuspended in lysis buffer (50 mM Tris pH 7.5; 600 mM NaCl; 0.33% w/v Thesit; 
10% Glycerol; 1 mM PMSF) and lysed by sonication on ice. Lysed cells were centrifuged at 
58,500 RCF for 45 minutes at 4°C, and the supernatant was filtered through a 0.45 µM filter and 
loaded onto a 5-mL His-Trap column pre-equilibrated with buffer A (50 mM Tris pH 7.4; 600 mM 
NaCl; 0.05% w/v Thesit; 10% Glycerol). The column was washed with buffer A for 70 mL, buffer 
A with 25 mM imidazole for 50 mL, and buffer A with 50 mM imidazole for 50 mL. The protein 
was eluted with buffer A with 250 mM imidazole. The eluted fraction was diluted 1:1 with Buffer 
A. Sumo protease was added and the protein was dialyzed overnight at 4°C against 1L of Buffer 
!126
A. The dialyzed protein was loaded back onto the His-Trap column equilibrated with buffer A. 
The cut-DHODH was eluted with buffer A with 50 mM imidazole. The purified protein was 
concentrated to 5 mL and injected onto S-200 gel filtration column (GE Healthcare) equilibrated 
with: 50 mM HEPES pH 7.7, 400 mM NaCl, 10% Glycerol, 1mM EDTA, 0.05 % w/v Thesit. 
Eluted fractions consistent with monomer size were collected, concentrated, flash frozen, and 
stored at -80°C. 
Recombinant DHODH enzyme assay 
Evaluation of DHODH inhibition was performed as previously described(Baumgartner et al., 
2006). Purified recombinant DHODH was incubated in an aqueous solution (total volume, 1.0 
mL) containing 500 µM DHO, 200 mM K2CO3-HCl (pH 8.0), 0.2% triton X-100, and 100 µM 
coenzyme Q10 at 37 °C for 0, 15, 30, 45, or 60 m. An aliquot (100 µL) of the mixture of enzyme 
reaction mixture or cell/tissue lysate was mixed with 100 µL of 0, 0.5, or 1.0 µM orotic acid, 50 
µL of H2O, 250 µL of 4.0 mM 4-TFMBAO, 250 µL of 8.0 mM K3[Fe(CN)6], and 250 µL of 80 mM 
K2CO3 and then heated at 80 °C for 4 m. The reaction was stopped by cooling in an ice-water 
bath and the absorbance was measured with a spectrofluorometer (FP-6300 Jasco, Tokyo, 
Japan): excitation and emission wavelengths were 340 nm and 460 nm, respectively. 
Crystallization of DHODH with OSU-03012 and TAK-632 compounds 
For co-crystallizaion of DHODH and OSU-03012, crystals were obtained using the same 
conditions reported in previously published DHODH structures(Lewis et al., 2016; Baumgartner 
et al., 2006; Das et al., 2013; Davies et al., 2009; Erra et al., 2011; Hurt, Sutton, & Clardy, 2006; 
Ladds et al., 2018; Liu, Neidhardt, Grossman, Ocain, & Clardy, 2000; McLean et al., 2010; 
Sainas et al., 2018; Walse et al., 2008), namely 1.6 – 2.6 M ammonium sulfate and 5-30% 
glycerol in the well in pH 4.5, with 20 mg/mL DHODH with 2 mM dihydroorotate (DHO), 20.8 mM 
dodecyldimethyl-N-amineoxide (DDAO), and 400 µM inhibitor. Protein was mixed 1:1 with 
mother liquor and hanging drops were used at room temperature. Crystals appeared after 48 
hours and reached maximal size within one week. Molecular replacement used 4OQV (Deng et 
al., 2014) as the starting model. Interestingly, DHODH-TAK-632 crystals grown in similar 
conditions to those used for the DHODH-OSU-03012 complex did not show TAK-632 density. As 
a result, novel DHODH crystallization conditions were identified using commercial screens. For 
co-crystallization of DHODH with TAK-632, crystals were obtained in conditions of 1.4-1.6 M 
sodium phosphate, pH 8.2. Protein solution (20 mg/mL DHODH with 2 mM DHO, 20.8 mM 
DDAO, and 400 µM inhibitor) was mixed 1:1 with mother liquor and hanging drops were used at 
room temperature. Crystals appeared after 48 hours and reached maximal size within one 
week. Ligplot+ (Laskowski & Swindells, 2011; Wallace, Laskowski, & Thornton, 1995) was used 
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to determine hydrophilic and hydrophobic interactions between inhibitors and DHODH 
molecules. 
Immunoblot analysis 
PBS-washed cell pellets were resuspended in cold RIPA buffer supplemented with protease and 
phosphatase inhibitors. Protein lysates were normalized using BCA assay, diluted using RIPA 
and 4x laemmli loading dye, resolved on 4-12% Bis-Tris gels and electro-transferred to 
nitrocellulose membranes. After blocking with 5% nonfat milk in TBS + 0.1% Tween-20 (TBS-T), 
membranes were incubated overnight in primary antibodies diluted (per manufacturers 
instructions) in 5% BSA in TBS-T. Membranes were washed with TBST-T and incubated with 
HRP-linked secondary antibodies prepared at a 1:2500 dilution in 5% nonfat dry milk in TBS-T. 
HRP was activated by incubating membranes by incubating membranes with mixture of 
SuperSignal Pico and SuperSignal Femto ECL reagents (100:1 ratio). Exposure of 
autoradiography film was used for detection. 
Statistical analyses 
Data are presented as mean ± SD with number of biological replicates indicated. Comparisons 
of two groups were calculated using indicated unpaired two-tailed Student’s t-test and P values 
less than 0.05 were considered significant. For some experiments, generated mean normalized 
values (ratios from two groups, treated to untreated) were compared to the hypothetical value 1 
(indicating equal values between treated and untreated), calculated using one-sample t-test, 
and P values less than 0.05 were considered significant. Comparisons of more than two groups 
were calculated using one-way ANOVA followed by Bonferroni’s multiple comparison tests, and 
P values less than 0.05/m, where m is the total number of possible comparisons, were 
considered significant.  
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RESULTS 
Design of a differential metabolic modifier screen for identification of novel modulators 
of pyrimidine nucleotide metabolism 
While redundant routes for UMP biosynthesis can complicate targeting, impaired proliferation 
resulting from simultaneous restriction of both routes can be used to identify selective modifiers 
of either NSP or DNP pathway activity (Figure S1A). A differential metabolic modifier screen 
was developed for the discovery of small molecule modulators of UMP production by leveraging 
this biosynthetic redundancy. This cell-based screening platform concurrently tests the effects of 
small molecule compounds on the proliferation of cells in baseline (NSP and DNP active), NSP-
only, and DNP-only conditions (Figure 1A). Molecules which inhibit proliferation in baseline 
conditions are classified as non-specific inhibitors. Those which inhibit proliferation in NSP-only 
conditions are NSP inhibitors, while those that inhibit growth in DNP-only conditions are DNP 
inhibitors. The screen design was validated using the known DHODH inhibitor NITD-982 (Wang 
et al., 2011) and the FDA-approved nucleotide transport inhibitor dipyridamole (DPA), using 
CellTiter-Glo (CTG) to evaluate proliferation impairment (Figure S1B). 
Cancer cell lines exhibited varying degrees of sensitivity to NITD-982 (as determined by 
doubling-time-normalized proliferation inhibition) and were all rescued by uridine (rU) 
supplementation (Figure S2)(Hafner, Niepel, Chung, & Sorger, 2016). MIAPACA2 PDAC cells 
were utilized in the screen due to their ability to maintain baseline proliferation levels in NSP-
only or DNP-only conditions, while also exhibiting a significant decrease in proliferation upon 
simultaneous NSP and DNP inhibition (Figure S3A). 
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A library of 430 protein kinase inhibitors was chosen for evaluation, the rationale being twofold. 
First, we hypothesized that our synthetic lethality screen may identify compounds that indirectly 
target pyrimidine metabolism by inhibiting regulatory signal transduction pathways. Second, 
because the majority of kinase inhibitors are ATP-mimetics, and given their resemblance to 
nucleotides, we predicted that protein kinase inhibitors may posses additional, non-canonical 
targets within nucleotide metabolism. Consistently, several protein kinase inhibitors, specifically 
those exhibiting similarities with the phenylamino pyrimidine (PAP) imatinib scaffold, and a 
subset of p38 MAPK inhibitors, exhibit activity against nucleoside transporters(Damaraju, 
Weber, Kuzma, Cass, & Sawyer, 2016; Huang et al., 2002). The library was screened at 7-point 
dose response in duplicate. Composite NSP and DNP pathway selectivity scores were 
calculated for each compound as the sum of condition-specific anti-proliferative effects across 
the dose range (Figure S3B). Assay quality was monitored using the Z-factor metric (Figure 
S3C)(Ji-Hu Zhang, Kevin R. Oldenburg, 1999). 
The JNK inhibitor JNK-IN-8, the BTK inhibitor CNX-774, and the VEGFR inhibitor AMG-706 
were active in the NSP-only condition (Figure 1B). The selectivity of these hits was unique 
among inhibitors of JNK (Figure 1C), BTK, and VEGFR (Figures S3D-S3F), indicating this 
phenotype likely did not result from on-target effects. 
The PDK1 inhibitor OSU-03012 (also known as AR-12) and the pan-RAF inhibitor TAK-632 were 
identified as eliciting potent and selective inhibition of proliferation in the DNP-only condition 
(Figure 1D)(Zhu et al., 2004; Okaniwa et al., 2013). Among the four PDK1 inhibitors and 14 
RAF inhibitors tested, OSU-03012 and TAK-632 were unique in their ability to selectively inhibit 
the DNP, suggesting that their ability to inhibit the pyrimidine DNP was not the consequence of 
on-target effects (Figures 1E-1F). Hit selectivity was confirmed using an orthogonal long-term 
proliferation inhibition assay (Figure S3G). 
JNK-IN-8 inhibits nucleoside uptake in vitro and in vivo 
While three protein kinase inhibitors were identified as selective inhibitors of the pyrimidine NSP, 
JNK-IN-8 was exceptionally so. We reasoned that the activity of JNK-IN-8 could arise from 
either the inhibition of nucleoside shuttling across the plasma membrane, achieved by 
concentrative (CNT) or equilibrative (ENT) nucleoside transporters, or of UCKs. To determine 
the level at which JNK-IN-8 is active, the uptake of tritiated rU and dC was quantified. These 
nucleosides rely upon the same transporters to enter the cell but require unique kinases for 
conversion into their respective monophosphate forms and resultant intracellular accumulation 
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(Figure 2A). The assay revealed that JNK-IN-8 inhibited the uptake of rU and dC with similar 
potency (33 nM and 31 nM, respectively), suggesting that the compound was inhibiting 
nucleoside transport (Figure 2B). Additionally, JNK-IN-8 treatment rescued JURKAT cells from 
the anti-proliferative effects of gemcitabine, a dCK-dependent nucleoside analog prodrug which 
relies upon nucleoside transporters to enter the cell, with an EC50 of 15.2 nM (Figure S4A, 
S4B).  
After demonstrating the ability of JNK-IN-8 to inhibit the pyrimidine NSP in vitro, we assessed its 
ability to block accumulation of a dCK-specific nucleoside analog PET probe, 18F-clofarabine 
([18F]CFA), in CCRF-CEM xenograft tumors formed in NSG mice(Kim et al., 2016). Following 
treatment, PET imaging revealed that tumor [18F]CFA PET uptake was decreased in JNK-IN-8-
treated mice, relative to vehicle-treated controls (Figure 2C-2D). 
Identification de novo UMP biosynthesis target of OSU-03012 and TAK-632 
Two kinase inhibitors, TAK-632 and OSU-03012, were identified as potent and selective 
inhibitors of the DNP (Figure S4C). We reasoned that these compounds could target either 
CAD, DHODH, or UMPS enzymes in de novo pyrimidine biosynthesis (Figure 3A). Both 
compounds induced S-phase arrest in MIAPACA2 cells, a phenotype associated with insufficient 
dNTP biosynthesis to sustain DNA replication and activation of intra-S phase signaling 
checkpoints. This effect was rescued by orotate (the product of DHODH) supplementation and 
could be completely reversed by rU supplementation (Figures 3B-3C). DHODH inhibition 
emerged as a likely mechanism, as it catalyzes one of three committed steps within the DNP 
and is a druggable protein (Madak et al., 2019). Additionally, both OSU-03012 and TAK-632 
posses fluorine substituents which have been shown to stabilize bioactive conformations of 
DHODH inhibitors (Bonomo, Tosco, Giorgis, Lolli, & Fruttero, 2013; Baumgartner et al., 2006). 
In an in vitro colorimetric recombinant human DHODH activity assay, TAK-632 and OSU-03012 
both inhibited DHODH activity in a dose-dependent manner (Figure 3D) (Baumgartner et al., 
2006). In screening a panel of 23 PDAC cell lines we found the sensitivity to OSU-03012 to be 
heterogenous (Figure S6A). Importantly, the response to TAK-632 or OSU-03012 correlated 
with the response to a known DHODH inhibitor in this cell line panel (Figure 3E). 
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To determine the molecular interactions between the protein and its putative inhibitors, complete 
DHODH co-crystallization data sets were obtained and processed to 1.4 Å and 2.7 Å for 
OSU-03012 and TAK-632, respectively (Figure S5a). Both compounds bind in a hydrophobic 
channel composed by two N-domain α-helices through which ubiquinone travels, consistent with 
previously identified DHODH inhibitors (Baumgartner et al., 2006). A long-range hydrogen bond 
between Arg 69 and OSU-03012 helps orient the molecule to the hydrophobic pocket where the 
phenanthrene moiety inserts, while the remainder of the molecule lays on the outer surface of 
DHODH, blocking the hydrophobic channel (Figures 4A, S5B). Three hydrogen bonds stabilize 
TAK-632 in the same hydrophobic pocket: two with Tyr 37 and Leu 66 help stabilize the inhibitor 
at the opening of the channel, while a third with Gln 46 helps pull the inhibitor deep into the 
pocket (Figures 4B, S5C).  
OSU-03012 synergizes with replication stress response inhibitors to induce cancer cell 
death 
OSU-03012 was recently reported to synergize with replication stress response kinase inhibitors 
in RSK-subtype mutant KRAS cancer models(Yuan et al., 2018). However, after confirming that 
OSU-03012 binds DHODH, we hypothesized that the observed synergy resulted from DHODH 
inhibition rather than PDK1 inhibition. We treated MIAPACA2 cells with M6620, an inhibitor of 
the proximal replication stress response kinase ATR, and either OSU-03012 or the PDK1 
inhibitor GSK-2334470 for 72 h. We observed a synergistic increase in cell death when 
OSU-03012 and an ATR inhibitor were combined, whereas the combination of GSK-2334470 
and M6620 demonstrated only a nominal increase in cell death (Figure S6B). Immunoblot 
analysis of S6K and S6 phosphorylation, PDK1 downstream targets, confirmed that 
GSK-2334470 potently blocked PDK1 while OSU-03012 triggered CHEK1 phosphorylation, a 
replication stress biomarker, only in the absence of rU (Figure S6C). Taken together, these data 
indicate that replication stress triggered by OSU-03012 is the consequence of DHODH inhibition 
rather than inhibition of its canonical target.  
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DISCUSSION 
Our screening strategy expands on previous “nutrient-sensitized” genetic and small molecule 
screens, the general design of which can be applied to any number of metabolic systems, so 
long as said system produces a critical metabolite through parallel and redundant biosynthetic 
pathways(Arroyo et al., 2016; Gohil et al., 2010). UMP biosynthesis (i.e. pyrimidine metabolism) 
was identified as an amenable extension for this type of screen, as it consists of convergent 
pathways, and UMP depletion triggers a quantifiable change in phenotype. 
JNK-IN-8, developed as an irreversible inhibitor of c-Jun N-terminal kinases 1, 2, and 3 with low-
nanomolar affinity, was the most potent of three NSP inhibitors identified(Zhang et al., 2012). 
Our data show that it is additionally a potent inhibitor of nucleoside transport, both in vitro and in 
vivo. We conclude that JNK-IN-8 should not be used in conjunction with compounds, including 
cancer-treating antimetabolites, which rely upon nucleoside transport for their research or 
therapeutic purpose. Furthermore, JNK-IN-8 should not be used in research settings wherein 
upregulation of the pyrimidine DNP may confound experimental results. 
The structurally and functionally unrelated OSU-03012 and TAK-632 were identified as inhibitors 
of the pyrimidine DNP. A recent report described the ability of OSU-03012 and analogs to inhibit 
virus propagation via pyrimidine nucleotide biosynthesis inhibition, specifically implicating 
DHODH (Yang et al., 2018). Our work substantiates these findings, is the first to unambiguously 
confirm the affinity of OSU-03012 for DHODH through crystallography studies, and the first to 
demonstrate the same for TAK-632. Notably, our studies show that OSU-03012 and TAK-632 
bind in the same hydrophobic tunnel of DHODH as known inhibitors brequinar and teriflunomide 
(active metabolite of leflunomide). This suggests that these two protein kinase inhibitors 
compete with ubiquinone, a redox partner of DHODH which traverses the hydrophobic tunnel to 
regenerate FMN from FMNH2. By competitively inhibiting the binding of ubiquinone, these 
compounds prevent DHODH from completing its redox cycle which effectively abrogates its 
activity.  
OSU-03012 has orphan drug designation in the European Union for treatment of tularaemia and 
cryptococcosis. We hypothesize that its effectiveness in these indications stems from its ability 
to inhibit DHODH, rather than from ‘on-target’ effects against PDK1. Indeed, DHODH inhibitors 
have demonstrated efficacy against viruses such as dengue virus and respiratory syncytial virus 
(Bonavia et al., 2011; Yang et al., 2018; Wang et al., 2011). In anticancer settings, OSU-03012 
was recently demonstrated to synergize with CHK1 inhibitors in KRAS-mutant cancers (Yuan et 
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al., 2018), which was initially attributed to its ability to inhibit PDK1. However, our data show that 
GSK-2334470, a PDK1 inhibitor more potent than OSU-03012, displayed markedly little synergy 
with ATR inhibition. In light of our crystallographic data, we conclude that the synergy observed 
between OSU-03012 and ATR inhibition is likely a result of the DHODH-inhibitory ability of the 
former. Taken together, our data suggest that DHODH inhibitors have utility in oncology, 
particularly if used in conjunction with ATR inhibitors or other DNA-damage response/replication 
stress response pathway inhibitors(Le et al., 2017). 
In summary, we designed and applied a metabolic modifier screen which identified multiple 
protein kinase inhibitors as having non-canonical targets within pyrimidine metabolism. Similarly 
constructed phenotypic screens designed against other metabolic networks containing 
convergent nodes may find use in drug discovery campaigns or in repurposing screens using 
existing compounds. 
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FIGURES 
 
Fig. 4.1 | Identification of UMP-DNP and -NSP modulators in a small molecule protein 
kinase inhibitor library. (A) Phenotypic screening strategy. The impact of 430 protein kinase 
inhibitors on cell proliferation was evaluated in MIAPACA2 cells plated in 3 distinct growth 
conditions; 1) NSP + DNP (media + 10 µM uridine (rU)); 2) NSP only (media + 10 µM rU + 1 µM 
NITD-982); or 3) DNP only (media alone). % proliferation values were calculated using CellTiter-
Glo (CTG) following 72 h treatment (7-point dose response; n=2). (B, C) Waterfall plots ranking 
library compounds based on NSP (B) or DNP (C) pathway selectivity scores determined as 
described in Fig. S3B. (D-F) Summary of NSP and DNP selectivity scores across library 
compounds annotated as JNK (D), PDK1 inhibitors (E), or RAF inhibitors (F). (G) Structures of 
hit compounds. 
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Fig. 1 | Identification of UMP-NSP and -DNP modulators in a small molecule protein kinase inhibitor library. (A) Phenotypic 
screening strategy. The impact of 430 protein kinase inhibitors on cell proliferation was evaluated in MIAPACA2 cells plated in 3 
distinct growth conditions; 1) NSP+DNP (media +10 µM uridine (rU)); 2) NSP only (media +10 µM rU +1 µM NITD-982); or 3) DNP 
only (media alone). % proliferation values were calculated using CellTiter-Glo (CTG) following 72 h treatment (7-point dose 
response; n=2). (B-C) Waterfall plots ranking library compounds based on NSP (B) or DNP (C) pathway selectivity scores. (D-F) 
Summary of NSP and DNP selectivity scores across library compounds annotated as JNK (D), PDK1 inhibitors (E), or RAF 
inhibitors (F). (G) Structures of hit compounds.
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Fig. 4.2 | JNK-IN-8 inhibits nucleoside transport in vitro and in vivo. (A) Nucleoside uptake 
can be prevented by inhibition of either nucleoside transporters or kinases. (B) Uptake of 3H-rU 
or 3H-dC in CCRF-CEM cells following 2 h incubation ± JNK-IN-8 (mean±SD; n=2). IC50 values 
are indicated. (C) Representative PET/CT scans of CCRF-CEM subcutaneous tumor bearing 
NSG mice imaged with [18F]CFA X h after treatment with vehicle (n=2) or JNK-IN-8 (50 mg/kg; 
n=3) T, tumor. (D) Quantification of [18F]CFA tumor uptake in C (%ID/g: percentage injected 
dose per gram; mean±SD; student t-test, * P<0.05). 
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Fig. 2 | JNK-IN-8 inhibits nucleoside transport in vitro and in vivo. (A) Nucleoside uptake can be prevented by inhibition of either 
nucleoside transporters or kinases. (B) Uptake of 3H-rU or 3H-dC in CCRF-CEM cells following 2 h incubation ± JNK-IN-8 (mean±SD; 
n=2). IC50 values are indicated. (C) Representative PET/CT scans of CCRF-CEM subcutaneous tumor bearing NSG mice imaged with 
[18F]CFA X h after treatment with vehicle (n=2) or JNK-IN-8 (50 mg/kg; n=3) T, tumor. (D) Quantification of [18F]CFA tumor uptake in C 
(%ID/g: percentage injected dose per gram; mean±SD; student t-test, * P<0.05). 
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Fig. 4.3 | OSU-03012 and TAK-632 inhibit DHODH. (A) Summary of UMP biosynthesis. (B) 
Propidium iodide cell cycle analysis of MIAPACA2 PDAC cells treated ± 5 µM TAK-632; 5 µM 
OSU-03012 supplemented with 50 µM orotate (OA) or 10 µM rU (N.S.: no supplement). Insert 
indicates % S-phase cells. (C) Summary of fold changes in S-phase cells from experiment in 
(mean±SD; n=2; one-way ANOVA corrected for multiple comparisons by Bonferroni adjustment, 
ns: not significant; * P<0.05; ** P<0.01).  (D) in vitro DHODH enzyme assay performed in the 
presence of OSU-03012 or TAK-632. (E) Correlation between DHODHi (1 µM NITD-982) and 
OSU-03012 (3.12 µM) or TAK-632 (3.12 µM) response across a panel of 27 PDAC cell lines 
determined using CTG following 72 h of treatment. Response calculated as doubling time 
normalized proliferation inhibition. Pearson correlation coefficient is indicated. 
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Fig. 3 | OSU-03012 and TAK-632 inhibit DHODH. (A) Summary of UMP biosynthesis. (B) Propidium iodide cell cycle analysis of 
MIAPACA2 PDAC cells treated ±5 µM TAK-632 or ±5 µM OSU-03012 and supplemented with 50 µM orotate (OA) or 10 µM rU (N.S.: 
no supplement). Insert indicates % S-phase cells. (C) Summary of fold changes in S-phase cells from B (mean±SD; n=2; one-way 
ANOVA corrected for multiple comparisons by Bonferroni adjustment, ns: not significant; * P<0.05; ** P<0.01). (D) in vitro DHODH 
enzyme assay performed in the presence of OSU-03012 or TAK-632. (E) Correlation between DHODHi (1 µM NITD-982) and 
OSU-03012 (3.17 µM) or TAK-632 (3.17 µM) response across a panel of 23 PDAC cell lines determined using CTG following 72 h 
treatment. Respons  calculated as doubling time normalized proliferation inhibition. Pearson correlation coefficient is indicated.
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Fig. 4.4 | OSU-03012 and TAK-632 bind DHODH. (A,B) Crystal Structure of DHODH with 
OSU-03012 (A) or TAK-632 (B). 2mFo-DFc electron density for OSU-03012 (carbons in yellow) 
or TAK-632 (carbons in green) contoured at 1 σ. Dashed black lines represent hydrogen bonds 
between the ligands and DHODH. Interacting residues as predicted by LigPlot+  are shown and 
labeled. 
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Figure 4
Fig. 4 | OSU-03012 and TAK-632 bind DHODH. (A,B) Crystal Structure of DHODH with compounds OSU-03012 (A) or TAK-632 (B). 
2mFo-DFc electron density for OSU-03012 (carbons in yellow) or TAK-632 (carbons in green) contoured at 1 σ. Dashed black lines 
represent hydrogen bonds between the ligands and DHODH. Interacting residues as predicted by LigPlot+  are shown and labeled.  
A B
Supplementary Figures 
Fig. S4.1 | Validation of UMP as a critical, convergent metabolic node in cancer cells. (A) 
UMP can be produced by a de novo pathway (DNP) from glucose, glutamine, bicarbonate and 
aspartate or from extracellular uridine (rU) by a nucleoside transporter and kinase-dependent 
salvage pathway (NSP). (B) Dose response curves of DHODH inhibitor NITD-982 and 
nucleoside transport inhibitor dipyridamole (DPA) in JURKAT cells cultured in NSP + DNP 
(media + 10 µM rU), NSP only (media + 10 µM rU + 1 µM NITD-982), or DNP only (media 
alone) for 72 h as determined by CellTiter-Glo (CTG; mean±SD; n=4). 
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Fig. S1 | Validation of UMP as a critical, convergent metabolic node in cancer cells. (A) UMP can be produced by a de novo 
pathway (DNP) from glucose, glutamine and aspartate or from extracellular uridine (rU) by a nucleoside transporter and kinase-
dependent scavenging pathway (NSP). (B) Dose response curves of DHODH inhibitor NITD-982 and nucleoside transport inhibitor 
dipyridamole (DPA) in JURKAT cells cultured in NSP + DNP (media + 10 µM rU), NSP only (media + 10 µM rU + 1 µM NITD-982), or 
DNP only (media alone) for 72 h as determined by CellTiter-Glo (CTG; mean±SD; n=4).
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Fig. S4.2 | UMP-DNP and NSP are interchangeable in sustaining proliferation across a 
panel of cancer cell lines. Uridine titration in cancer cell lines cultured in media + 10% dFBS 
±1 µM NITD-982 (n=4). Relative proliferation rate (PR) was calculated by normalizing % 
proliferation values at 72 h to cell line proliferation rate. Proliferation rates were calculated 
utilizing CTG measurements at the time of treatment (t0) and vehicle-treated controls at 72 h. 
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Fig. S2 | UMP-DNP and NSP are interchangeable in sustaining 
proliferation across a panel of cancer cell lines. Uridine titration in cancer 
cell lines cultured in media + 10% dFBS ± 1 µM NITD-982 (n=4). Relative 
proliferation rate (PR) was calculated by normalizing % proliferation values at 
72 h to cell line proliferation rate. Proliferation rates were calculated utilizing 
CTG measurements at the time of treatment (t0) and vehicle-treated controls 
at 72 h.
Figure S2
 Fig. S4.3 | Phenotypic screen identifies UMP-NSP and -DNP inhibitors. (A) CTG analysis of 
MIAPACA2 cells cultured in NSP+DNP (media +10 µM rU), DNP (media alone), NSP (media 
+10 µM rU +1 µM NITD-982) or starvation conditions (media + 1 µM NITD-982) for 72 h 
(mean±SD; n=4; one-way ANOVA corrected for multiple comparisons by Bonferroni adjustment, 
** P < 0.01; *** P < 0.001) (B) Methodology applied to determine UMP-DNP and -NSP 
selectivity scores (n=2). (C) Z’-scores calculated for individual assay plates from experiment in 
Figure 1. (D) Selectivity scores for BTK inhibitors included in the screen. (E) Selectivity scores 
for VEGFR inhibitors included in the screen. (F) Structures of hit compounds. (G) Validation of 
hit compounds using 7 d crystal violet proliferation assay. MIAPACA2 cells were treated with 1 
µM JNK-IN-8, 1 µM OSU-03012, 1 µM TAK-632 in NSP+DNP, DNP or NSP conditions. 
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Fig. S3 | Phenotypic screen identifies UMP-NSP and -DNP inhibitors. (A) CTG analysis of MIAPACA2 cells cultured in NSP+DNP 
(media +10 µM rU), DNP (media alone), NSP (media +10 µM rU +1 µM NITD-982) or starvation conditions (media + 1 µM NITD-982) 
for 72 h (mean±SD; n=4; one-way ANOVA corrected for multiple comparisons by Bonferroni adjustment, ** P < 0.01; *** P < 0.001) (B) 
Methodology applied to determine UMP-DNP and -NSP selectivity scores (n=2). (C) Z’-scores calculated for individual assay plates 
from experiment in Figure 1. (D) Selectivity scores for BTK inhibitors included in the screen. (E) Selectivity scores for VEGFR inhibitors 
included in the screen. (F) Structures of hit compounds. (G) Validation of hit compounds using 7 d crystal violet proliferation assay. 
MIAPACA2 cells were treated with 1 µM JNK-IN-8, 1 µM OSU-03012, 1 µM TAK-632 in NSP+DNP, DNP or NSP conditions.
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Fig. S4.4 | Evaluation of UMP-NSP and -DNP inhibitor potency and selectivity. (A) 
Calculation of JNK-IN-8, CNX-774, and AMG-706 IC50 values for JURKAT cells cultured in 
NSP+DNP, DNP-only, and NSP-only conditions, and EC50 values for gemcitabine (dFdC) 
rescue. (B) JNK-IN-8 and DPA dose response in JURKAT cells treated with 10 nM dFdC (n=4; 
mean±SD) for 72 h determined using CTG. (C) Calculation of OSU-03012 and TAK-632 IC50 in 
JURKAT cells treated for 72 h determined using CTG. 
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Fig. S4 | Evaluation of UMP-NSP and -DNP inhibitor potency and selectivity. (A) Calculation of JNK-IN-8, CNX-774, and AMG-706 
IC50 values for JURKAT cells cultured in NSP+DNP, DNP-only, and NSP-only conditions, and EC50 values for gemcitabine (dFdC) 
rescue. (B) JNK-IN-8 and DPA dose response in JURKAT cells treated with 10 nM dFdC (n=4; mean±SD) for 72 h determined using 
CTG. (C) Calculation of OSU-03012 and TAK-632 IC50 in JURKAT cells treated for 72 h determined using CTG.
Figure S4
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Fig. S4.5 | Evaluation of DHODH / inhibitor interactions. (A) Stereoscopic image of Figure 
4A (OSU-03012). (B) Stereoscopic image of Figure 4B (TAK-632).(C) Crystallographic data 
collection and refinement statistics. aHigh resolution shell in parenthesis; r.m.s., root- mean-
square; a.u., asymmetric unit  
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Figure S5
Fig. S5 | Evaluation of DHODH / inhibitor interactions. (A) Stereoscopic image of Figure 4A (OSU-03012). (B) Stereoscopic image 
of Figure 4B (TAK-632).(C) Crystallographic data collection and refinement statistics. aHigh resolution shell in parenthesis; r.m.s., root-
mean-square; a.u., asymmetric unit
C
B
Crystallographic	Data	Collection	and	Refinement	Statistics	
Structure DHODH + OSU-03012 DHODH + TAK-632 
PDB codes 6OC0 6OC1 
Data collection statistics 
X-ray source and detector LS-CAT 21-ID-D LS-CAT 21-ID-G 
Dectris Eiger x 9M MARCCD 300 
Wavelength (Å) 0.99987 0.97872 
Temperature (K) 100 100 
Resolutiona	(Å)	 1.40 (1.48-1.40) 2.7 (2.85-2.7) 
Number of Reflections 
 Observed 1,090,019 (113,565) 306,440 (48,502) 
 Unique 114,363 (17,418) 13,751 (2,169) 
Completeness (%) 99.0 (94.2) 99.9 (99.8) 
Rmeas (%) 7.0 (54.5) 17.0 (183.3) 
CC1/2 (%) 99.9 (87.8) 99.9 (71.1) 
Average I/σ(I) 19.2 (2.8) 21.6 (2.1) 
Space group P 32 2 1 P 21 3 
Unit cell: a, b, c (Å) 90.01, 90.01, 123.07 113.67, 113.67, 113.67 
Unit cell: α, β, γ (°) 90, 90, 120 90, 90, 90 
Wilson B-factors (Å2) 13.9 66.4 
Refinement statistics 
Refinement program REFMAC5 REFMAC5 
 Rwork (%) 15.7 23.4 
 Rfree (%) 19.1 29.1 
Resolution range (Å) 48.55-1.40 46.45-2.70 
Protein molecules per a.u. 1 1 
Number of atoms: 
 Protein 2845 2769 
 Water molecules 232 36 
 ORO + FMN 42 42 
 Inhibitor 34 39 
R.m.s. deviation from ideal: 
 Bond length (Å) 0.009 0.0021 
 Bond angles (°) 1.7114 1.264 
Average B-factors (Å2)     
 Protein 23.9 73.0 
 Water molecules 32.6 44.7 
 ORO + FMN 12.2 56.6 
 Inhibitor 29.3 73.0 
Ramachandran plot statistics (%) 
 Most favored regions 97 86 
 Additionally allowed regions 3 14 
 Outlier regions 0 1 
aHigh resolution shell in parenthesis; r.m.s., root-mean-square; a.u., asymmetric unit. 
A
 Fig. S4.6 | AnnexinV/PI flow cytometry analysis of OSU-03012 / ATRi combination. 
Representative flow cytometry plots from experiment in Figure 3H. 
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Fig. S6 | Characterization of OSU-03012 response in pancreatic cancer cell lines. (A) Summary of normalized proliferation 
inhibition values for 23 pancreatic ductal adenocarcinoma (PDAC) cell line panel treated with 3.17 µM OSU-03012 as described in 
Figure 3E. (B) Summary of normalized proliferation inhibition values PDAC cell line panel treated with 3.17 µM TAK-632. (C) Annexin 
V/PI flow cytometry analysis of MIAPACA2 PDAC cells treated with 1 µM OSU-03012 (OSU) or 1 µM PDK1 inhibitor GSK-2334470 
(GSK) ± 500 nM M6620 (ATRi) ± 25 µM rU for 72 h (mean±SD; n=2; one-way ANOVA corrected for multiple comparisons by Bonferroni 
adjustment; ns: not significant; ** P<0.01; *** P<0.001).). (D) Immunoblot analysis of MIAPACA2 cells treated ± 1 µM PDK1 inhibitor 
GSK-2334470 ± 1 µM OSU-03012 ± 25 µM rU.
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CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS 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One of the most pervasive hallmarks of cancer is genomic instability. It is clear that the 
maintenance of physiological dNTP levels is critical to sustain cellular proliferation and genome 
integrity. Through these studies, we have developed small molecule inhibitors that can modulate 
dNTP levels quantity and quality. We have further elucidated the interconnections between DNA 
synthesis and stress response signaling mechanisms, and generated strategies to obliterate 
cancer cells while sparing normal tissues.  
Chapter 1: Nucleotide metabolism-RSR crosstalk 
1. Quantification of alterations of nucleotide biosynthetic pathways in leukemia cells by ATR, 
the most upstream kinase in the replication stress response (RSR) pathway. 
2. New therapeutic strategy to limit dNTP pools by combining existing modulators of nucleotide 
metabolism and RSR pathway.  
3. Future studies  
1. Clinically applicable companion biomarkers like endogenous RS measurement that are 
predictive of responses in human tumors. 
2. Stratification of tumors based on contributions of de novo and salvage biosynthetic 
pathways. 
3. Therapeutic efficacy of targeting ATR and dCK in solid tumors with hypoxic tumor 
microenvironment (limited de novo activity). 
Chapter 2: Pharmacology of dCK inhibitor, (R)DI-87  
1. Preclinical development and pharmacology of a novel dCK inhibitor, (R)DI-87. 
2. [18F]CFA PET probe is used as a pharmacodynamic biomarker for measuring dCK activity to 
optimize DI-87 dose that resulted in maximal dCK inhibition. 
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3. PK-PD models for both dCK inhibition and tumor growth inhibition studies were used to 
optimize dosing schedules for first in-human clinical studies.  
Chapter 3: Development of a potent copper ionophore 
1. HCT-13, a novel isoquinoline based HCT was identified as a highly potent anti-proliferative 
against PDAC, SCLC and PC cancer models. 
2. HCT-13 functions as a copper ionophore, and its cytotoxicity is attributed to production of 
ROS, and is mitochondrial function dependent.  
3. Further, HCT-13 interferes with DNA replication arresting cells in S-phase, activating RSR 
pathway, and interacts with ATR inhibitor synergistically.  
4. Ongoing studies - Development of Cu complex of HCT-13 and loading them in Mesoporous 
silica nanoparticles (MSN) for optimal bio distribution and delivery to tumors. 
5. Future studies - Preclinical efficacy studies of MSN loaded Cu[HCT-13] in Prostate and 
PDAC cancer models. 
Chapter 4: Metabolic modifier screen to identify secondary targets 
1. Cell-based metabolic modifier screen is developed for the discovery of modulators of 
nucleotide biosynthetic pathways.  
2. JNK-IN-8, a JNK inhibitor was discovered to be potent nucleoside transporter inhibitor. 
3. OSU-03012, a PDK1 inhibitor was discovered to be a potent DHODH inhibitor, and 
confirmed by co-crystal structure with DHODH.  
4. Clinical implications - JNK-IN-8 should not be used in conjunction with compounds, including 
cancer-treating antimetabolites, which rely upon nucleoside transport for their research or 
therapeutic purpose. 
5. Similarly constructed phenotypic screens designed against other metabolic networks 
containing convergent nodes may find use in drug discovery campaigns or in repurposing 
screens using existing compounds. 
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